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ABSTRACT 
Human Regulatory T (Treg) cells play a critical role in the immune system. They can 
suppress the activation, proliferation and cytokine production of various immune cells 
including T cells, B cells, Dendritic Cells (DCs), natural killer (NK) cells and 
macrophages. This special suppressive capacity to control immune responses makes Treg 
cells indispensable for self-tolerance and the prevention of over-reactivity to maintain 
immune homeostasis. Deficiency and dysfunction of Treg cells lead to severe 
autoimmune disease like immune dysregulation, polyendocrinopathy, enteropathy, X-
linked syndrome (IPEX), allergy and asthma, inflammatory bowel disease, graft versus 
host disease (GVHD), as well as fetal-maternal intolerance during pregnancy. Hence, 
understanding Treg cell physiology is of vital importance. 
In humans, Treg cell differentiation starts from 8.2 gestational weeks in utero under the 
influence of the maternal immune environment. The increase in the fetal Treg cell 
compartment compared to adults proves that the fetal immune system is prone to 
differentiate into Tregs in order to maintain a tolerogenic status. Whilst there is abundant 
indirect evidence from clinical observations for transplacental Treg cell programming, 
there is a paucity of direct mechanistic data. It is known that various soluble 
immunomodulatory factors, including anti-inflammatory cytokine IL-10 and microbiota 
metabolites, short chain fatty acids (SCFAs), contribute to the transplacental immune 
programming by shaping the fetal immune system, specifically Treg cells. Therefore, this 
thesis aims to provide further evidence for the Treg cell transplacental programming, and 
to explain how IL-10 and SCFAs contribute to this process. 
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SCFAs are organic fatty acids with fewer than 6 carbon atoms. They are the major 
bacterial fermentation products in the human intestine. SCFAs have been shown to have 
profound influences on both the innate and adaptive immune systems, particularly Treg 
cells. Upon production in the GI tract, they are absorbed into the gut epithelium cells and 
then circulated to other organs to exert immune regulatory effects through the portal vein. 
In the animal models, it has already been proven that they contribute greatly to the pTreg 
induction in vivo, as well as iTreg induction in vitro. In addition, SCFAs also suppress 
the expression of pro-inflammatory cytokines by murine DCs, skewing murine colonic 
macrophages and DCs towards a tolerogenic phenotype, thus promoting Treg induction. 
Although their effects have been consistently proven in different animal models, their 
efficacy in modulating immune cells in humans still remains unclear. Therefore, I aim to 
explore thoroughly the effects of SCFAs on different types of immune cells, especially 
Treg cells in vitro; and to investigate how SCFAs alter the histone acetylation of genes 
involved in immune tolerance. 
To study Treg cell transplacental programming, various types of experiments were 
conducted, such as animal experiments, serum acetate level detection, TCR sequencing 
and flow cytometric analyses. To explore thoroughly the effects of SCFAs on different 
types of immune cells, especially Treg cells in vitro, mononuclear cells from cord blood 
and adult peripheral blood were isolated. After in vitro culture with SCFAs, cells were 
examined phenotypically using multi-colour flow cytometry and functionally by in vitro 
suppression assay.  
Our collaborators were able to demonstrate how the maternal microbial composition 
influences fetal thymus and Treg cell development. The absence of maternal gut 
microbiota caused significantly reduced fetal thymus size and fewer thymic Foxp3+ Treg 
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cell numbers. Supplementation of acetate could rescue all these reductions in thymus size 
and thymic output. Moreover, the fetal-maternal correlation of serum acetate levels we 
found in human pregnancy implied that maternal acetate likely crossed the placenta. TCR 
sequencing data also suggested that fetal antigen receptor immunity was not inherited, 
but rather driven by local immunomodulatory factors. Taken together, it can be concluded 
that maternally acquired metabolites (acetate) play an important role in shaping fetal 
thymic development and output, hence exerting their influences on fetal immunity. 
In addition to the context of pregnancy, this thesis extends the knowledge of the 
regulatory effects of SCFAs on both neonate and adult immune cells in vitro. The most 
essential finding is that we are the first to demonstrate the effectiveness of SCFAs in Treg 
cell differentiation via histone acetylation inhibition in vitro in humans. The addition of 
butyrate and propionate, but not acetate, enhanced histone 3 and histone 4 acetylation of 
various immune tolerance related gene loci, thus potentiating the expression of these 
phenotypic markers. The suppressive capacity of induced human Treg cells was therefore 
augmented. Compared to Cord Blood Mononuclear Cells (CBMCs), adult PBMCs had a 
completely different induction pattern with a reduced level of activation. We postulated 
that this differential induction patterns of adult iTregs accounted for the inconsistent 
effectiveness of human iTregs as well as the concealment of SCFAs’ effects, considering 
the higher proportion of non-activated iTregs in adults. ChIP analysis also provided 
additional evidence for the observed differential induction patterns in adults. The 
epigenetic histone acetylation due to SCFAs treatment initiated much later in adult cells 
compared to cord blood cells. Additionally, we also proved the tolerogenic effects of 
SCFAs on other immune cells in humans, including MoDCs and different T cell subsets. 
We showed that both butyrate and propionate, but not acetate, could inhibit the 
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differentiation and maturation of MoDCs, skewing them towards immature or tolerogenic 
status. When cocultured with naive CD4+ T cells, these tolerogenic MoDCs upregulated 
the immune tolerance related phenotypic markers and increased the suppressive capacity 
of cultured CD4+ T cells. These tolerogenic effects of SCFAs also applied to different T 
cell subsets regardless of their Foxp3 expression in vitro. These results highlight the 
important role of SCFAs in immune tolerance, particularly in Treg cell physiology. 
In conclusion, maternally derived SCFAs play a pivotal role in the Treg cell transplacental 
programming in utero and during early life. Additionally, SCFAs can potentiate the 
expression of immune tolerance related phenotypic markers via histone acetylation 
inhibition, thus promoting the differentiation of tolerogenic human iTregs and MoDCs in 
vitro. These results provide theoretical evidence for a new non-pharmaceutical approach 
as immune therapeutic manipulation, not only feasible during pregnancy, but also in 
infancy and adulthood. Since diet is closely interlinked with the composition of gut 
microbiota and SCFAs production, dietary interventions or direct SCFAs 
supplementation, may alleviate or treat various non-communicable diseases, or even 
prevent the development of autoimmune diseases via modulating Treg cells. Most 
importantly, this non-pharmaceutical immune therapy is cost-effective, side-effects 
free, and beneficial for all generations.  
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1.1 Immune system 
The immune system, involving multiple organs and cells, is a holistic and complicated 
defence system, which helps to protect the body from a variety of potential threats. To 
function properly, the immune system requires tight regulatory processes to maintain a 
fine balance. A hyper or hypoactive immune system can lead to different types of 
diseases. Reduced or absent responses to foreign antigens, can cause recurrent or life-
threatening infections, while over-active responses, including those against self-antigens, 
can result in autoimmune diseases.  
1.1.1 Innate immune system 
The immune system can be divided into innate and adaptive immune systems. The innate 
immune system provides first-line protection against pathogens infiltrating the body (3). 
A broad, non-specific inflammatory response is initiated immediately. Foreign substances 
are identified and removed by specialised phagocytes. Then immune cells migrate to the 
site of infection guided by cytokines and chemokines. In addition, the complement 
cascade is activated by pathogens directly or indirectly via antibodies. This is followed 
by a transition that activates the adaptive immune system (4), initiated by antigen 
presentation to orchestrate a more targeted immune response and combat the foreign 
pathogen. 
There are several types of immune cells involved in innate immune responses, including 
granulocytes, NK cells, monocytes, macrophages, and DCs. Granulocytes generally 
arrive first at the site of infection, where they identify and remove the foreign substances 
in a similar manner to macrophages. Rather than directly attacking the invading 
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pathogens, NK cells eliminate cells with decreased levels of major histocompatibility 
complex (MHC) I, which is known as “missing self-recognition” (5). The majority of 
cancer cells also exhibit down regulation of MHC I expression (6), thus can be recognised 
and cleared by NK cells. Monocytes are the progenitors of macrophages and DCs. 
Macrophages are the most competent phagocytes to engulf and destroy pathogens. Other 
immune cells can be recruited by macrophages to the site of infection (7). Finally, DCs 
are professional antigen presenting cells (APCs), which play a pivotal role in regulating 
the adaptive immune system (8, 9).  
1.1.2 Adaptive immune system and antigen presentation 
Unlike the innate immune system, the adaptive immune system is highly antigen specific. 
B lymphocytes can directly recognise antigens in their native forms via the B cell receptor 
(BCR). However, T lymphocyte activation requires antigen presentation by APCs. The T 
cell receptor (TCR) can only recognise antigens that have been processed into peptides 
presented on MHC molecules (10). MHC molecules consist of MHC-I and MHC-II, 
which are recognised by CD8+ and CD4+ T cells, respectively. MHC-I molecules are 
displayed on the surface of all nucleated cells. De novo generated antigens are processed 
into peptides intracellularly by the proteosome and loaded onto MHC-I (11). They are 
recognised by naïve CD8+ T cells, which then differentiate into cytotoxic T lymphocytes.  
MHC-II molecules are mainly expressed on the surface of professional APCs, such as 
dendritic cells, macrophages and B cells. Extracellular antigens are internalised through 
endocytosis, processed into peptides, and then bound to MHC-II (12). This complex is 
subsequently recognised by naïve CD4+ T cells, which differentiate into effector and 
memory T helper cells. 
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1.1.3 T lymphocytes differentiation 
The differentiation of T lymphocytes from hematopoietic stem cells (HSCs) involves 
multiple stages, and it mainly takes place in the thymus. Figure 1.1 summarises T cell 
development (adapted from (13)). 
 
Figure 1.1 T lymphocyte differentiation in the thymus. 
Early thymic progenitors, originating from HSCs in the bone marrow, become double 
negative (DN) cells after losing the potential to differentiate into B cells and dendritic 
cells (14). DN cells do not express either the TCR or the co-receptors CD4 and CD8. 
During this stage in the thymic cortex, the essential rearrangement of TCR genes occur. 
Double positive (DP) cells are generated after TCRβ gene selection (refer to β selection 
in Figure 1.1) and they express the CD4 and CD8 co-receptors. After this selection, the 
TCR α-chain locus rearranges to complete the αβ TCR (15). T cells which fail to acquire 
contact with MHC molecules die by neglect. DP cells develop into either CD4 or CD8 
single positive (SP) cells, which is known as positive selection (16). Then in the medulla 
region of the thymus, the strength of TCR self-reactivity determines the destiny of T cell 
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differentiation. SP cells with high avidity to MHC–peptide ligands undergo negative 
selection, whereas SP cells with low avidity eventually develop into naive T cells and 
migrate out to the periphery where they undergo further selection (17). 
Regulatory T (Treg) cells, a special type of suppressive cells, originate in this late stage 
of thymic development. The transcription factor Forkhead box P3 (Foxp3) is upregulated 
when a small proportion of self-reactive CD4+ thymocytes with an intermediate avidity 
for MHC class II molecules escape negative selection (18). Then with an appropriate 
duration of TCR stimulation, these Foxp3+ cells eventually develop into Treg cells (19). 
1.2 Immune tolerance 
Antigens recognised by T cells can be divided into “self” antigens, which are synthesised 
by the organism’s own cells and “non-self” or foreign antigens, which do not derive from 
cells of the organism. The ability to discriminate “self” and “non-self” antigens to avoid 
attacking own cells in the body is of vital importance. The immune system needs to trigger 
sufficient immune responses to basically all foreign antigens, meanwhile avoids harmful 
immunity to self by distinguishing between self from non-self and maintaining a proper 
grade of immune responses (20). The process of “Self” and “Non-self” discrimination is 
referred to as immune tolerance, which was first proposed in the 1950s by Sir F. 
Macfarlane Burnet theoretically and Medawar experimentally (21, 22).  
Immune tolerance first takes place in the thymus. Currently, it is widely accepted that 
during T cell development, thymocytes undergo multiple selection stages, among which 
negative selection occurred in the medulla of the thymus is the most important one to 
eliminate self-reactive TCR repertoires (17). Medullary epithelial cells provide the source 
6 
 
of “self” antigens by expressing tissue restricted antigens (TRAs) ectopically induced by 
Autoimmune Regulator (AIRE) (23). The expression of TRAs initiates after AIRE 
expression, and they are positively correlated in a dose-dependent manner (24). T cells 
with receptors that strongly recognise these TRAs are eliminated by negative selection 
(25). This process is called central tolerance, a variety of autoimmune diseases can occur 
if this process is jeopardised (26). 
Self and non-self discrimination also takes place in the extrathymic environment, and this 
process is referred to as peripheral tolerance. T cells with intermediate avidity to self-
antigen can escape the negative thymic selection and migrate into the periphery (27). 
These cells pose a threat to cause pathogenic autoimmune diseases. Several mechanisms 
are proposed as to how these self-reactive cells are eliminated. DCs play a role in the 
peripheral tolerance via T cell anergy. When DCs fail to present costimulatory factors, T 
cells could not proliferate upon stimulation of self-antigen alone (28). T cell depletion 
caused by activation-induced cell death through CD95 (Fas) signalling is another 
mechanism (29). Moreover, these self-reactive T cells are selectively downregulated by 
Qa-1-restricted CD8+ T cells (30). Regulatory B cells (Bregs) (31, 32) and innate 
lymphoid cells (ILCs) (33, 34) also contribute to the peripheral immune tolerance. 
However, the most intriguing cell type involved is Treg cells. Thymus-derived Treg cells 
are produced to suppress self-reactive cells that have escaped thymic negative selection 
in the periphery  (35).   
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1.2.1 Regulatory T Cells 
1.2.1.1 History 
In 1970, a thymus-derived suppressive lymphocyte population was first discovered in 
mice by Gershon and Kondo (36). The existence of these suppressor T cells was 
confirmed in animal models by different groups (37-40). They performed thymectomy 
on rodents at around day 3 after birth, resulting in severe autoimmune diseases, which 
showed that these suppressor T cells were crucial for maintaining immune tolerance. 
Suppressor T cells were later renamed Treg cells. They are naturally present in the 
immune system (41). In healthy human peripheral blood mononuclear cells (PBMCs), the 
percentage of CD4+ Tregs within CD4+ T cells is around 6.7-9.9%. In comparison, the 
percentage of CD8+ Tregs within CD8+ T cells is more variable and much lower (0.1–
1%) (42). Generally, three main subsets of Treg cells have been described, thymus-
derived Treg cells or natural Treg cells (tTregs), peripheral-derived Treg cells (pTregs) 
and in vitro induced Treg cells (iTregs) (43).  
1.2.1.2 Phenotypic Markers 
The first specific marker CD25 (IL-2 receptor α-chain) was not defined until 1995 in 
mice. T cells prepared from BALB/c mice lymph nodes and spleens were depleted of 
CD4+CD25+ cells. Subsequently, these CD4+CD25+ depleted T cells were adoptively 
transferred to BALB/c athymic nude mice. All BALB/c athymic mice subsequently 
developed evident autoimmune diseases spontaneously (44). In mice, this CD4+CD25+ 
population was distinct; however, in humans CD4+CD25+ consisted of both 
CD4+CD25low and CD4+CD25high populations. The CD4+CD25low cells could not 
suppress the proliferation of co-cultured CD4+CD25- responder T cells, whereas the 
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CD4+CD25high cells cultured alone could strongly inhibit the proliferation of responder 
cells (45). Therefore, CD25 alone was insufficient to define Treg cells in humans and 
more surrogate markers were needed. 
This later resulted in the use of Foxp3, a member of the forkhead/winged-helix family of 
transcription factors, as an appropriate marker for tTregs. However, the associations 
between FoxP3 and Treg cells were confirmed much later than its initial discovery. Foxp3 
was first discovered in the Scurfy mouse in 1949 (46). Scurfy is an X-linked recessive, 
fatal lymphoproliferative disorder (47-50). In 2001, DNA sequencing revealed that IPEX 
was the human equivalent of mouse scurfy (51). It was confirmed that mutations of the 
human Foxp3 gene, the ortholog of the gene mutated in Scurfy mice, led to impaired Treg 
cell development and function, subsequently causing IPEX (41, 52). 
As for the Foxp3 gene locus,  there is one promoter as well as three conserved non-coding 
sequences (CNS), which are the main targeted regions for epigenetic modifications and 
transcriptional factor modulations (53, 54). The promoter region containing a TATA box, 
a GC box and a CAAT box, is cell-specific and induced following TCR engagement (55). 
It is completely demethylated (1.4%±0.95% methylated) in human CD4+CD25high Treg 
cells, while CD4+CD25low T cells had a 27.9%±7.1% methylated promoter region (56). 
Although stimulated CD4+CD25low T cells remained partially demethylated, they could 
only transiently express Foxp3. Thus, the promoter demethylation status might regulate 
the stable Foxp3 expression and Treg commitment (56). CNS-1, containing binding 
motifs for Smad3, NFAT, AP-1 and retinoic acid receptor (RAR), is a transforming 
growth factor-β (TGF-β) sensitive enhancer region, hence crucial for the peripheral 
induction of Foxp3 in gut-associated lymphoid tissues but not in the thymus (57). In 
contrast, the pioneer element CNS-3, binding c-Rel and p65, is indispensable for potently 
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initiating Foxp3 induction in the thymus as well as the periphery (54, 58). CNS-2, also 
known as Treg cell specific demethylated region (TSDR), is rich in CpG motifs (details 
refer to section 1.3.3.1). Although expendable for Foxp3 induction, CNS-2 is more 
important in promoting the stabilization of Foxp3 expression in Treg cells (57, 59). 
1.2.1.3 Regulatory T Cell Differentiation 
As stated in Section 1.1.3, Treg cell differentiation occurs quite late during T cell 
development and starts with an upregulation of the Foxp3 expression. Despite the 
significance of the Foxp3 expression in Treg cell development, various experiments 
proved that the expression of this transcriptional factor alone is insufficient to establish 
the Treg cell lineage. Growing evidence has suggested that in humans, a small subset of 
CD4+ and CD8+ T cells transiently up-regulate Foxp3 expression at a low level upon in 
vitro stimulation without acquiring Treg cell suppressive activity (60, 61). Thus, the 
expression of Foxp3 is normal following T cell activation, thus not a specific marker for 
iTregs in humans. Furthermore, in Foxp3gfp mice, where Foxp3 expression has been 
disrupted by the insertion of the GFP gene, thymocytes could still develop into T cells 
sharing the same Treg characteristics (62). These features include similar thymic 
development, the exclusive expression of αβTCRs, and cell surface phenotype (62). 
Therefore, Treg cell development appears to involve multiple processes, and other 
independent processes may also be obligatory for Treg cell development (63). For 
example, epigenetic modifications such as Treg-cell-specific DNA hypomethylation (64, 
65).   
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1.2.1.3.1 Epigenetic Modifications 
Epigenetics is defined by the regulation of gene expression without changing nucleotide 
sequences in the genome (66, 67). There are various types of epigenetic modifications, 
such as histone modifications, DNA methylation, and chromosome conformational 
changes (68). In particular, DNA methylation and histone modifications are involved 
greatly in the cell-lineage determination and maintenance because they are inheritable 
through cell divisions (69), which have already been documented at the Foxp3 locus (64, 
69).  
Complete demethylation of CpG motifs (Treg cell specific DNA hypomethylation, Treg-
Me) and histone modifications within the conserved region was shown by Bisulfite 
sequencing and chromatin immunoprecipitation (ChIP) assays in ex vivo 
CD4+CD25+Foxp3+ Tregs (70). CpG hypomethylation of Foxp3 TSDR is exclusively 
imprinted in tTreg cells compared with other T cell subpopulations including retroviral 
Foxp3-overexpressing conventional T cells (Tconv) and iTregs (64). This indicates that 
the establishment of Treg-Me is independent of the Foxp3 expression over the course of 
tTreg cell development from the thymus to the periphery (64). Foxp3-expressing 
thymocytes without the Treg-Me pattern lost the Foxp3 expression and failed to 
differentiate into Treg cells (19).  
1.2.1.3.2 Role of TCR Signalling 
Several animal studies have revealed the significance of TCR signalling in Treg cell 
development, which is also confirmed by direct sequence analysis of the TCR repertoires 
between Treg and non-Treg cells. TCR transgenic mice, but not recombination activating 
gene (RAG) deficient αβTCR transgenic mice, developed CD4+CD25+ T cells that 
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predominantly expressed TCRs with endogenous α-chains (71). There are also 
considerably reduced numbers of Foxp3+ Treg cells in αβTCR and βTCR transgenic 
mice, suggesting that gene rearrangement at the TCR α-chain locus is required in Treg 
cell development in the thymus (72, 73). Direct sequence analysis of the TCR repertoires 
expressing a fixed transgenic TCR-β chain showed the diversity of TCR-α sequences in 
Treg cells and they only partially overlapped with non-Treg cells (74, 75). Wolf et al. also 
found that there were only a limited number of TCR sequences shared between Tconv 
and Tregs (76).  
TCR signalling plays a pivotal role in the induction of Foxp3 expression as well as Treg-
Me to support Treg cell development. However, the quality of TCR stimulation required 
for the Foxp3 induction or Treg-Me seems to be different (19). The intensity of TCR 
stimulation mainly determines Foxp3 induction (73), whereas the acquisition of Treg-Me 
chiefly depends on the duration of TCR stimulation (64).  
1.2.1.3.3 Co-stimulatory Factors and Cytokines 
CD28 is expressed on T cells. After binding to its ligands CD80 (B7.1) and CD86 (B7.2), 
CD28 serves as costimulatory signals for T cell activation or inhibition in addition to TCR 
signals (77). In the B7−/− non-obese diabetic (NOD) mice, a significant reduction of 
CD4+CD25+ T cells was observed, suggesting that the CD28/B7 costimulatory pathway 
contribute greatly to Treg cell development and homeostasis (78, 79). Tai et al. proved 
that CD28 co-stimulation independently promoted the expression of Foxp3 in TCR-
signalled, double positive thymocytes hence initiating tTreg differentiation (80).   
Cytotoxic T lymphocyte associated protein 4 (CTLA-4, CD152) and CD28 are homologs, 
both binding to B7 and have opposing functions (81). Zheng et al. found that TGF-β was 
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unable to induce Foxp3 expression in CTLA-4−/− mice and the addition of anti-CTLA-4 
to CD4+CD25− cells in vitro eliminated TGF-β induce iTregs completely in a mouse 
model (82). Wing et al. generated BALB/c mice with an impaired CTLA-4 gene 
expression, and found that CTLA-4 deficiency led to the spontaneous development of 
fatal T cell-mediated autoimmune disease (83). This exhibited the same pathological 
condition seen with the Foxp3 deficiency in both humans (51) and mice (52), 
demonstrating that both CTLA-4 and CD28 play significant roles in the Treg 
differentiation. 
Foxp3+ Treg cells were found to be generated from peripheral CD4+ T cells in 2003 when 
Chen et al. used TCR stimulation and TGF-β to induce Foxp3 expression and convert 
naïve peripheral murine CD4+CD25−Foxp3− T cells into Foxp3+ pTreg cells (84). The 
role of TGF-β in Treg development was confirmed later in humans both in vitro (85, 86) 
and in vivo (87). Whilst TGF-β contributes greatly to the differentiation of pTreg and 
iTreg cells, there is also increasing evidence pointing to its critical role in the generation 
of tTreg cells (88-90).  
IL-2 is essential for T cell growth in vitro and plays a critical role in the maintenance of 
the Foxp3 expression and T cell tolerance in vivo (91, 92). IL-2 alone is inadequate to 
induce the Foxp3 expression, but it is indispensable for TGF-β-mediated Foxp3 induction 
in naïve CD4+ cells (93).  
1.2.1.4 Treg Cell Subsets 
Though tTregs, pTregs and iTregs are of different origin, all three subsets share common 
features, including expression of phenotypical markers Foxp3, CD25 and CTLA-4 (65, 
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94). The differences will be discussed in terms of Treg-Me, TCR repertoire, the stability 
of the Foxp3 expression and suppressive function.  
Treg-Me, especially at the Foxp3 CNS2 domain (TSDR), is similar between tTreg cells 
and pTreg cells (95) but is different from iTreg cells.  In vitro TGF-β treatment failed to 
induce complete DNA hypomethylation characteristic of tTregs (64). However, it should 
be noted that the timing of TSDR hypomethylation detection for different types of Treg 
cells varied significantly in these studies. Timing might be critical since TSDR 
demethylation in CD4+Foxp3+ tTreg cells is not yet complete in the thymus (70).  
According to their cell origin, pTregs and iTregs inherit TCR repertoires from naïve 
conventional T cells (96). In contrast, tTregs which recognise self-antigens have different 
TCR repertoires from pTregs and iTregs. 
Since stable Foxp3 expression relies on the status of TSDR methylation (70, 95), 
epigenetic differences at the Foxp3 TSDR locus leads to a difference in the Foxp3 
expression stability between tTregs, pTregs and iTregs. iTregs rapidly lose their Foxp3 
expression either in vitro (70, 97) or following adoptive transfer in vivo (97-99). 
Moreover, the instability of the Foxp3 expression in iTreg correlates with the strength of 
TCR signals in vivo (97), and it can be stabilised by modulating TSDR hypomethylation. 
Distinct functional differences have not been conclusively demonstrated between tTregs 
and pTregs. tTregs play an important role in preventing autoimmune diseases, whereas 
pTregs are mostly involved in the mucosal tolerance and inflammatory reactions towards 
foreign antigens (65, 100).  As for iTregs, the results are controversial. iTregs have been 
shown to effectively prevent the development of inflammation in Scurfy mice (101) and 
several animal disease models including Myasthenia Gravis (102), type 1 Diabetes (103), 
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Experimental Autoimmune Encephalomyelitis (98), and Autoimmune Gastritis (104). In 
humans, Treg cells have already been tested for treating various medical conditions 
especially GVHD since 2009 (105, 106). However, all the candidate cells used in 
immunotherapy for autoimmune diseases till now are ex vivo expanded Tregs due to their 
stable Foxp3 TSDR demethylation (107), rather than iTregs. Various studies showed that 
unlike in mice, human iTregs were neither anergic nor suppressive and produced pro-
inflammatory cytokines upon stimulation even with stable Foxp3 expression (86, 108). 
1.2.1.5 Mechanisms of Treg cell-mediated immune tolerance 
Treg cells are naturally present in the immune system (41). They can suppress the 
activation, proliferation and cytokine productions of various immune cells including T 
cells, B cells, DCs, NK cells and macrophages (109). This particular suppressive capacity 
to control immune responses makes Treg cells indispensable for self-tolerance and the 
prevention of over-reactivity to maintain immune homeostasis (109). Deficiency and 
dysfunction of Foxp3+ Treg cells lead to severe autoimmune disease such as IPEX (41, 
52), allergy and asthma (110), inflammatory bowel disease (IBD) (41, 111), GVHD 
(112), as well as fetal-maternal intolerance during pregnancy (109, 113, 114).  
There are several mechanisms by which Tregs contribute to immune tolerance as 
summarised in Figure 1.2 (115-118). Tregs can act directly by cell-contact dependent 
suppression or by the secretion of immunosuppressive cytokines. They can also indirectly 
act through modifications of APCs. 
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Figure 1.2 Mechanisms involved in the SCFA-medicated immune tolerance. 
The mechanism of cell-contact-dependent suppression first came from in vitro studies. In 
order to evaluate the suppressive capacity of Treg cells, they were cocultured with 
responder cells and stimulated with a specific antigen or a polyclonal TCR stimulator in 
the presence or absence of APCs in vitro (119, 120). Tregs failed to suppress the 
proliferation of responder T cells when they were separated by a semi-permeable 
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membrane (119, 120), suggesting a cell-contact-dependent mechanism. After direct cell 
contact, Tregs may exert cytotoxicity on APCs and responder T cells through either 
granzyme A/B and perforin (121-123), or induce cell cycle arrest via Galectin-1 
expression (118, 124). By competing for IL-2, Tregs could also inhibit the proliferation 
of responder cells, causing Bim-mediated apoptosis (125). 
Different from the direct cell-contact mechanism discovered in the in vitro suppression, 
in vivo experiments and disease models mentioned above indicated that secretion of 
immunosuppressive cytokines worked as another mechanism (109, 126). Interleukin (IL)-
10 and TGF-β are proposed as the main negative immunoregulators secreted by Tregs 
(115-118). Despite mounting evidence showing the importance of IL-10 and TGF-β in 
Treg-mediated suppression, there are some controversial results. Autoimmune gastritis in 
BALB/c mice was successfully prevented by IL-10-deficient T cells (127).  Blockage of 
IL-10 exerted no effect on the suppressive capacity of Tregs in the in vitro proliferation 
assay (119, 120). In addition, the suppression mediated by tTregs isolated from neonatal 
TGF-β knockout mice were intact in vitro (128). These tTregs could also prevent IBD in 
vivo (129). Another cytokine investigated was IL-35. IL-35-deficient Tregs had no 
therapeutic effect on IBD in vivo and recombinant IL-35 could suppress T effector (Teff) 
cells in vitro (130). Bardel et al. investigated the expression of IL-35 in Treg cells isolated 
from multiple human organs (131). Unlike their murine counterpart, IL-35 expression of 
Treg cells was not detected. 
Furthermore, Tregs could also functionally modify APCs via three pathways: (a) 
downregulating or preventing upregulation of CD80 and CD86 (132); (b) upregulating 
the expression a potent regulatory molecule, indoleamine 2,3-dioxygenase (IDO) on DCs 
to suppress Teff cell activation (133); and (c) Lymphocyte activation gene 3 (LAG-3, 
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CD223) engagement with MHC II inhibiting DC activation (134, 135); hence maintaining 
the tolerogenic status of APCs. 
Interestingly, pathways (a) and (b) mentioned above appear to be CTLA-4 dependent 
(132, 133). Wing et al. generated BALB/c mice with flawed CTLA-4 gene expression 
and found that CTLA-4 deficiency in Tregs could lead to the spontaneous development 
of fatal T cell-mediated autoimmune disease (83). CTLA-4-deficient Tregs could still 
develop and survive without altering thymic selection, only affecting Treg suppressive 
capacity in the periphery as well as in vitro. This is probably due to CTLA-4 dependent 
mechanisms dampening the potency of APCs described above (132, 133). 
1.2.1.6 Other Genes Related to Treg-mediated Immune Tolerance 
Apart from Foxp3 and CTLA-4, there are also various other genes contributing to immune 
tolerance mediated by Treg cells.  
1.2.1.6.1 Glucocorticoid-Induced TNFR-related protein (GITR) 
Glucocorticoid-induced TNF-related protein (GITR) is also known as tumour necrosis 
factor receptor superfamily member 18 (TNFRSF18). GITR is predominantly expressed 
on Treg cells. GITR contributes to the maturation and expansion of tTregs in both humans 
and mice (136). Moreover, GITR plays a crucial role in Treg cell function and is involved 
in various diseases (136). Antibodies against GITR reverse the suppressive capacity of 
CD4+CD25+ T cells (137), thus producing autoimmune disease in mice (138). Removal 
of GITR-expressing T cells can also result in autoimmunity (138).  
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1.2.1.6.2 CD39 
CD39 is nucleoside triphosphate diphosphohydrolase-1 (NTPDase 1), an ectoenzyme that 
degrades ATP to AMP. CD39 is expressed primarily by Treg cells in both humans and 
mice (139). In mice, it is present on nearly all CD4+CD25+ cells; while in humans, only 
around 60% of Tregs are CD39+ (139). Foxp3+CD39+ Treg cells display a demethylated 
TSDR and higher suppressive capacity. The secretion of the pro-inflammatory cytokines 
interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α) are also diminished in CD39+ 
Tregs after in vitro stimulation (140). The suppressive capacity of Treg cells isolated from 
CD39-deficient mice are diminished in vitro, and these cells were unable to block 
allograft rejection in vivo (141). CD39 contributes to the suppressive effects through 
catalytic inactivation and conversion of extracellular pro-inflammatory ATP (139).  
1.2.1.6.3 Inducible T-cell CoStimulator (ICOS, CD278) 
Inducible T-cell costimulator (ICOS, CD278) belongs to CD28-superfamily (142). It is 
expressed at low levels on resting naïve T cells. Upon TCR recognition and CD28 
costimulation, it is upregulated and highly expressed on activated T cells (143). In gene 
knockout ICOS−/− mice, the early expansion of Treg cells was jeopardised and the 
percentage of CD4+Foxp3+ Treg cells was significantly lower (144). The addition of 
ICOS-blocking antibody could lead to the impaired Treg differentiation and function in 
humans as well (145). In addition, IL-10 production was significantly reduced by 
CD4+Foxp3+ Treg cells in the ICOS−/− mice (143, 144). In fact, IL-10 production was 
found to be significantly correlated to the levels of ICOS expression on CD4+ T cells 
(146). In ICOS-deficient patients, there was also extensive T cell dysfunction, including 
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imbalance between effector and regulatory cells (147). Collectively, ICOS is pivotal for 
the expansion, maintenance and IL-10 production of Treg cells.  
1.2.1.6.4 Programmed Cell Death Protein 1 (PD-1, CD279) and Programmed Cell 
Death-Ligand 1 (PD-L1, CD274)  
Programmed cell death protein 1 (PD-1, CD279) is another B7 family member and a 
CD28 homologue. It is a cell surface receptor mainly expressed on T cells, B cells, and 
NK cells (148). PD-1 is not expressed on naive T cells, but it can be upregulated in 
response to T cell activation (149). It binds to its ligands Programmed cell death-ligand 1 
(PD-L1, CD274) and Programmed cell death-ligand 2 (PD-L2). While the expression of 
PD-L2 is restricted, PD-L1 is widely expressed on different immune cells (including T 
cells, B cells, DCs and macrophages), as well as various organs and solid tumour cells 
(150). Apart from PD-1, PD-L1 also binds to B7-1 to inhibit T cell responses, and this 
interaction is specifically restricted to PD-L1 but not PD-L2 (151). 
The pathway involving the interactions between PD-1 and PD-L1 (PD-1: PD-L1) 
contributes greatly to the maintenance of self-tolerance by exerting inhibitory signals to 
prevent autoimmunity (152, 153). A deficiency of PD-1 in mice led to various types of 
autoimmune diseases, such as Type 1 diabetes and experimental autoimmune 
encephalomyelitis (154, 155). The generation of CD4+Foxp3+ Tregs was greatly 
increased by PD-L1, and PD-L1−/− APCs were unable to induce Tregs, indicating the 
important role of PD-L1 in Treg cell induction (156, 157). In addition to its essential role 
in autoimmunity, PD-1: PD-L1 has been demonstrated to successfully reduce tumour 
growth and suppress metastasis, providing a ground-breaking therapeutic intervention for 
cancer treatment (150). 
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1.2.1.6.5 CD127 
Interleukin-7 receptor subunit alpha (IL7R-α) is also known as CD127. In humans, 
CD127 is downregulated on all T cells upon T cell activation, then re-expression occurs 
on most of the effector and memory T cells (158, 159). However, CD127 expression 
remains low for Foxp3+ Treg cells (160). Unlike CD25, which has no correlation with 
Foxp3 in CD4+ cells, CD127 expression was inversely associated with not only Foxp3 
expression, but also the suppressive function of Treg cells in both humans and mice (160). 
These results indicate that low CD127 expression is also a typical feature of Treg cells, 
compared to conventional T cells.  
1.2.1.6.6 Human Leukocyte Antigen – antigen D Related (HLA-DR) 
Human leukocyte antigen – antigen D related (HLA-DR) belongs to MHC-II class, 
encoded by the HLA complex on chromosome 6 (161). Interestingly, the expression 
HLA-DR is restricted to human Tregs only, since murine Tregs cannot transcribe CIITA 
required for MHC-II expression (162). Compared to HLA-DR- Tregs, in vitro generated 
HLA-DR+ Tregs have higher Foxp3 expression and exhibit better suppressive capacity 
(163). Moreover, the suppressive capacity of ex vivo isolated HLA- DR+ Tregs is also 
more effective (163). Hence, HLA-DR expression identifies a highly functional subset of 
Tregs. 
1.2.2 Antigen Presenting Cells 
Professional APCs are a group of specialised cells which present antigens via MHC-II at 
the cell surface and express costimulatory signals recognised by TCRs and costimulatory 
receptors respectively on T cells. They include DCs, macrophages and B cells. The main 
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role of APCs is to process and present antigens to initiate the adaptive immune responses 
conferred by T cells. Apart from their contributions to immunity, there is growing 
research indicating that APCs also play a significant role in immune tolerance. 
APCs, particularly DCs, regulate immune responses towards either immunity or 
tolerance, depending on the context of antigen exposure and different environmental 
stimuli. Several signals are required for DCs to activate T cell responses, involving the 
MHC-II complex, the expression of costimulatory molecules and secretion of soluble 
factors (164). All three types of signals are integral components for the initiation of T cell 
differentiation. 
1.2.2.1 Dendritic Cells 
DCs are present in various tissues, such as the skin, the inner layer of the respiratory tract 
and gastrointestinal tract, which have straight contact with the outer environment. Once 
activated by antigens, DCs migrate to the draining lymph nodes and interact with mainly 
T cells to trigger the adaptive immune responses. As implied in their name, they grow 
branched projections (dendrites) during certain developmental stages. The term 
“Dendritic Cells” was first introduced by Ralph Steinman in 1973 (165). He was awarded 
the Nobel Prize in Physiology/Medicine in 2011 for his breakthrough discovery of 
dendritic cells and their role in orchestrating the adaptive immune response (8, 9).  
The DC lineage is perhaps the most complicated hematopoietic pathway yet to be 
explained (166). The observation of Flt3 expression led to the identification of a common 
precursor for monocytes, macrophages, and classical DCs in the bone marrow, known as 
macrophage-DC progenitor (MDP) (167). It has been confirmed that MDPs can 
differentiate into monocytes, macrophages and classical DCs depending on different 
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cytokine milieus both in vivo (168) and in vitro (169). Common-DC progenitor (CDP), 
identified downstream of MDPs, are a DC-restricted progenitor producing 
classical/myeloid dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs) (168). 
The split in monocyte, macrophages and DC lineage begins between the MDP and CDP 
stages (170). In humans, research into DC differentiation is restricted to in vitro studies, 
which utilised monocytes and CD34+ hematopoietic precursor cells (8, 171, 172) to 
generate human DCs. The exact contribution that lymphoid precursors, myeloid 
precursors and monocytes make to the human DC pool in vivo is, however, unclear.  
The definition and classification of human DCs are somewhat ambiguous, due to their 
heterogeneity. Typically, a set of inclusion and exclusion criteria is used to define DCs. 
Firstly, cells expressing leukocyte lineage markers (such as CD3, CD19, CD14, CD16 
and CD56) need to be excluded. Then MHC II (such as HLA-DR) and CD11c (a 
leukocyte integrin surface marker for all DCs in mouse) expressions are used as inclusion 
criteria (173, 174). Depending on their tissue-specific presence, DCs exhibit phenotypic 
differences (175). For example, CD1a is used in Langerhans cells in the skin (176). In 
human peripheral blood, blood dendritic cell antigens (BDCAs) can identify distinct 
subsets (173).  In various other tissues, CD83 has been used as a specific marker of mature 
DCs (177). 
DCs are normally divided into cDCs and pDCs (178). Compared to cDCs, pDCs express 
high levels of CD123 and low levels of MHC-II, whereas CD11c is expressed equally in 
both types. PDCs accumulate mainly in the lymphoid tissues and blood. Upon recognition 
of viruses, they produce high amounts of interferon-α and acquire the capacity to present 
foreign antigens (179). cDCs refer to all DCs other than pDCs. They are usually located 
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in the spleen marginal zone and nonlymphoid tissues, where they constantly acquire 
tissue antigens  (175). 
DCs are versatile in their function in accordance with their activation status. Under steady 
state conditions, DCs are referred to as immature DCs (iDCs) with a weak T cell 
stimulating property due to the low expression of MHC-II molecules and costimulatory 
molecules, including CD80/CD86, PD-L1 as well as CD40 (180). These iDCs located in 
the blood and lymph nodes, favour the differentiation of pTreg cells. Taken together, 
iDCs contribute greatly to peripheral tolerance (8, 9). Under pathogenic or inflammatory 
conditions, iDCs become activated or matured (referred to as mDCs) after capturing, 
processing and presenting foreign antigens in MHC-II complexes. After activation, they 
migrate from various tissues into spleen and lymph nodes, where they can activate 
antigen-specific T cells, produce pro-inflammatory cytokines, hence inducing immunity 
(8, 9). Thus, it is the maturation status that distinguishes between tolerogenic and 
immunogenic DCs (181).   
1.2.2.2 Monocyte-Derived Dendritic Cells 
Monocyte-derived DCs (MoDCs) are a special type of DCs differentiated in vitro, sharing 
similar dendritic morphology and antigen presenting ability as DCs in vivo. They are 
differentiated from monocytes when cocultured with granulocyte macrophage - colony 
stimulating factor (GM-CSF) and IL-4 in vitro (172). These immature MoDCs can further 
differentiate into mature MoDCs when presented with various stimuli (172, 182), such as 
lipopolysaccharide (LPS). Monocytes are the most commonly used cells for DC 
generation in vitro. 
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1.2.3 Regulatory B cells 
Breg cells are a collection of B cells with suppressive capacity. They were first discovered 
in guinea pigs in the mid-1970s. Upon the adoptive transfer of sensitised splenocytes, B 
cells were able to suppress delayed-type hypersensitivity (183). The suppressive nature 
of B cells was confirmed later in mice, where B-cell-deficient mice failed to recover from 
experimental autoimmune encephalitis (184). The term Bregs was introduced only in 
2002 by Bhan, who showed that IL-10 producing B cells featured by CD1d upregulation 
appeared in chronic intestinal inflammatory conditions (185). Bregs were not discovered 
in humans until 2007, and these cells also produce IL-10 (186).  
Several disease models demonstrate that Bregs are heavily involved in autoimmune 
diseases, allergies, tumour immunity, infection, and transplantations (32). Breg cells can 
inhibit the differentiation of pro-inflammatory T cells, especially T helper (Th) 1 and 
Th17 cells, through the production of IL-10, TGF-β, and IL-35. In contrast, the 
differentiation of anti-inflammatory T cells, such as Foxp3+ T cells and T regulatory 1 
(Tr1) cells, can be induced by Bregs (31). However, most data are only focused on the 
interaction between Bregs and T cells, but not on other immune cells. 
1.2.4 Innate lymphoid cells 
ILCs are a special type of innate immune cells discovered in 2009 (187). Later, 
researchers found that there was a variety of cells sharing the same features. These cells 
are defined by the absence of antigen-specific BCRs or TCRs, and they do not express 
myeloid or dendritic cell markers. ILCs belong to the lymphoid lineage and are defined 
as cell lineage marker-negative cells (188, 189). The ILC family contains cytotoxic ILCs 
(NK cells) and non-cytotoxic ILCs. The latter normally divides into three distinct groups 
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according to the differential expression of cell surface markers, transcription factors and 
functional criteria: group 1 ILCs (ILC1s), group 2 ILCs (ILC2s) and group 3 ILCs 
(ILC3s) including lymphoid tissue inducer (LTi) cells(189). ILC1s are involved in 
immunity to intracellular pathogens due to their capability of producing IFN-γ and TNF-
α. On the other hand, ILC2s secrete Th2 cell-associated cytokines (IL-4, IL-5, IL-9 and 
IL-13), hence take part in defence against parasite infections, allergens, and epithelial 
injuries. Finally, ILC3s contribute to combating bacterial and fungal infection, since they 
produce the Th17 cell-associated cytokines IL-17 and IL-22 (33, 34). IL-22 is part of the 
IL-10 family and contributes to innate and nonspecific immunity in tissues (190).    
ILCs, despite lacking antigen presentation capability, are functionally similar to their 
adaptive immune system counterparts in the T helper cell population (33). ILCs react 
promptly to signals from infected or injured tissues and release a wide range of cytokines 
to initiate innate responses or regulate the adaptive immune system via the expression of 
MHC II molecules or through the regulation of DCs. Dysregulated ILC responses result 
in chronic inflammatory diseases, autoimmune diseases, metabolic disorders and cancers 
(33, 34). 
1.3 Immune Tolerance and Programming during Pregnancy  
1.3.1 Medawar’s hypotheses 
One of the foremost enigmas of reproductive biology is that a healthy woman with a 
normal functioning immune system can carry a semi-allogeneic fetus successfully to full 
term without apparent immune rejection. The maternal immune system undergoes 
relevant immunological changes for the semi-allogeneic fetus so that it can be tolerated 
(191). This phenomenon proves the involvement of immune tolerance during a normal 
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pregnancy. In humans, the semi-allogeneic fetus has to be successfully tolerated 
throughout pregnancy, which is typically 40 weeks.  
Fetal alloantigens encoded by polymorphic genes inherited from biological father should 
theoretically trigger a maternal immune rejection, which does not normally occur (192). 
The remarkable nature of this immunological paradox was recognised by Sir Peter 
Medawar in 1953, who worked on skin graft rejection in genetically different individuals. 
He hypothesized that the recognition of fetal alloantigens by maternal immune cells is 
dampened by the placenta, which works as a physiological barrier that strictly separates 
the fetus from maternal tissues (193). At the time, he proposed three mechanisms in 
pregnancies which contribute to the prevention of maternal rejection of the fetal allograft:  
an anatomical separation between the mother and the fetus, the reduced number of 
antigens possessed by the fetus (194), and the rendered inertness of the maternal immune 
system (195).  
Undoubtedly, Medawar pioneered the research relating to immunological tolerance 
during pregnancy and his hypotheses were proven to a certain extent. It is now known 
that the placenta, extravillous trophoblast (EVT) cells per se, separates most of the fetal 
antigens from the maternal immune system. EVTs have poor antigen presentation 
property due to the lack of classical MHC-I (except HLA-C) and MHC-II molecules 
(194). It would seem plausible that the maternal immune system is compromised by non-
recognition of fetal antigens in favour of a successful pregnancy. However, as there is 
accumulated evidence indicating the existence of anti-fetal HLA antibodies in maternal 
serum (196, 197), the maternal immune system has continuously been activated by fetal 
cells (195). 
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1.3.2 Immune Tolerance during pregnancy 
During pregnancy, immune adaptations happen locally in the fetal-maternal interface, the 
decidua, as well as systemically. Immediately after implantation, fetal trophoblast cells 
infiltrate in the endometrium and gradually develop into the decidua. This trophoblast 
invasion needs proper immunological regulation to maintain the survival of fetal 
trophoblast cells while limiting their invasion (198). Local immune cells, such as NK 
cells, macrophages, DCs and Treg cells, are present in situ before implantation. They are 
subject to certain adaptations (for example, increased cell numbers)  immediately 
following implantation (199). After the final establishment of the placenta circulation in 
the first trimester (before 12 weeks of gestation), the fetal syncytiotrophoblasts begin to 
come in close contact with maternal peripheral blood (200), hence inducing systemic 
immune responses. For the purpose of this thesis, special attention will be focused on the 
decidua and regulatory T cells.  
1.3.2.1 The Fetal-Maternal Interface: Decidua 
The decidua is the interface between the fetus and the maternal uterine endometrium 
during pregnancy. The decidua consists of decidua basalis, decidua capsularis, and 
decidua parietalis based on their anatomical location. At the fetal-maternal interface, the 
decidua participates in exchanges of nutrients, gases, and waste. Most importantly, it 
plays an essential role in immune tolerance during pregnancy. There are mainly three 
types of cells in the decidua: fetal EVTs, decidua stromal cells, and maternal immune 
cells (which accounts for nearly 50% of cells) such as uterine NK cells (201). There is a 
bidirectional passage of cells across the fetal-maternal interface, proved by the presence 
of microchimerism in both the mother and the fetus (202, 203). Microchimerism refers to 
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the existence of low numbers of cells originated from another individual and genetically 
distinct from the host cells (204).  
1.3.2.2 Regulatory T cells in Human Pregnancy 
It is now evident that there is a systemic increase in maternal Treg cells during normal 
pregnancy (205, 206). In contrast, deficits in Treg cell number and function result in 
unexplained infertility (207), miscarriage (208) and pre-eclampsia (206). In addition, 
there was a specific and significant correlation of Treg cells in the paired maternal-fetal 
(dyads) samples, while this correlation didn’t exist between the father and the fetus (209). 
This indicated that transplacental immune regulation was through a soluble immune 
modulatory factor(s), which can cross the placenta. Since fetal T cells, including Treg 
cells, are of different origins from adults (210), it is less likely that maternal Treg cells 
migrate into the fetal Treg cell compartment.   
1.3.3 Transplacental Immune Programming 
During pregnancy, the maternal immune system undergoes changes to adjust to the semi-
allogeneic fetus while the fetus also develops its own immune system. Though separated 
by the placenta, there is crosstalk between the mother and the fetus. For example, maternal 
IgG antibodies can cross the placenta to either pass on temporary protective passive 
immunity to the offspring (211),  or cause neonatal hyperthyroidism by the presence of 
maternal TSH receptor antibodies (212). Also, the presence of fetal microchimerism was 
found in the peripheral blood of the mother (203). 
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1.3.3.1 Developmental Origins of Health and Disease 
This transplacental immune programming is part of the theory of Developmental Origins 
of Health and Disease (DOHaD). It was originally postulated by Barker and Osmond in 
1984 (213). Together with other observational studies, Barker formulated his 
developmental programming hypothesis, stating that nutrition in prenatal and early life 
periods is essential for noncommunicable diseases (for example, ischemic heart disease) 
later in life. Since then, numerous investigations proved that fetal organ systems during 
this sensitive period of development experience programmed structural or functional 
changes depending on the intrauterine environment. These changes lead to various 
diseases later in adulthood (214).  
Numerous human studies support the DOHaD theory in the context of inflammatory and 
immune diseases (215-217). The mechanism for immune programming is not yet well 
defined, but evidence suggests that both fetal innate and adaptive immune systems are 
involved (209, 216, 218-222). 
1.3.3.2 The development of the fetal immune system 
In human fetuses, hematopoietic stem cells migrate to the thymus as early as 8.2 
gestational weeks, then T cell differentiation starts (223). In the fetal thymus, T cell 
differentiation is similar to the adult, achieved through positive selection in the cortex and 
negative selection in the medulla. However, Treg cell development is somewhat different. 
A population of thymocytes already initiates the expression of CD25, during the transition 
from DP CD27– cells to DP CD27+ cells (224). From 10 weeks of gestation, T cells 
migrate from the thymus to peripheral lymphoid organs (223). Unlike newborns and 
adults, the frequency of fetal Treg cells is significantly higher, around 15-20% of total 
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CD4+ T cells (225). This increase in the Treg cell compartment proves that the fetal 
immune system is prone to differentiate into Tregs upon stimulation in order to maintain 
a tolerogenic status. 
1.3.3.3 The influence of maternal immune environment on the fetal immune system 
In response to stimulation with maternal alloantigens, fetal T cells differentiate into Tregs 
and those specific for non-inherited maternal alloantigens (NIMAs) are maintained for a 
long time until adulthood (226). It can also be proved in a study focus on the effects of 
tolerance to NIMAs on the survival of kidney transplantation from haploidentical 
siblings.  The 10-year graft survival rate from sibling donors expressing NIMAs was 
similar to that from HLA-identical siblings, indicating the maternal modulation of the 
fetal immune system induced a long-lasting form of tolerance (227).  
There is also other evidence for transplacental immune regulation during pregnancy. In 
BALB/c mouse model, maternal Th1 and regulatory immune responses to schistosome 
infection could protect the offspring from the onset of allergic airway inflammation. 
Associated schistosome-specific cytokine and gene expression changes were also seen 
within the fetal-maternal interface (228). In addition, the offspring of tolerised mice were 
completely protected against asthma due to the transplacental transfer of allergen-specific 
IgG (218). Additionally, in both humans and mice, microbial stimulation of the pregnant 
mother could lead to decreased levels of atopic sensitisation and asthma in the offspring 
(229-231).  
The mechanisms for immune programming are still not well understood. The 
transplacental transport of allergen-specific IgG contributes to the protection of asthma 
via the fetal innate immune system (218). Moreover, the expression of Toll-like receptors 
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(TLRs; pattern recognition receptors that recognise bacterial components) is elevated 
upon maternal contact with farm animals and cats (219), which contributes to the 
prevention of allergy pathogenesis (220). As for the fetal adaptive immune system, the 
frequency and function of Treg cells are increased and associated with lower Th2 cytokine 
secretion after maternal farm exposure (216), possibly via soluble factors such as IL-10 
(209) or bacterial metabolites (221). Collectively, these findings provide evidence that 
appropriate stimulation of the maternal immune system in utero may educate and shape 
the fetal immune system.  
1.4 Gut Microbiota, Immune Homeostasis and Dietary Manipulation  
1.4.1 Gut Microbiota 
The mammalian gastrointestinal (GI) tract is home to a massive number of 
microorganisms (approximately 100 trillion) (232), and a majority of them are 
commensal bacteria. This gut microbial community (referred to as microbiota) has 
evolved together with its host. Various factors, including age, genetics, environment, 
antibiotics and diet, play an essential role in the composition of gut microbiota (232, 233). 
Depending on the mode of delivery (vaginal birth or through Caesarean Section), infants 
have different compositions of gut microbiota at birth, due to the different maternal 
colonization in situ. The gut microbiota develops quickly during the first year of life based 
on the feeding habits (breastfeeding or formula) (234, 235), and reaches maturation 
eventually at around 2-3 years old, having a similar composition compared to adults 
(236). Antibiotic exposure, which is commonly seen during early life, also has significant 
effects on the gut microbiota and later onset of allergies (237). The overall diversity is 
compromised and there are more Proteobacteria and less Actinobacteria populations 
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(238). Despite harbouring trillions of microbes, adult gut microbiota is mainly dominated 
by three types of bacterial phyla, Firmicutes, Bacteroidetes, and Actinobacteria (232, 
239).  
1.4.2 Diet Influence the Gut Microbiota 
Various global cross-sectional studies showed that the diet significantly influences the 
diversity of the intestinal microbiota, and subsequently its metabolites production (240). 
The effect of long-term diet on the composition of the gut microbiota has been well 
demonstrated (232, 241, 242). Interestingly, it has been shown that even short-term 
change in diet could influence the gut microbiota (243, 244). The relative abundance of 
each bacteria changed rapidly within hours of a diet switch in gnotobiotic mice (243), 
which are colonised by known strains of bacteria and other microorganisms. It was also 
confirmed in humans that gut microbiota could be altered rapidly and reproducibly (244). 
Only specific categories of bacterial species are stimulated according to the major 
macronutrient in a particular type of diet (245). For example, high fibre diet is always 
associated with increased Bacteroidetes production (221, 246).  
1.4.3 Gut Microbiota and immune homeostasis  
It is well accepted that the composition and metabolic products of the gut microbiota have 
profound and critical effects on immune homeostasis. A germ-free (GF) animal model is 
established by raising animals in a sterile environment so they have never been exposed 
to any microorganisms. This GF model unveils the significance of the gut microbiota in 
modulating both innate and adaptive immunity (247). Aberration in the gut microbiota 
and thus its impact on immune homeostasis will result in various diseases, including IBD, 
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multiple sclerosis, rheumatic arthritis, type 1 diabetes and metabolic syndrome (248, 
249). 
1.4.3.1 Gut Microbiota and innate immunity 
Gut microbiota and its crosstalk with the innate immune system are important for the 
immune homeostasis locally as well as systemically. Pattern-recognition receptors 
(PRRs) are heavily involved in these interactions, since they can sense microorganisms 
through conserved molecular structures, hence acting as the monitoring system for the 
gut microbiota (250). TLRs and nucleotide-binding oligomerization NOD-like receptors 
(NLRs) are two typical PRRs (251). 
1.4.3.1.1 APCs 
There is direct evidence about the critical role gut microbiota plays in the development 
of local APCs in GF animal models. There was no DCs in the diffuse lymphoid tissue of 
the jejunum in GF animals (252). As for macrophages, the results are not conclusive. 
However, they were devoid of any co-expression of MHC class II, thus their role may be 
restricted to mainly phagocytic (252, 253). 
The distinct character of intestinal APCs is to maintain immune homeostasis towards the 
normal resident gut microbiota, while at the same time protecting the body from infection. 
DCs isolated from Peyer's patches are able to produce IL-10 in large amounts, and prime 
T cells to secrete much less IFN-γ, compared to DCs isolated from the spleen (254). Apart 
from DCs, intestinal macrophages also have much less production of the pro-
inflammatory cytokines, even after bacteria phagocytosis (255). This inflammatory 
“anergy” feature is due to NF-kappaB (NF-kB) inactivation (256). Though derived from 
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peripheral blood monocytes, the phenotypic expression and cytokine production of 
intestinal macrophages are completely downregulated even with high phagocytic and 
bacteriocidal activity (257). These macrophages also have impaired or no expression of 
innate response receptors, growth factor receptors, and the integrin LFA-1. In addition, 
production of pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-α, is also 
abolished (257).   
1.4.3.1.2 Innate Lymphoid Cells 
The development of ILCs is independent of the gut microbiota (258). However, gut 
colonization does contribute significantly to the maturation and proper function of ILCs 
(259, 260). ILCs contribute to the local anatomical containment of the gut microbiota via 
IL-22 production (261), since IL-22 receptor is mainly expressed in the epithelial cells of 
the intestine (190). In addition, they also regulate commensal microbiota-specific CD4+ 
T cell responses for immune tolerance (262), specifically ILC3 cells (263).  
1.4.3.2 Gut Microbiota and adaptive immunity 
Apart from their unique function in shaping the innate immune system, the gut microbiota 
also induces B cell differentiation. Most gut-associated B cells are plasma cells and they 
produce large amounts of IgA (264). The number of plasma cells and IgA level were 
significantly reduced in the intestine of GF animal models (265), which could be reversed 
by microbial colonization (266).  
However, the effects of gut microbiota on the differentiation of CD4+ T cells attract most 
attention. In GF mice, the number of CD4+ cells was reduced markedly in the gut (267) 
as well as in the spleen and mesenteric lymph node, together with an imbalance between 
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Th1 and Th2 cells (268). Growing evidence reveals the correlations of specific bacterial 
species with the development of different T cell subsets.  
1.4.3.2.1 Th17 cells 
Th17 cells are a lineage of CD4+ T helper cells expressing RAR-related orphan receptor 
(ROR)γt (269). They are mostly found in the lamina propria of the intestine. The 
microbiota is pivotal for Th17 cell differentiation as demonstrated by GF animal models, 
where the number of Th17 cells is diminished in the lamina propria of the intestine (270). 
Th17 cells control various bacterial and fungal infections at mucosal cells through their 
signature cytokine production, including IL-17A, IL-17F, and IL-22 (271). However, 
they also show significant pathogenic features. Upon stimulation with IL-1β, IL-23, and 
certain types of fatty acids, Th17 cells result in autoimmune diseases through the cross-
reactivity between microbial peptides and self-antigens, or alternatively, microbiota-
specific Th17 cells lowering the activation threshold of auto-reactive T cells after 
migrating into the targeted organs (272). 
1.4.3.2.2 Regulatory T cells 
Among all the above-mentioned cells, Treg cells are the most important cell type for gut 
homeostasis due to their IL-10 production and contribution to the suppression of the 
abnormal activation of other effector cells. The intestine contains thymus-derived 
tTreg cells, peripherally differentiated RORγt- and RORγt+ pTreg cells (272). The gut 
microbiota is indispensable for the development of RORγt+ pTreg cells in the colon, 
especially several species of Bacteroides (273, 274). These cells do not exist in GF animal 
models. On the other hand, RORγt- pTreg cells are induced by dietary antigens in the 
small intestine (275).   
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Short chain fatty acids (SCFAs), which are the end metabolic products from fermentation 
by the gut microbiota, mainly Bacteroidetes, can also promote de novo generation of 
pTreg cells in mice (276-278).  
1.5 Short chain fatty acids 
1.5.1 Production and Absorption 
SCFAs are organic fatty acids with fewer than 6 carbon atoms. They are the major 
bacterial fermentation products in the human intestine (279). They are derived from 
polysaccharide, oligosaccharide, protein, and glycoprotein precursors. However, 
carbohydrates are the most important source for SCFAs production (280, 281). The 
principal SCFAs are acetate (C2), propionate (C3) and butyrate (C4).  Other types of 
SCFAs including formate, valerate, caproate, the branched chain fatty acids isobutyrate, 
2 methyl butyrate and isovalerate are produced in lesser amounts (280). The production 
of SCFAs is highly affected by the host internal environment and gut microbiota. Among 
all the bacterial phylum, Bacteroidetes plays an essential role in the production of SCFAs 
(221, 246). Oligosaccharide prebiotics can also produce acetate, butyrate and propionate 
after digestion resistance in the small intestine and microbial fermentation in the colon 
(279). Since gut microbiota is closely interlinked with diet and its composition can be 
rapidly changed even after a short-term diet shift (refer to section 1.4.2 for detail), the 
production of SCFAs is not steady and the concentration varies significantly.  
SCFAs are water soluble and thereby easily absorbed or transported via carriers (cell 
surface receptors or transporters) into cells, because there are relatively shorter 
hydrophobic chains as well as the hydrophilic carboxyl group in the molecular structure 
(282). The SCFAs are predominantly absorbed by simple passive diffusion, since there is 
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linear absorption under various concentrations and no competition or enhancement of 
absorption when multiple SCFAs were present (283). SCFAs are either be utilized in the 
colon as fuel for epithelial cells or circulated to other organs through the portal vein. 
Changes in the molar ratios of the three principal SCFAs (% of total 
acetate+propionate+butyrate) moving from the colon to portal blood, then to the hepatic 
vein indicated the differential uptake patterns. Butyrate is mainly (70–90%) absorbed by 
the colonic epithelium, whereas propionate is mostly taken up by the liver (279). The ratio 
of the three principle SCFAs (butyrate: propionate: acetate) metabolised by the 
colonocytes is 9:3:5 (284), hence making butyrate the most essential SCFA in colonocyte 
metabolism. 
Total SCFAs concentration was high in the colon, ranging from 131±9 mMol/Kg in the 
caecum to 80±11mMol/Kg in the descending colon, whereas portal vein concentration 
was as high as 375±70 μM/L (279). However, total SCFAs in the peripheral blood 
dropped significantly to 79±22 μM/L. Among the types of SCFAs detected, acetate was 
the principal anion, and it was consistent in all studies that acetate was the main SCFA in 
peripheral blood. Meanwhile, propionate and butyrate concentrations (1–13 and 1-12 μM, 
respectively) were much lower (279). Despite the extremely low concentration already 
observed, Wolever et al. detected propionate and butyrate at a concentration of 4.5–6.6 
μM and 2.0–3.9 μM, respectively (285). Corresponding values recorded by Muir et al. 
were slightly higher at 17.8–32.8 μM and 36.3–65.5 μM in peripheral blood (286). This 
extremely wide range of serum concentrations of butyrate and propionate is mostly due 
to the non-standard collection protocols used across the different studies. In addition, the 
serum levels of SCFAs varied significantly during the day, with a tendency to decrease 
after breakfast and increase transiently after lunch and dinner (285, 286).  
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1.5.2 Receptors and Transporters of SCFAs 
Although SCFAs are predominantly absorbed by simple passive diffusion, they can enter 
cells via Na+/glucose coupled transporter SLC5a8 or by activating the G protein-coupled 
receptors (GPR) on the cell surface to exert their effects (287). 
1.5.2.1 G Protein-Coupled Receptor 41 and 43 
GPR41 and GPR43 belong to a homologous family of orphan G-protein–coupled 
receptors, which are encoded by a single chromosomal locus in both humans and mice 
(288). GPR41 shares 52% similarity and 43% identity with GPR43, and can be activated 
by similar ligands with short chain carboxylic acid anions in a dose-dependent and dose-
specific manner (288). The three principal SCFAs have different affinities towards 
GPR41 and GPR43. The rank order of the agonist activity potency on GPR43 is 
propionate > acetate = butyrate, while for human GPR41, the rank order of potency shows 
notable differences as propionate > butyrate >> acetate (289). 
GPR41 and GPR43 expressions are characterised by a high specificity using TaqMan 
quantitative reverse transcriptase (RT)-PCR. GPR41 mRNA levels were highest in 
human adipose tissue. Much lower expression levels were detected across all other normal 
human tissues, and there was no detection in lymphocytes, monocytes or dendritic cells 
(288, 289). Compared to GPR41, GPR43 expression appeared less widespread and at 
relatively high levels. Polymorphonuclear cells (PMNs), PBMCs, as well as purified 
monocytes,  had relatively more GPR43 mRNA (50-fold greater than that of the whole 
spleen). However, no signals were detected for both GPR41 and GPR43 in lymphocytes 
(288, 289). Furthermore, GPR41 and GPR43 were not expressed at functional levels in 
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bone marrow-derived dendritic cells and cultured CD4+ T cells regardless of SCFAs 
(290). 
GPR41-knockout and GPR43-knockout mice showed slower and reduced immune 
responses against pathogen, indicating the critical role of GPR41 and GPR43 on the 
modulation of host immune responses (291). Various intracellular signalling cascades are 
coupled to these two receptors, including intracellular Ca2+ release, inhibition of cAMP 
accumulation, extracellular signal-regulated kinase (ERK) 1/2 activation and p38 
mitogen-activated protein kinase (MAPK) activation (289). Upon activation, these 
signalling pathways can induce the production of chemokines and cytokines to regulate 
appetite, electrolyte and fluid secretion, and inflammatory responses (287). 
1.5.2.2 G Protein-Coupled Receptor 109a 
GPR109a (encoded by Niacr1), also known as hydroxycarboxylic acid receptor 2 or 
HCA2, is another G-protein–coupled receptor for nicotinate (292). It also recognises 
butyrate with low affinity, since a high concentration of butyrate (millimolar level) is 
required for the activation of GPR109a (293). GPR109a is expressed on the apical 
membrane of intestinal epithelial cells, white and brown adipose tissue as well as immune 
cells, including monocytes, neutrophils, macrophages, dendritic cells and epidermal 
Langerhans cells (293, 294).  
GPR109a signalling favours macrophages and dendritic cells to promote the 
differentiation of Treg cells and IL-10-producing cells, skewing colonic macrophages and 
dendritic cells towards an anti-inflammatory phenotype. Furthermore, GPR109a 
signalling also plays an essential role in IL-18 production in colonic epithelium to 
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suppress inflammation.  Therefore, mice with GPR109a deficiency tend to suffer from 
lethal colitis and colonic inflammation (295).  
1.5.2.3 SLC5A8 
Apart from binding to GPRs, SCFAs can also enter the cells directly with the assistance 
of transporters. The Slc5a8 gene encodes for a Na+/glucose coupled transporter for 
SCFAs. Exposure of this transporter to SCFAs induces inward currents under voltage-
clamp conditions in a Na(+)-dependent manner (296). SLC5a8 is expressed on the lumen-
facing apical membrane of epithelial cells in both small intestine and colon (297). It is 
expressed in T cells as well, albeit at low levels (298).  
SLC5A8 was originally discovered as a tumour suppressor silenced in colon cancer (299). 
A study of Slc5a8−/− mice revealed its effect on immune cells. Although there was no 
difference in the Treg cell compartment in the colon between SLC5a8−/− mice and WT 
mice, butyrate/SLC5a8 could robustly facilitate DCs to suppress the generation of IFN-
γ+ T-cells from naïve T cells (300). The differentiation of DCs was also blocked by 
butyrate/SLC5a8 signalling in vitro (301). 
1.5.3 SCFAs as Histone Deacetylase Inhibitor 
1.5.3.1 Histone Deacetylase 
Two duplicates of each histone protein (H2A, H2B, H3, and H4) form an octamer, 
wrapped with 145–147 base pairs of DNA to form a nucleosome core (302). Histone 
deacetylases (HDACs) are a class of enzymes that remove acetyl moiety of acetyl 
coenzyme A (acetyl-CoA) from a ε-N-acetyl lysine amino acid on the core histones, so 
that the histones can wrap the DNA more tightly. Allfrey et al. discovered this histone 
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modification in the 1960s (303). HDACs are now also called lysine deacetylases 
(KDAC), because it has become clear that they target various protein complexes in 
addition to histones (304). 
In humans, HDACs are classified into four classes according to their structure: class I 
(including HDAC1, HDAC2, HDAC3, HDAC8), class IIa (including HDAC4, HDAC5, 
HDAC7, HDAC9), class IIb (including HDAC6, HDAC10), class III (including SIRT1 
to SIRT7) and class IV (HDAC11) (305).  These HDAC classes have similarities to 
different yeast transcriptional repressors. Class I is homologous to yeast Rpd3 and both 
class II HDACs are more similar to yeast Hda1, whereas HDAC11 shows comparable 
homology to both Rpd3 and Hda1, thus defined as a different group (class IV) (305). 
Analysis of the silent information regulator (SIR) protein in yeast and its homologues in 
higher eukaryotes (SirT 1–7) has unravelled a nicotinamide adenine dinucleotide (NAD+) 
dependent HDAC activity (306),  referred to as class III HDACs. 
1.5.3.2 SCFAs as pan-HDAC Inhibitor 
SCFAs, particular butyrate, were proved to inhibit histone deacetylation in the 1970s. The 
addition of millimolar concentration of butyrate can cause hyperacetylation of H3 and H4 
in various vertebrate cell lines (307, 308). Other SCFAs including acetate, isobutyrate, 
and propionate, also have inhibitory effects of deacetylases in vitro, albeit at different 
efficiencies with butyrate being highest (80%) (309). With the exception of H2A, other 
core histones H2B, H3 and H4 are acetylated at four or five sites; thus a nucleosome has 
potentially 28 or more sites of acetylation (310).  Apart from the increased histone 
acetylation, SCFAs can also decrease repressive histone trimethylation, for example, 
H3K9Me3 and H3K27Me3 (311).  
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The inhibitory effects of SCFAs on the histone deacetylation mainly target class I and 
class II HDACs, but class III SirT1 is also involved (311).  Activated CD4+ T cells have 
higher HDAC activity, and SCFAs (C2, C3 and C4) can effectively suppress the HDAC 
activity in T cells in a dose-dependent manner (290).  
1.5.4 The Mechanisms of SCFAs-mediated Immune Tolerance 
SCFAs have been shown to have profound influences on both the innate and adaptive 
immune systems. Upon production in the GI tract, they are absorbed into the gut 
epithelium cells and exert immune regulatory effects. Figure 1.3 summarises the 
mechanisms involved in the regulation of SCFA-medicated immune tolerance. SCFAs 
exert their regulatory effects via three major ways: GPRs-mediated signalling pathways, 
energy metabolism, and HDAC inhibition. 
1.5.4.1 GPRs-mediated signalling pathway 
After SCFAs bind to the GPR41 and GPR43 on the surface of the gut epithelial cells, 
several intracellular signalling cascades are initiated, including intracellular Ca2+ release, 
inhibition of cAMP accumulation, ERK1/2 activation, and p38 MAPK activation (289). 
Subsequently, downstream transcriptional factors are activated, such as activating 
transcription factor 2 (ATF2) (312). Activation of these intracellular cascades can result 
in the production of inflammatory regulators and chemokines, which play a pivotal role 
in leukocyte recruitment and T cell activation in response to inflammatory stimuli (291). 
IL-18 induction is also increased through butyrate-GPR109a activation, and IL-18 
contributes to the suppression of colonic inflammation and inflammation-associated 
cancers (295). When GPR41 and GPR43 on enteroendocrine cells are activated, the 
induction of glucagon-like peptides (GLP-1 and PYY) is promoted, and these peptides 
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take part in the gut barrier function locally and in the energy metabolism of other organs, 
including adipose tissue, liver and pancreas (313).  
SCFAs can also regulate immune cells via GPRs activation. Neutrophils undergo 
chemotaxis (289, 314) and degranulation (315) in a GPR43-dependent manner. GPR109a 
signalling skews colonic macrophages and dendritic cells towards a tolerogenic 
phenotype to promote the differentiation of Treg cells and IL-10 producing cells (295). 
As for lymphocytes, RT-PCR was unable to detect signals at functional levels for all the 
three types of GPRs (288, 289, 294). Moreover, no significant differences were observed 
in the percentages of IL-10+ T cells, Th17 and Th1 cells in several different organs of 
GPR41-deficient and GPR43-deficient mice (290). Therefore, the role of the GPR-
mediated signalling pathway is dispensable for the SCFA effect on T cells. 
1.5.4.2 Energy Metabolism Regulation 
SCFAs act as the core energy source for the gut epithelial cells, once entering the cells 
via simple diffusion or the Na+/glucose coupled transporter SLC5a8. SCFAs are 
converted to Acetyl-CoA (316), which plays a vital role in energy metabolism. Its main 
function is to facilitate energy production and increase cellular ATP levels by conveying 
the carbon atoms within the acetyl group to the Krebs cycle for oxidization (317).  
In addition to the energy production, SCFAs regulate the differentiation between Teff and 
Treg cell lineage commitment by activating the mTOR pathway (318).  Since mTOR is 
influenced by the intracellular concentration of ATP and mTOR is an ATP sensor itself 
(319), SCFAs also increase both the local IgA and systemic IgG production of B cells via 
energy metabolism regulation. Cellular metabolism (including acetyl-CoA level, lipid 
44 
 
droplets and ATP/ADP ratio) is elevated in B cells to boost mTOR activation and promote 
plasma B cell differentiation and antibody responses (320).  
1.5.4.3 HDAC Inhibition 
HDAC inhibition increases the acetylation of core histones to unwrap DNA and facilitate 
DNA transcription. The acetylation of protein is modified by HDAC inhibition as well to 
prevent proteasome degradation (321).  Therefore, SCFAs can influence a variety of 
genes and proteins in different cells. Whether the SCFA receptors are involved in the 
process of HDAC inhibition is controversial and is dependent on the cell type. SCFAs 
can enter cells directly without binding to the surface receptors of neutrophils to exert 
their inhibitory activity (322). However, in GF mouse models, SCFAs can only restore 
and promote the colonic Treg compartment and function via enhanced histone 
acetylation-dependent on the GPR43 expression (277). 
The major mechanism proposed for the regulatory effect of SCFAs on T cells is HDAC 
inhibition, especially considering the lack of significant levels of GPRs on the T cell 
surface. SCFAs act as a pan-HDAC inhibitor to various intracellular pathways. For 
example, NF-kB, ERK, p70 S6 kinase (S6K, downstream of mTOR pathway) are hyper-
acetylated and initiate downstream effector protein expression (290). It has been 
confirmed both in vivo and in vitro that SCFAs promote the generation of pTregs by 
enhancing histone H3 acetylation at both promoter and CNS3 regions of the Foxp3 gene 
locus and Foxp3 protein via HDAC inhibition (276, 278). In addition, the expressions of 
IL-10, IFN-γ and IL-17 are also elevated in T cells (290). Collectively, these results 
suggest that the HDAC inhibition activity alone is enough to facilitate the SCFAs’ effect 
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on T cells. Apart from Tregs, effector T cells could also be regulated by SCFAs under 
different cytokine milieus (290).   
SCFAs also exert their regulatory effects on macrophages and DCs via HDAC inhibition. 
SCFAs act as HDAC inhibitors to suppress the expression of pro-inflammatory cytokines 
of DCs, thus promoting Treg induction (276). The reduction of NF-kβ transcriptional 
factor contributes to the SCFAs effect on macrophages and DCs (323-325). 
The mechanisms of SCFAs-mediated immune tolerance are summarised in Figure 1.3. 
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Figure 1.3 Summary of mechanisms involved in the regulation of SCFA-medicated 
immune tolerance. 
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1.5.4.4 Butyrate Induced Apoptosis 
Compared to other types of SCFAs, butyrate has a unique growth suppression function 
and apoptotic character (293, 298, 322, 326, 327). Butyrate exhibited much lower EC50 
value in the resazurin reduction assay, which is a cell viability assay. This effect of 
butyrate on cell proliferation is dose-dependent and HDAC mRNAs are downregulated 
(327). In comparison, the EC50 values were unable to be determined for acetate and 
propionate due to their low cytotoxicity (326).  
In T cells, the apoptosis induced by butyrate is via HDAC inhibition and is Fas-mediated, 
since Fas promoter hyperacetylation and Fas upregulation were induced by butyrate 
mediated HDAC1 inhibition (298). Butyrate-induced apoptosis of neutrophils is also 
likely related to the HDAC inhibition activity irrespective of GPRs (322). In colon cancer 
cells, butyrate triggers re-expression of GPR109a and induce apoptosis. However, the 
inhibition of histone deacetylation does not take part in this apoptosis via GPR109a 
activation in colon cancer cells (293). It is the downregulation of Bcl-2, Bcl-xL, and 
cyclin D1 and the upregulation of the death receptor pathway involved in the primary 
changes in this apoptotic process.   
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1.6 Aims and Hypotheses 
1.6.1 Aims 
The aims of this PhD thesis are to address in detail the human Treg cell physiology, from 
in utero stages to adult life, and investigate the exact role of SCFAs in human Treg cell 
differentiation. 
a) To provide evidence on Treg cell transplacental programming, and how IL-10 and 
SCFAs contribute to this process; 
b) To test whether SCFAs could skew different human T lymphocyte subsets, 
especially Treg cells, towards tolerogenic phenotypes in vitro; 
c) To investigate how SCFAs alter the histone acetylation of genes involved in 
immune tolerance applying ChIP-qPCR; 
d) To investigate the effects of SCFAs on the tolerogenic potential of MoDCs in 
vitro. 
1.6.2 Hypotheses 
1.6.2.1 Treg cell programming in utero and during early life 
a) Microbiota metabolites (acetate), rather than genetics, are pivotal in the 
transplacental programming for fetal thymus and T cell development in utero 
b) Treg cell ontogeny early in life: IL-2 enhances gut homing potential of 
human naïve Treg cells during early life 
c) Soluble immunomodulatory IL-10 contributes to transplacental Treg cell 
programming via potentiating Treg cell induction 
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1.6.2.2 Short chain fatty acids exert a tolerogenic effect on human lymphocytes in 
vitro by histone acetylation of genes associated with immune tolerance 
a) There are differential induction patterns in the generation of human Tregs 
between cord blood and adult peripheral blood cells in vitro via SCFAs 
b) Butyrate and propionate, but not acetate, potentiate the expression of 
phenotypic markers of human TGF-β–induced Tregs in vitro 
c) Butyrate and propionate, but not acetate, enhance the suppressive capacity 
of human TGF-β–induced Tregs in vitro 
d) Butyrate and propionate augment iTreg cell phenotype and function 
through Histone deacetylation inhibition  
e) SCFAs also have tolerogenic effects on other T cell subsets 
1.6.2.3 Short chain fatty acids induce human tolerogenic MoDCs in vitro 
a) SCFAs skew human monocyte-derived dendritic cells towards tolerogenic 
phenotype in vitro 
b) The proliferation of naïve CD4+ T cells was influenced by SCFA-treated 
monocyte-derived dendritic cells 
c) CD4+ T cells cocultured with SCFA-treated monocyte-derived dendritic 
cells had enhanced suppressive capacity  
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Chapter 2 – Materials and Methods  
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2.1 Materials 
2.1.1 Patients and subjects 
All research was conducted according to ethically approved protocols. Research 
conducted at Nepean Hospital was reviewed and approved by the Human Research Ethics 
Committee (HREC) of Nepean Blue Mountains Local Health District according to the 
Declaration of Helsinki. Various cohorts of donors were recruited on a volunteer basis. 
All volunteers were informed of the study and signed a written consent prior to donating 
blood.  
For IL-10 potentiates differentiation of human induced regulatory T cells: peripheral 
blood was obtained from healthy volunteers (n=20). 
For in vitro Treg induction, a total of 23 samples, including 13 healthy adults and 10 cord 
blood samples from healthy pregnancies, were recruited from 09/2015 to 07/2016.   
For MoDC phenotyping and functional assay, a total of 14 peripheral blood samples were 
collected from healthy adults from 08/2016 to 08/2017. 
For PBMC culture, a total of 7 peripheral blood samples were collected from healthy 
adults from 11/2016 to 02/2017. 
All subjects with a history of atopy, autoimmunity or concurrent infections were 
excluded. Indications for all pregnant women undergoing Caesarean Sections (C.S.) 
include repeated C.S., malpresentation or other non-medical issues. Women with 
gestational diabetes, chorioamnionitis, placenta praevia, chronic villitis or twin 
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pregnancies were excluded. Detailed characteristics of adult participants and newborns 
are summarised in Table 2-1 and 2-2 separately. 
Table 2-1 Characteristics of Adult Participants. 
Study Numbers of Participants Gender (N) Age (Mean±SD) 
in vitro Treg induction 13 
Male (9) 27.1±6.6 
Female (4) 34.3±4.8 
MoDC phenotyping 8 
Male (3) 23.7±0.6 
Female (5) 29.6±5.8 
MoDC functional assay 6 
Male (2) 24.0±1.4 
Female (4) 37.0±9.3 
PBMC culture 7 
Male (2) 27.7±11.6  
Female (4) 30.5±11.4 
 
Table 2-2 Characteristics of Newborns 
Numbers of 
Participants 
Newborn 
Gender (N) 
Maternal 
Age 
(Mean±SD) 
Gestational 
Week 
(Mean±SD) 
Parity 
(Mean±SD) 
Birth Weight 
(g) (Mean±SD) 
12 
Male (8) 28.1±5.7 38.6±1.3 2.4±0.9 3665.0±514.6 
Female (4) 32.3±4.5 39.3±0.1 2.3±0.5 3398.8±363.6 
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2.1.2 Blood collection and PBMC isolation 
❖ Lithium heparinised vacuum tubes (BD Biosciences, USA) 
❖ Ficoll-Paque Plus (GE Healthcare, Sweden) 
❖ Phosphate buffered saline (PBS; pH 7.4; Sigma-Aldrich, USA) 
❖ Trypan blue (0.4% stock; Life Technologies, USA) 
2.1.3 Cell culture media 
❖ RPMI 1640 medium (Life Technologies, USA) supplemented with: 
o 2mM Glutamax (Sigma-Aldrich, USA) 
o 100U/mL Penicillin (Sigma-Aldrich, USA) 
o 100ug/mL Streptomycin (Sigma-Aldrich, USA) 
❖ 10% Fetal Calf Serum (FCS) (Life Technologies, USA) 
❖ 1% HEPES (Life Technologies, USA) 
2.1.4 Other reagents for cell culture and functional assay 
Table 2-3 Reagents used for cell culture 
Products 
Concentration 
(for culture) 
Manu-
facturer 
Catalogue 
Number 
Application 
CD14 MicroBeads, 
human 
  Miltenyi 
130-050-
201 
Cell Isolation 
CD4+CD25+ Regulato
ry T Cell Isolation Kit, 
human 
  Miltenyi 
130-091-
301 
Cell Isolation 
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Products 
Concentration 
(for culture) 
Manu-
facturer 
Catalogue 
Number 
Application 
Treg Suppression 
Inspector, human 
  Miltenyi 
130-092-
909 
Functional 
Assay 
LEAF™ Purified anti-
human CD3, OKT3 
10 ug/ml  Bio-Legend 317304 Stimulation 
LEAF™ Purified anti-
human CD28, CD28.2 
2 ug/ml  Bio-Legend 302914 Co-stimulation 
Human GM-CSF, 
premium grade 
50 ng/ml Miltenyi 
130-093-
865 
Cell Culture 
Human IL-4, premium 
grade 
50 ng/ml Miltenyi 
130-093-
921 
Cell Culture 
Lipopolysaccharides 100 ng/ml 
Sigma-
Aldrich 
62326 Cell Culture 
Human IL-2 IS, 
premium grade 
50 U/ml Miltenyi 
130-097-
745 
Cell Culture 
Recombinant Human 
TGF-β1 
5 ng/ml Pepro-Tech 100-21 Cell Culture 
Sodium Acetate* 1000 uMol 
Sigma-
Aldrich 
S5636-
250G 
Cell Culture 
Sodium Butyrate* 500 uMol 
Sigma-
Aldrich 
B5887-
250MG 
Cell Culture 
Sodium Propionate* 1000 uMol 
Sigma-
Aldrich 
P5436-
100G 
Cell Culture 
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* Purchased in powder, then dissolved in sterile PBS according to the final concentration.  
2.1.5 Antibodies for flow cytometry 
The flow cytometer used was BD FACSverse. A maximum of 8 different fluorochromes 
was used at any one time. The fluorochromes used include: FITC or equivalent (Alexa 
Fluor 488), PE, PerCP-Cy5.5 or equivalent (PerCP efluor710/PerCP Vio700), PE-Cy7 or 
equivalent (PE-Vio770), APC, APC-Cy7 or equivalent (APC-H7), V450 or equivalent 
(Pacific Blue / eFluor450), and V500 or equivalent (BV510 / Fixable Aqua Dead Cell 
Stain). The antibodies used in this thesis are listed in Table 2. 
Table 2-4 Antibodies (against human antigens) and proteins used for flow cytometry.  
Abs 
Fluoro-
chrome 
Clone Isotype 
Manufact
urer 
Catalo-
gue No. 
Appli-
cation 
CD1a eFluor® 450 HI149 Ms IgG1, k 
eBio-
science 
48-0019-
42 
FC 
CD3 APC-H7 SK7 Ms IgG1, κ BD 560176 FC 
CD4 BV510 SK3 Ms IgG1, κ BD 562970 FC 
CD4 
PerCP-
Vio700 
REA623 
recombinant 
human IgG1 
Miltenyi 
130-109-
455 
FC 
CD8 BV510 SK1 Ms IgG1, κ BD 563919 FC 
CD11c PE-Cy7 3.9 Ms IgG1, k 
eBio-
science 
25-0116-
42 
FC 
CD14 APC-H7 MφP9 Ms IgG2b, κ BD 560180 FC 
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Abs 
Fluoro-
chrome 
Clone Isotype 
Manufact
urer 
Catalo-
gue No. 
Appli-
cation 
CD14 FITC REA599 
recombinant 
human IgG1 
Miltenyi 
130-110-
518 
FC 
CD25 APC 2A3 Ms IgG1, κ BD 340939 FC 
CD39 APC 
MZ18-
23C8 
Ms IgG1, κ Miltenyi 
130-093-
504 
FC 
CD45RO 
PerCP-
Vio700 
UCHL1 Ms IgG2a, κ Miltenyi 
130-097-
590 
FC 
CD80 
(B7-1) 
PerCP-
eFluor™ 710 
2D10.4 Ms IgG1, k 
eBio-
science 
46-0809-
42 
FC 
CD83 PE HB15e Ms IgG1, κ 
Bio-
legend 
305308 FC 
CD86 APC 2331 Ms IgG1, κ BD 555660 FC 
CD127 FITC 
HIL-7R-
M21 
Ms IgG1, κ BD 560549 FC 
CD127 
(IL-7Rα) 
PE A019D5 Ms IgG1, κ 
Bio-
legend 
351304 FC 
CD152 
(CTLA-4) 
APC L3D10  Ms IgG1, κ 
Bio-
legend 
349908 ICFC 
CD197 
(CCR7) 
PerCP-
eFluor™ 710 
3D12 Rat IgG2a, k 
eBio-
science 
46-1979-
42 
ICFC 
CD209 
(DC-Sign) 
FITC DCN46 Ms IgG2b, κ BD 551264 FC 
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Abs 
Fluoro-
chrome 
Clone Isotype 
Manufact
urer 
Catalo-
gue No. 
Appli-
cation 
CD274 
(PD-L1 / 
B7-H1) 
PE/Cy7 29E.2A3 Ms IgG2b, κ 
Bio-
legend 
329718 FC 
CD278 
(ICOS) 
VioBlue REA192 
Recombinant 
human IgG1 
Miltenyi 
130-100-
737 
FC 
CD279 
(PD-1) 
APC/Cy7 
EH12.2H7
  
Ms IgG1, κ 
Bio-
legend 
329922 FC 
CD284 
(TLR-4) 
APC HTA125 Ms / IgG2a, k 
eBio-
science 
17-9917-
42 
FC 
CD357 
(GITR) 
PE DT5D3 Ms IgG1, κ Miltenyi 
130-092-
895 
FC 
CXCL-9 
(MIG) 
PE J1015E10 Ms IgG2a, κ 
Bio-
legend 
357904 ICFC 
Foxp3 
Alexa Fluor® 
488 
259D Ms IgG1, κ 
Bio-
legend 
320212 ICFC 
HLA-DR 
Pacific 
Blue™ 
L243 Ms IgG2a, κ 
Bio-
legend 
307633 FC 
IFN 
gamma 
PE 4S.B3 Ms IgG1, k 
eBio-
science 
12-7319-
82 
ICFC 
IL-10 eFluor® 450 JES3-9D7 Rat IgG1, k 
eBio-
science 
48-7108-
42 
ICFC 
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Abs 
Fluoro-
chrome 
Clone Isotype 
Manufact
urer 
Catalo-
gue No. 
Appli-
cation 
IL-12 
(p35/p70) 
PE-Vio770 REA121 
recombinant 
human IgG1 
Miltenyi 
130-103-
677 
ICFC 
IL-12/IL-
23 p40 
Alexa Fluor® 
488 
C11.5 Ms IgG1, κ 
Bio-
legend 
501816 ICFC 
IL-4 APC 8D4-8 Ms IgG1, κ 
Bio-
Legend 
500714 ICFC 
IL-6 PE/Cy7 
MQ2-
13A5 
Rat IgG1, κ 
Bio-
legend 
501120 ICFC 
LAP 
(TGF-β1) 
APC TW4-2F8 Ms IgG1, κ 
Bio-
legend 
349608 FC 
TNF-α PerCP/Cy5.5 MAb11 Ms IgG1, κ 
Bio-
legend 
502926 ICFC 
LIVE/DEAD™ Fixable Aqua Dead Cell Stain Kit Invitrogen L34966 FC 
2.1.6 Buffers and reagents used for flow cytometry  
FACS buffer:  
❖ PBS (pH 7.4; Sigma-Aldrich, USA) 
❖ 0.1% FCS (Life Technologies, USA) 
❖ 0.02% Sodium azide (Sigma-Aldrich, USA) 
4% p-formaldehyde buffer 
❖ 4 g p-Formaldehyde (Sigma-Aldrich, USA) 
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❖ 100 mL PBS (pH 7.4; Sigma-Aldrich, USA) 
0.15% Saponin-PBS buffer 
❖ PBS (pH 7.4; Sigma-Aldrich, USA) 
❖ 0.5% FCS (Life Technologies, USA) 
❖ 0.02% Sodium azide (Sigma-Aldrich, USA) 
❖ Saponin (5% w/v stock, Sigma-Aldrich, USA) 
Table 2-5 Other reagents used for flow cytometry.  
Buffers/Reagents Manufacturer Catalogue No. Application 
BD GolgiStop™ BD 554724 Protein Transport 
Inhibitor 
BD™ CompBeads          
(Anti-Mouse Ig, κ) 
BD 552843 FC 
True-Nuclear™ Transcription 
Factor Buffer Set 
BioLegend 424401 ICFC 
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2.2 Methods 
2.2.1 Mononuclear Cell Isolation 
Blood samples from recruited women were drawn via venepuncture. For pregnant 
women, blood samples were drawn within 4 hours prior to caesarean section. Cord blood 
was collected via sterile aspiration of umbilical vein from the delivered placenta of 
recruited healthy pregnant women. All blood samples were processed within 2 hours of 
collection. Plasma was separated from the 1.5ml of collected blood via centrifugation, 
then stored at -800C.  
Human mononuclear cells were isolated from peripheral blood by Ficoll-Paque density 
gradient centrifugation. Blood collected in heparinised vacuum tubes was diluted in a 1:1 
ratio with sterile PBS. This mixture was carefully layered over Ficoll-Paque Plus in a 2:1 
ratio before centrifugation at 1700rpm for 30 minutes, without brake. The layer 
containing mononuclear cells was carefully aspirated and washed twice in PBS with 0.5% 
FCS at 1300rpm for 8 minutes. The mononuclear cells were then resuspended in PBS 
containing 0.5% FCS. Cells were stained using Trypan blue for counting. Cells were 
either used immediately for cell culture or processed for cell sorting.  
Protocols were summarized in Figure 2.4.  
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2.2.2 Enrichment of Specific Cell Populations 
2.2.2.1 Cell Enrichment by Magnetic Beads 
Three different magnetic bead selections were performed for various purposes: 
a) Enrichment of CD4+ T prior to cell sorting: CD4+ T cell Isolation Kit (Miltenyi) 
b) Generation of MoDCs: CD14 MicroBeads (Miltenyi) 
c) Preparing responder cells for suppression assay: CD4+CD25+ Regulatory T Cell 
Isolation Kit (Miltenyi) 
d) Enrichment of CD25high induced Treg cells for suppression assay: CD25 
MicroBeads from the CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi) 
The brief steps for the magnetic bead selection are as follows: 
a) Determine cell numbers and resuspend cells in 90 µL buffer per 10⁷ total cells 
b) Add 10µL CD4+ T Cell Biotin-Antibody Cocktail (labelling non-CD4+ cells) per 
10⁷ total cells, and incubate for 15 minutes in the fridge 
c) Add 20µL anti-Biotin MicroBeads per 10⁷ cells, and incubate for an additional 10 
minutes in the fridge 
d) Place LS Column in the magnetic field of a suitable MACS Separator and rinse 
with 3 ml buffer 
e) Apply cell suspension onto the column and wash three times. Collect flow-
through containing unlabelled CD4+ cells (negative selection for CD4+ cells). 
f) For monocytes, CD14+ cells are labelled for positive selection. Apply cell 
suspension onto the column and wash three times. Then the column needs to be 
removed from the separator and placed on a suitable collection tube. Pipette buffer 
onto the column, then immediately flush out the magnetically labelled cells by 
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firmly pushing the plunger into the column. To increase the purity of monocytes 
(≥90%), the eluted fraction is enriched over a second column. 
g) For responder cell preparation, repeat the labelling and magnetic separation 
process for CD25 Microbeads. Collect flow-through containing unlabelled 
CD4+CD25- cells. 
h) For enrichment of CD25high induced Treg cells, CD25 Microbeads are used and it 
is also a positive selection (refer to CD14 selection for detail). To increase the 
purity (≥95%), the eluted fraction is enriched over a second column.  
An example of purity of CD14+ and CD25+ bead-selected cells is shown below. 
 
Figure 2.1 Flow cytometry pseudocolour plots showing CD14 (left) and CD25 (right) 
purity after bead selection.    
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2.2.2.2 Cell Enrichment by FACS Sorting 
Dr Brigitte Nanan and I performed the flow cytometric sorting of lymphocytes. Freshly 
isolated cells were surface stained with the appropriate fluorochrome-conjugated 
antibody, including FITC-anti-CD127, PerCp-eFluor710-anti-CD45RO, BDV500-anti-
CD4, and APC-anti-CD25. Cells were sorted on a BD FACSAriaTM cell sorter (Westmead 
Millennium Institute) using the appropriate gating strategy. The pre-enriched CD4+ T 
cells are further sorted for either CD4+CD45RO-CD25-CD127hi for Treg induction, or 
CD4+CD45RO- cells for coculturing with MoDCs. Sorted cell populations had purities of 
≥ 97.5%. An example of purity of sorted cells is shown in Figure 2.2. 
 
Figure 2.2 Flow cytometry density plots showing the purity of FACS sorted cells. 
Flow cytometry density plots showing the purity of FACS sorted non-Treg cells from 
adult PBMCs (left), non-Treg cells from Cord Blood (middle), and naive CD4+ cells from 
adult PBMCs (right). Gating for non-Treg cells is based on the surface stain combination 
of CD25 and CD127, since intracellular stain with Foxp3 would render cells nonviable, 
preventing any further in vitro experiments. 
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2.2.3 In vitro Cultures 
2.2.3.1 In vitro Human Regulatory T Cell Induction Protocol 
FACS sorted naïve non-Treg cells of both adult and cord blood origins (CD4+CD45RO-
CD25-CD127hi, >99% purity) were cultured in cell culture medium (RPMI-1640 
containing 2mM L-Glutamine, 100U/ml penicillin, 100μg/ml streptomycin plus 10% 
FCS) in 48 well plates, with immobilised anti-CD3 (OKT3, 10µg/ml, coated overnight in 
PBS at 4°C) and mobilised anti-CD28 (2µg/ml). Cells were cultured at a concentration of 
3.5-5 x 105/48 well at 37°C for 5 days under standard culture condition (37°C with pH 
7.4 at a CO2 concentration of 5% and humidity 85-95%). Recombinant human IL-2 
(50U/ml), TGF-β (5ng/ml) and in selected cultures, sodium acetate (1000µMol), sodium 
butyrate (500µMol) or sodium propionate (1000µMol) were added on day 0 and day 3. 
On day 5, cells were harvested for phenotypic or further functional studies. The 
concentration of SCFAs was chosen based on the immune cell viability.  
For ChIP study: CD4+ cells generated from adult naive non-Tregs were harvest on day 3, 
while CD4+ cells generated from cord blood were harvest on day 1 and day 3 respectively. 
Cells were frozen and kept in the liquid nitrogen for later ChIP analysis. 
Restimulation for flow cytometric analysis: For certain gene expressions (such as CD39, 
GITR, and ICOS), iTreg cells needed to be restimulated with anti-CD3 (OKT3, 4µg/ml) 
for 3.5 hours at 37oC. Afterwards, cells were harvested and stained for flow cytometry as 
described in section 2.2.4. 
Protocols were summarized in Figure 2.5 and Figure 2.6.  
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2.2.3.2 Suppression Assay 
Carboxyfluorescein succinimidyl ester (CFSE) is a membrane permeable, fluorescent 
small molecule binding covalently to intracellular molecules (328). The concentration of 
CFSE is diluted in each subsequent cell division, therefore it can be used to trace cell 
proliferation. Responder cells were washed (1300rpm, 8mins) three times in RPMI-1640 
in the absence of FCS at room temperature (RT). T cells were then incubated with 0.5µM 
CFSE at 37oC for 7 minutes in the dark. The addition of 200μL of FCS could terminate 
the reaction. Afterwards, cells were washed 3 times with RPMI-1640 with FCS. Non-
CFSE labelled induced T cells and CFSE-labelled allogeneic responder cells were 
cultured at a ratio of between 1:1 to 1:16 and stimulated with Treg Suppression Inspector 
(cell: bead ratio is 1:1, Miltenyi) in 96 U-bottom plates. Cells were cultured in medium 
for 3 days under standard culture condition and subsequently harvested for flow 
cytometry. The percentage of suppression was determined as the difference in the 
proliferation between negative control and the test sample, expressed as a percentage of 
the former. An example of suppression assay with negative control is shown in Figure 
2.3.  
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Figure 2.3 Representative flow cytometry analysis for suppression assay. 
Lymphocytes (left) were selected and CFSE-labelled responder cells (middle) were gated 
separately from non-labelled cells (induced T cells). Histogram (lower panel) shows 
reduced proliferation of suppressed responder cells by induced T cells, compared to 
histogram (upper panel) showing the normal proliferation of responder cell alone.   
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2.2.3.3 Monocyte-Derived Dendritic Dell Induction 
CD14+ monocytes were isolated from the PBMCs of healthy donors using CD14 
MicroBeads (Miltenyi), and purity of > 90% was routinely achieved by additional column 
selection. 5 x 105 monocytes were plated in each well of a 48 well plate with cell culture 
medium under standard culture conditions. GM-CSF (50ng/ml), IL-4 (50ng/ml), and in 
selected cultures, sodium acetate (1000µMol), sodium butyrate (500µMol) or sodium 
propionate (1000µMol) were added to the culture medium on day 0, 3 and 5. 50% of the 
culture medium plus additives was also replaced on day 3 and 5. On day 6, LPS 
(100ng/ml, Sigma-Aldrich) was added to selected cultures to induce maturation of 
MoDCs 24 hours prior to harvesting. On day 7, cultured cells were harvested and washed 
for flow cytometric analysis or later used for coculture experiments. Immature MoDCs 
without adding LPS were adherent. Therefore, they were harvested vigorously three times 
with PBS. Protocols were summarized in Figure 2.7. 
2.2.3.4 Naïve CD4+ T cells Proliferation via MoDCs 
After being harvested on day 7, MoDCs were pulsed with anti-CD3 (OKT3, 2µg/ml) at 
37°C for 3 hours. Then MoDCs were washed extensively with PBS three times to remove 
any excessive anti-CD3. Afterwards, MoDCs were added to the FACS sorted autologous 
naïve CD4+ cells (CD4+CD45RO-, >99% purity) in 48 well plates at a ratio of 1:4-5 
(MoDCs: naïve CD4+ cells). Naive CD4+ cells (4-5x105/well), together with autologous 
MoDCs (1x105/well) were cocultured for 5 days under standard culture condition 
supplemented with recombinant human IL-2 (50U/ml). On day 5, cells were harvested 
for flow cytometry or further functional studies. Protocols were summarized in Figure 
2.8. 
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2.2.3.5 PBMC culture with SCFAs 
Freshly isolated PBMCs at a concentration of 1 x 106/48 well were cultured in RPMI-
1640 plus 10% FCS under standard culture condition for 5 days, in the presence of 
immobilised anti-CD3 (OKT3, 2µg/ml, coated overnight in PBS at 4°C). Recombinant 
human IL-2 (100U/ml), and in selected cultures, sodium acetate (1000µMol), sodium 
butyrate (500µMol) or sodium propionate (1000µMol) were added on day 0 and day 3. 
On day 5, cells were harvested for flow cytometry analyses.  Protocols were summarized 
in Figure 2.9. 
2.2.3.6 PBMC culture with IL-2 
Thawed adult PBMCs or CBMCs at a concentration of 1 x 106/48 well were cultured in 
RPMI-1640 plus 10% FCS under standard culture condition for 72 hours in the presence 
or absence of recombinant human IL-2 (100U/ml, eBioscience). On day 3, cells were 
harvested for flow cytometry analyses.  
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2.2.4 Flow Cytometry 
Flow cytometric analyses using BD FACSVerse were applied to all the cultured cells, 
including iTregs, MoDCs and proliferated CD4+ cells.  
2.2.4.1 Dead Cell Stain 
LIVE/DEAD™ Fixable Aqua Dead Cell Stain Kit was used to determine the viability of 
all the cultured cells prior to the fixation and permeabilization required for intracellular 
antibody staining. The brief steps for the stain are as follows: 
a) Cultured cells were harvested into polystyrene round-bottom 12x75mm BD 
Falcon tubes. 
b) Cells were washed (centrifugation at 1600rpm, 4mins) twice with PBS and the 
cell concentration was adjusted to 1x106 cells/ml with PBS. 
c) 1µl/ml of the reconstituted fluorescent dye was added to the cell suspension, 
which was then incubated at RT for 30 min (protected from light). 
d) Cells were washed again in PBS before proceeding with surface staining as 
described in section 2.2.4.2. 
2.2.4.2 Surface Stain (FC) 
The brief steps for surface stain are as follows: 
a) Cells were washed and resuspended in 50µl FACS buffer. 
b) A cocktail of the titrated concentration of fluorochrome-conjugated antibodies 
was then added to the cell suspension. 
c) After mixing, cells were incubated for 20 min at 4°C in the dark.  
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d) Cells were washed once with FACS buffer after incubation, then proceeded to 
intracellular stain.  
e) If no intracellular stain was needed, cells were fixed with 4% p-Formaldehyde for 
20 minutes at RT in the dark, washed once with FACS buffer and resuspended in 
200µl cold FACS buffer. Cells were kept on ice or at 4°C in the dark until 
acquisition for the flow cytometer. 
2.2.4.3 Intracellular Stain (ICFC) 
Two types of fixation and permeabilization buffer, thus different staining protocols were 
used for intracellular staining.  
For intracellular staining of Foxp3 and CTLA-4 staining for iTregs and proliferated CD4+ 
cells: True-Nuclear™ Transcription Factor Buffer Set was used. The brief steps are as 
follows: 
a) 1mL of the True-Nuclear™ 1X Fix Concentrate was added to each tube, and cell 
mixture was incubated at RT in the dark for 50 minutes.  
b) 2mL of the True-Nuclear™ 1X Perm Buffer was added to each tube for washing. 
c) Repeated the washing once with 2mL of the True-Nuclear™ 1X Perm Buffer. 
d) The cell pellet was resuspended in 50µL of the True-Nuclear™ 1X Perm Buffer 
after discarding the supernatant. 
e) A cocktail of the titrated concentration of fluorochrome-conjugated antibodies 
was added into cell suspension (Dilution was made in True-Nuclear™ 1X Perm 
Buffer), which was then incubated for 30 min at RT in the dark. 
f) After incubation, cells were washed once with 2mL of the True-Nuclear™ 1X 
Perm Buffer, and once with FACS buffer. 
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g) Cells were finally resuspended in 200µl cold FACS buffer and kept on ice or at 
4°C in the dark until acquisition in the flow cytometer. 
Intracellular cytokine labelling for MoDCs: 0.67µl/ml protein transport inhibitor 
(monesin, BD GolgiStop™) was added no longer than 12 hours before flow cytometric 
analyses. 4% p-Formaldehyde buffer and 0.15% Saponin-PBS buffer were used instead 
of the True-Nuclear™ Transcription Factor Buffer Set. Otherwise, the protocol was the 
same. 
2.2.4.4 Multicolour flow cytometry panel design 
The panel design is important in multicolour flow cytometry to minimize spectral overlap. 
Compensation was achieved on the BD FACSVerse using pre-designed matrixes. A 
compensation matrix was constructed using the corresponding combination of antibody 
labelled Compensation Beads (BD™ CompBeads). An isotype control was included to 
account for non-specific staining. The panels used in this thesis are listed in the following 
tables. 
Table 2-6 Staining panel for Treg ontogeny 
 FITC PE PE-
Cy7 
PerCp-
Cy5.5 
APC APC-
Cy7 
V450 V500 
Phenotype-1 Foxp3 7  CD45RA CLA CD3 CD127 CD4 
*Used for Section 3.3.4 
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Table 2-7 Staining panel for iTregs and proliferated CD4+ cells 
 FITC PE PE-
Cy7 
PerCp-
Cy5.5 
APC APC-
Cy7 
V450 V500 
Phenotype-1 Foxp3 CD127 PD-L1 CD4 CTLA-4 PD-1 
HLA-
DR 
Live/
Dead 
Phenotype-2 
(after 
restimulation) 
Foxp3 GITR  CD4 CD39  ICOS 
Live/
Dead 
*Used for Section 4.3.2 and Section 5.3.2  
Table 2-8 Staining panel for MoDCs 
 FITC PE PE-
Cy7 
PerCp-
Cy5.5 
APC APC-
Cy7 
V450 V500 
Phenotype-1 DCsign CD83 CD11c CD80 CD86 CD14 
HLA-
DR 
Live/
Dead 
Phenotype-2 CD14  PD-L1 CCR7 TLR4 PD-1 CD1a 
Live/
Dead 
Cytokine-1 
IL-12/ 
IL-23 
CXCL9 IL-12 TNF-α TGF-b CD14 IL-10 
Live/
Dead 
Cytokine-2   IL-6   CD14  
Live/
Dead 
*Used for Section 5.3.1 
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Table 2-9 Staining panels for PBMCs 
 FITC PE PE-
Cy7 
PerCp-
Cy5.5 
APC APC-
Cy7 
V450 V500 
Phenotype-1 Foxp3 CD8 PD-L1 CD4 CTLA-4 PD-1 CD127 
Live/
Dead 
Phenotype-2 
(after 
restimulation) 
Foxp3 GITR CD8 CD4 CD39 CD14 ICOS 
Live/
Dead 
*Used for Section 6.3  
2.2.4.5 Analysis of Flow Cytometry Results 
Acquired samples (FCS files) were analysed on FlowJo Version10 (Treestar, San Carlos, 
CA). Consistent gating strategies were used for all samples in the same set of experiments. 
An isotype control was included to help with the gating. Mean Fluorescence Intensity 
(MFI) was calculated using the geometric mean on FlowJo.  
74 
 
2.2.5 Summary of the protocols 
The protocols used in this thesis are summarised in flow charts. 
 
Figure 2.4 Flow chart for cell preparation. 
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Figure 2.5 In vitro Human Treg cell induction protocol 
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Figure 2.6 Summary of analyses for iTregs after induction 
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Figure 2.7 In vitro Human MoDCs induction protocol 
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Figure 2.8 Summary of analyses for MoDCs after induction 
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Figure 2.9 Protocol for PBMCs culture and analyses 
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2.2.6 ChIP Study 
T-cell chromatin isolation, ChIP, and quantitative assessment of H3 or H4 histone 
acetylation by polymerase chain reaction (PCR) were conducted as established and 
thoroughly validated before (329). PCR primers used in the present study are given in 
Table S-1. Intra- and inter-assay coefficients of variation calculated for percent 
enrichment should not exceed 10% (329). All samples were processed according to the 
same standardized protocol and analysed blinded and in a randomized order. 
The enrichment was calculated using the following formula: % enrichment = 100 × 2[(CT 
input - 3.3) - CT sample]. The percent enrichment of the negative control (IgG) was subtracted 
from this value and then normalized to the RPL32 housekeeping gene (HKG). The 
advantage of the application of an HKG measurement method is that the same ChIP 
samples are used to analyse both sequences of interest and control sequences, eliminating 
variation caused by sample handling. The normalization was done according to the 
following formula: normalized enrichment to desired gene = % enrichment to desired 
gene/% enrichment to HKG.  
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2.2.7 Statistical Analyses 
Statistical analyses were performed on GraphPad, Prism 7 (La Jolla, CA, USA) or IBM 
SPSS v26 (USA). All the data were not normally distributed due to the small sample size. 
Therefore, for comparisons among two or more groups, Mann-Whitney test or Friedman 
test with Dunn’s multiple comparison test (post hoc) were used to determine statistical 
significance. For the suppression assay with multiple variables, two-way ANOVA with 
Tukey’s multiple comparison test (post hoc) was used. Spearman’s correlation coefficient 
was used for correlation studies. For all analyses, a p value of less than 0.05 was deemed 
statistically significant. Consultations were made with a statistician at all stages of the 
thesis. 
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Chapter 3 – Treg Cell Programming during Early 
Life  
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3.1 Introduction 
The theory of Developmental Origins of Health and Disease (DOHaD) was originally 
postulated by Barker and Osmond in 1984 (213). Since then, numerous investigations 
proved that fetal organs and systems during this sensitive period of development 
experience programmed structural or functional changes according to the intrauterine 
environment alterations, leading to various diseases later in adulthood (214).  
There are growing numbers of studies in human suggesting that the DOHaD theory also 
applies to the inflammatory and immune diseases (215-217). Collectively, these findings 
provide evidence that appropriate stimulation to the maternal immune system in utero 
may educate and shape the fetal immune system (209, 216, 218-222). For the purpose of 
this thesis, special attention will be focused on T cells, especially Treg cell programming. 
Fetal and adult T cells are differentiated from different HSCs (210). Upon stimulation 
with maternal alloantigens, fetal T cells differentiate into Tregs in the fetal thymus, and 
these Tregs are specific for NIMAs (226). They migrate from the thymus to peripheral 
lymphoid organs from the 10th gestational week (223, 224). There is an increased 
proportion of Treg cells in the fetus during mid-gestation (210), around 15-20% of total 
CD4+ T cells (225), significantly higher than in newborns and adults. At the fetal-maternal 
interface, Foxp3+ Treg cell percentage is also higher compared to peripheral blood, and 
half of them are generated locally in the decidua, and are not of thymic origin (330). These 
changes in Treg cell compartment prove that fetal immune system is prone to differentiate 
into either tTregs or pTregs in response to stimulation to maintain a tolerogenic status.   
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Our group previously made a surprising discovery (209) that there was a specific and 
significant correlation of Treg cells (but not Th1, Th2 or Th17 cells) between maternal-
fetal dyads (pairs). The possibility of maternal Treg cells migrating to the fetus could be 
excluded by HLA typing of the fetal Treg cell population. However, this correlation didn’t 
exist in the paternal fetal dyads, indicating that transplacental factors rather than the 
genetics cause this alignment. Gene microarray analysis suggested that IL-10 pathway 
may play a role and it was confirmed by the specific alignment of serum IL-10 at the 
protein level. The mechanism of how IL-10 contributes to the Treg generation will be 
explained in detail later (refer to section 3.3.3).  
In addition to anti-inflammatory cytokine IL-10, various other environmental factors, 
such as pregnancy-related hormones or microbiota metabolites, also contribute to the 
transplacental programming of Treg cells (331). The offspring of C57BL/6 pregnant mice 
fed with high fibre diet had increased levels of serum SCFAs until day 22 after birth, and 
these offspring also had a higher percentage of Treg cells accordingly (332). Moreover, 
the concentration of SCFAs was much lower or undetectable, and there were no 
Bacteroidetes (essential for the SCFAs production (246)) in the gut contents of offspring 
at day 1 after birth, thus indicating SCFAs derived from the maternal gut were transferred 
to the fetus throughout pregnancy.   
Apart from in utero stage, the programming or ontogeny of Treg cells happens after birth 
as well (333). Early exposure to environmental factors could increase the prevalence of 
allergies and IBD (334-336) via the modulation of Treg cells. The skin homing marker 
Cutaneous Lymphocyte Antigen (CLA) is expressed on the majority of adult Treg cells 
(337), whereas in cord blood there is a higher proportion of gut-homing 47 integrin 
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(made of 4 and 7 subunits) expressing Treg cells (338); thus suggesting age-related 
differences in Treg cell homing molecule expression.  
Therefore, three aspects are explored in detail in this chapter: a) Thymus and Treg cell 
programming in utero, b) postnatal Treg cell ontogeny, and c) how IL-10 contributes to 
the generation of iTregs.  
This chapter is a summary of collaborative works about T cell (especially Treg cell) 
programming during pregnancy and infancy. Some of these results are unpublished 
except for section 3.3.3 (1) and section 3.3.4 (2). A detailed list of contributions made by 
myself and our collaborators will be provided at the beginning of each section. 
3.2 Subjects 
3.2.1 Fetal Thymus and Treg Cell Development 
GF and SPF C57BL/6 mice were used for this section. Some of the pregnant GF mice 
were fed at libitum with sodium acetate (200 mM) provided in the drinking water. Mouse 
thymic analyses were performed from two to three separated cohorts of pups to obtain 
reproducibility.  
For serum acetate levels, forty-six maternal peripheral blood samples were collected, and 
cord blood samples were collected within 4 hours following maternal blood sampling. All 
babies were born by caesarean section at term. 
3.2.2 Unique TCR Repertoires in Cord Blood  
Five term healthy pregnant women from Nepean Hospital (Sydney, NSW, Australia) 
were included in this study with a mean age of 31.1±10.1 years. All babies were born by 
86 
 
caesarean section at a gestational age of 39.0±6 days with a mean weight of 3,546±189 
grams. Paired paternal partners were also included with a mean age of 35.8±3.77. Patients 
with diabetes, infectious conditions, chromosomal abnormalities, and/or morphological 
anomalies were excluded. 
3.2.3 IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells 
Peripheral blood was obtained from healthy volunteers (n=20). 
3.2.4 Treg cell ontogeny during early life 
Peripheral blood was obtained from healthy infants and children aged 0-16 years (n=50) 
undergoing general anaesthetic for elective surgery. Blood samples were collected at the 
time of cannulation prior to surgical procedures.  
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3.3 Results 
3.3.1 Fetal Thymus and Treg Cell Development 
Table 3-1 List of contributions for Section 3.3.1 
 Affiliation 
Sample 
Collection 
and 
Processing 
Serum 
Acetate 
Quantif
ication 
Animal 
Experiment 
Data 
Analysis 
Manuscript 
Preparation 
Eliana Marino   
Moreno 
Monash 
University   √ √ √ 
Fiona Collier, 
Peter Vuilleman 
Deakin 
University  √   √ 
Myself University 
of Sydney √   √ √ 
It has been proven that bacterial metabolites influence T cells, particularly Treg cell 
development. Additionally, maternal supplementation of acetate protected offspring 
against the development of food allergy through modulation of Treg and dendritic cells 
(339). Animal experiments by our collaborators showed that maternal bacterial load could 
affect fetal thymic development and Treg cell differentiation (unpublished data).  
The fetal thymic weights of fetuses born to GF or SPF mice were measured at 3 weeks. 
The fetal thymic weight in GF mice was significantly lower (around half) compared to 
SPF mice (Figure 3.1A). Most importantly, the reduction of fetal thymic weight could be 
completely rescued by supplementing acetate in drinking water to maternal GF mice, and 
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the final thymic weight became comparable to SPF mice. In addition, there was also a 
significant reduction in the total thymic CD4+ T cells numbers (Figure 3.1B), total thymic 
Foxp3+ Treg cell numbers (Figure 3.1C) and the Foxp3 protein expression per cell in Treg 
cells (Figure 3.1D) in GF mice. Interesting, they could also be rescued by acetate 
supplementation until comparable levels of SPF mice, though the increase in the total 
Treg cell numbers of GF ADW group was not significant. Lastly, in a separate cohort of 
paired maternal and fetal serum (collected no longer than 4 hours apart), we noticed a 
significant correlation (Spearman’s test, r=0.4158 and p=0.004) between cord blood and 
maternal blood acetate levels (Figure 3.2), consistent with transplacental acetate transfer. 
Collectively these results indicate that metabolites, such as acetate, is pivotal in the 
transplacental programming for fetal thymus and Treg cell development.  
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Figure 3.1 Impaired Thymus and Treg Cell Development in GF Mice can be Rescued 
by Maternal Acetate Consumption. 
Cumulative data showing thymus’s analyses from pooled female and male C57/Bl6 mice 
at 3 weeks-old born from SPF mothers and GF mothers treated with normal drinking water 
(Ctrl) or acetate (ADW) as indicated (n=7-11 per group). Summary dot plot showing (A) 
the thymus weight, (B) total thymic lymphocytes, (C) total thymic CD4+ T cell number, 
(D) total Foxp3+ Treg cell numbers, and (E) MFI of Foxp3 expression per cell on a per-
cell basis in thymic CD4+Foxp3+ T cells. Data were analysed by one-way ANOVA with 
Bonferroni’s multiple comparisons test. Each data set represents two to three independent 
experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (Figure adapted from our 
manuscript.) 
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Figure 3.2 Correlation of serum acetate levels between paired maternal peripheral 
blood and cord blood. 
Scattered dot plot showing the relative serum acetate levels in paired term maternal 
peripheral blood and cord blood (n=44). The acetate levels were based on peak heights 
from the NMR spectra normalized to the total intensity. Spearman's rank correlation was 
used. Coefficient r and p values as indicated. (Figure adapted from our manuscript.)  
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3.3.2 Unique TCR Repertoires in Cord Blood 
Table 3-2 List of contributions for Section 3.3.2  
 Affiliation 
Sample 
Collection 
and 
Processing 
TCR 
repertoire 
sequencing 
Data 
Analysis 
Manuscript 
Preparation 
Thomas Watkins, 
John Miles 
James 
Cook 
University 
 √ √ √ 
Myself University 
of Sydney √   √ 
Together with our collaborators from James Cook University, we also examined the TCR 
repertoire in family sets (maternal blood-MB, paternal blood-PB, and cord blood-CB) to 
investigate about TCR repertoire inheritance (unpublished data).  
In general, TCR sharing between patients and offspring and between anatomical sites 
were infrequent and of low abundance, typically <0.5% of the repertoire. Strikingly, it 
was apparent that the highest degree of TCR repertoire sharing across all T cell subsets 
was between genetically unrelated newborns rather than between parent-newborn dyads 
(Figure 3.3). The TCR sharing between MB and CB was very low, and the frequency was 
similar between CB and PB for all T cell subsets, including memory CD8+ T cells (Figure 
3.3A), memory CD4+ T cells (Figure 3.3B), naïve CD8+ T cells (Figure 3.3C), and naïve 
CD4+ T cells (Figure 3.3D). In contrast, sharing between unrelated CBs was significantly 
higher in all T cell subsets, especially for memory CD4+ T cells (Figure 3.3B) and naïve 
92 
 
CD8+ T cells (Figure 3.3C). To confirm this unusual observation of the high degree of 
sharing (>10% within the top 50 clonotypes) in the memory CD4+ T cells of CB, we 
analysed three unrelated CB sets (Figure 3.3E). Across sets, we observed similar patterns 
with an average of 10.3% ± 1.2% sharing within the top 50 clonotypes. The antigen 
specificity and function of this high frequency shared memory clonotypes in neonates are 
unknown.  
We next determined the transcriptional profiles of T cell subsets across MB, PB and CB. 
Transcriptomic comparisons of both naïve CD8+ T cells (Figure 3.4A) and CD4+ T cells 
(Figure 3.4B) showed the least degree of variation compared to memory CD8+ T cells 
(Figure 3.4C) and CD4+ T cells (Figure 3.4D). The CB genes were almost uniformly 
downregulated when compared to MB except for a few genes, including the chemokine 
receptor CCR4 and the transcription factor IRF4.  
Collectively, the TCR sharing and transcriptomic data showed that neonates are born with 
TCR repertoire and T cell phenotype that resemble more closely to unrelated neonates 
compared with parents, indicating again that the environmental cues rather than genetics 
play a role in the transplacental T cell programming.  
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Figure 3.3 TCR repertoires sharing across T cell subsets. 
Percentage overlap of memory CD8+ T cells (A), memory CD4+ T cells (B), naïve CD8+ 
T cells (C) and naïve CD4+ T cells (D) by descending clonotype abundance across paired 
MB, PB and DT samples and unrelated CB sample. (E) Percentage overlap in memory 
CD4+ T cells between unrelated CB samples by descending clonotype abundance. (Figure 
adapted from our manuscript.) 
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Figure 3.4  Heatmap of differentially expressed genes between MB and CB. 
Heatmap of differentially expressed genes between MB and CB memory CD8+ T cells 
(A), memory CD4+ T cells (B), naïve CD8+ T cells (C) and naïve CD4+ T cells (D) with 
a paired t-test p value less than 0.05. Row normalization ((expression value - mean) / SD) 
was performed out for each gene. Colour gradient spans highest (yellow) to lowest (blue) 
gene expression. (Figure adapted from our manuscript.)    
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3.3.3 IL-10 potentiates differentiation of human induced regulatory T cells 
Table 3-3 List of contributions for Section 3.3.3 
 Affiliation 
Sample 
Collection 
and 
Processing 
In vitro 
Experi
ment 
Flow 
Cytometry 
Data 
Analysis 
Manuscript 
Preparation 
Brigitte 
Nanan 
Sydney Medical 
School Nepean √ √ √ √ √ 
Peter Hsu The Children’s 
Hospital at 
Westmead 
√   √ √ 
Myself University of 
Sydney  √ √  √ 
To examine the role of IL-10 and IL-6 in human iTreg cell induction, we stimulated FACS 
sorted naïve CD4+CD45RO-CD25-CD127hi T cells (>97% purity) with anti-CD3/anti-
CD28 in the presence of IL-2 and TGF- with or without IL-10 for 5 days then rested the 
cells in the presence of IL-2 for 2 days. There was a modest but significant increase in the 
percentage of Foxp3+ T cells in cultures treated with IL-10 (Figure 3.5A, B), associated 
with significantly enhanced Foxp3 (Figure 3.5C) and CTLA-4 (Figure 3.5D) expression, 
as assessed by mean fluorescence intensity. This was also confirmed on the mRNA level. 
We further show that IL-10 (and to a lesser extent IL-6) treated Foxp3+ T cells secreted 
significantly less IFN corresponding to reduced IFN on the mRNA level (Figure 3.5 
E&F).  These results indicate that IL-10 enhances the phenotype of iTreg cells.  
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We next tested the suppressive function of cultured cells in vitro. IL-10 treated iTreg cells 
suppressed the in vitro proliferation of autologous CD4+CD25- cells significantly more 
than non-IL-10 treated iTreg cells. This was true at all suppressor: responder cell ratios 
(Figure 3.6A, B) and was highly statistically significant (Figure 3.6C). The suppressive 
capability of those IL-10 treated iTreg cells was comparable to that of FACS sorted 
CD4+CD25+CD127lo natural Treg cells isolated from the same donor and 
stimulated/rested in vitro for the same period (Figure 3.6B). In stark contrast, IL-6 
significantly reduced the suppressive function of TGF--induced iTreg cells (Figure 3.6). 
Overall, these results demonstrate that in contrast to IL-6, IL-10 present at the time of 
iTreg cell induction, augments the suppressive function of iTreg cells.  
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Figure 3.5 IL-10 potentiates human TGF--induced iTreg cells.  
(A) Representative contour plots gated on live CD3+CD4+ T cells showing % Foxp3+ 
cells induced after culture under various conditions: Ctrl (IL-2+TGFβ), IL-10 (IL-
2+TGFβ+IL-10) and IL-6 (IL-2+TGFβ+IL-6) compared to isotype control. (B) Summary 
bar graphs showing mean and SEM of % Foxp3 induced under various conditions as 
indicated (10 independent experiments. *p<0.05, ***p<0.001). Foxp3 (C) and CTLA-4 
(D) expression of live CD3+CD4+ T cells cultured under various conditions, as shown by 
representative histogram (left panel), summary bar graph of MFI (10 independent 
experiments. *p<0.05, **p<0.01) (middle panel) and mRNA expression as fold change 
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relative to Ctrl (5 independent experiments. *p<0.05) (right panel). (E) Representative 
contour plots showing % IFNγ secreting cells within live CD3+CD4+Foxp3+ T cells 
induced under various conditions and summarized by bar graph (6 independent 
experiments. *p<0.05, **p<0.01) and confirmed by mRNA expression (F) relative to 
Ctrl. (Figure adapted from (1).) 
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Figure 3.6 IL-10 enhances the suppressive capacity of human TGF--induced iTreg 
cells 
(A) Representative histograms (at suppressor: responder ratio of 1:4) showing 
proliferation of CFSE-labelled responder cells alone (shaded) or co-cultured with Ctrl, 
IL-10 and IL-6 treated iTreg cells. (B) Percentage suppression of nTreg cells (dotted line) 
and iTreg cells (coloured line) cultured under various suppressor: responder ratio and 
various conditions as labelled. Percentage suppression was calculated as (proliferation of 
T responder alone – the proliferation of co-cultured T responder) / proliferation of T 
responder alone x 100. Data show at least 5 independent experiments in each group. (C) 
Statistical analysis of the suppressive capacity of nTreg cells (grey) and iTreg cells 
(coloured) cultured under various conditions as indicated. ANOVA testing for variance 
between groups at each suppressor: responder ratio is indicated by F and p values. Data 
show at least 5 independent experiments in each group. Stars indicate significant p values 
compared to the Ctrl group based on a student’s t-test (*p<0.05, ** p<0.01, ***p<0.001). 
(Figure adapted from (1).)  
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3.3.4 Treg Cell Ontogeny during Early Life 
Table 3-4 List of contributions for Section 3.2 
 Affiliation 
Sample 
Collection 
and 
Processing 
In vitro 
Experi
ment 
Flow 
Cytometry 
Data 
Analysis 
Manuscript 
Preparation 
Catherine Lai The Children’s 
Hospital at 
Westmead 
√ √ √ √ √ 
Peter Hsu The Children’s 
Hospital at 
Westmead 
   √ √ 
Myself University of 
Sydney √ √ √ √ √ 
Apart from in utero stage, the programming or ontogeny of Treg cells happens after birth 
as well (333). We first examined the Treg cell ontogeny in terms of three different subsets 
in healthy children of varying ages. We found that the proportion of CD45RA+Foxp3low 
resting Treg cells (rTreg) within CD4+ T cells slowly decreases with age, whereas the 
proportion of CD45RA-Foxp3hi activated Treg cells (aTreg) and CD45RA-Foxp3low 
activated Tconv cells (aTconv) increase with age (Figure 3.7). This is consistent with age-
related antigen encounter/activation.  
We next The skin homing marker cutaneous lymphocyte antigen (CLA) is expressed on 
the majority of adult Treg cells (337), whereas there is a higher proportion of gut-homing 
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47 integrin (made of 4 and 7 subunits) expressing Treg cells in cord blood (338); 
thus suggesting age-related differences in the Treg cell homing molecule expression. 
Therefore, we examined the gut and skin tropism of peripheral blood Treg cells. We used 
7 integrin as a surrogate marker for gut tropism since almost all 7+ T cells (>99%) are 
also 4+. CLA was used as a marker of skin tropism. Circulating 7+ gut homing Treg 
cells (as a proportion of total circulating CD4+ T cells) were most abundant early in life 
and decreased with age (Figure 3.8A, B). As a comparison, we next examined skin 
homing Treg cells and found they were almost absent in cord blood and increased with 
age (Figure 3.8A, B). We also examined Th2 cells using CRTH2, a well-accepted surface 
marker for human Th2 cells (340). We then calculated the gut and skin Treg: Th2 ratio 
by dividing the percentage of gut and skin homing Treg cells with Th2 cells. Here we 
found that both gut homing and skin homing Treg: Th2 ratios were highest in the first 25 
months of life and reduced rapidly with age. In particular, the gut homing Treg: Th2 ratio 
was higher than the skin homing Treg: Th2 ratio early on but equalised later in life (Figure 
3.8C). Overall, the gut homing Treg: Th2 ratio was higher compared to the skin Treg: 
Th2 ratio (Figure 3.8D). This suggests that the gut homing peripheral T cell population 
may be more primed towards tolerance acquisition compared to skin-homing T cells, 
especially early in life. 
A higher proportion of 7+ Treg cells were also positive for both CD45RA and CD31 (a 
marker for recent thymic emigrants) (341), compared to CLA+ Treg cells (Figure 3.9A, 
B). We then examined the expression of 7 integrin in the thymus. CD3+ thymocytes 
were gated based on their expression of CD4 and CD8 (Figure 3.9C). Within the 
CD4+Foxp3+ cells, approximately 10% of the cells expressed 7 integrin, whereas in the 
CD4+Foxp3- cells, only about 5% of the cells expressed 7 integrin (Figure 3.9C), 
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compared to the peripheral blood where 60-80% of cord blood Treg and Tconv express 
7. This result was confirmed by immunohistochemistry, where there was minimal 
staining of 7 integrin in the fetal thymus (Figure 3.9D). Collectively, these results 
suggest that Treg cells likely acquire gut tropism early in their development. However, 
the induction of 7 expression most likely occurs post-thymic emigration, where they 
encounter the microbiota metabolites SCFAs.  
 
 
Figure 3.7  Age-dependent changes in Treg cell subsets in children.  
CD4+Foxp3+ cells are subdivided into 3 subsets, CD45RA+Foxp3low resting Treg (rTreg), 
CD45RA-Foxp3hi activated Treg (aTreg) and CD45RA-Foxp3low activated conventional 
T cells (aTconv), with their respective age-related change in percentage within CD4+ 
cells. (Figure adapted from (2).)  
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Figure 3.8  Age-related changes in gut and skin homing Treg and Th2 cells in 
children.  
(A) Representative flow plots showing distinct patterns of gut and skin homing expression 
of Treg cells in cord blood and adult blood. (B) Age-related change in the percentage of 
gut and skin homing Treg cells within CD4 cells. (C) Age-related changes in gut and skin 
homing Treg: Th2 ratio. (D) Direct comparison of gut and skin homing Treg/Th2 ratio. 
(Figure adapted from (2).)  
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Figure 3.9 Phenotype of gut and skin homing Treg cells. 
(A) Representative plot showing the percentage of CD45RA+CD31+ cells within gut and 
skin homing Treg cells in a healthy child. (B) Comparison of CD45RA+CD31+ cell 
percentage within gut and skin homing Treg cells. (C) Representative flow plot showing 
7 expression of CD4+Foxp3+ and CD4+Foxp3- cells gated from live CD3+ thymocytes 
(data representative of two samples). (D) Immunohistochemistry showing 7 integrin 
(pink) and Foxp3 (brown) staining in the human fetal thymus. (Figure adapted from (2).)  
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3.4 Discussion 
Many factors may potentially affect the fetal immune development in utero. Previously 
we showed that IL-10 may be involved in the fetal-maternal alignment of Treg cells (209). 
In addition to the anti-inflammatory cytokine IL-10, various other environmental cues, 
especially microbiota metabolites, SCFAs, also contribute to the transplacental 
programming of Treg cells (331, 342). Therefore, we aim to test whether maternal 
microbial composition influences fetal thymus and immune development. In the mouse 
model, we showed that absence of maternal gut microbiome leads to reduced fetal thymus 
size, fewer thymic CD4+ T cells and Foxp3+ Treg cells. Supplementation of acetate in 
maternal drinking water, which is the most abundant SCFA in human serum (279), could 
rescue all the reduction in thymus size and thymic output. These results are also consistent 
with the fetal-maternal correlation of serum acetate levels we found in human pregnancy 
and implies that maternal acetate likely crosses the placenta. Collectively, we conclude 
that maternally acquired acetate plays important roles in shaping fetal thymic 
development and output, hence exerting its influences on fetal immunity. 
The TCR repertoires in neonates showed no bias toward either maternal or paternal 
repertoires. TCR overlap was minimal and comparative when overlaying either maternal 
or paternal datasets of memory and naïve T cells. The most surprising observation of the 
study was the level of TCR sharing between genetically unrelated neonates. 
Approximately 1-in-50 clonotypes were shared when analysing the most abundant 
clonotypes in the memory CD8+ T cell compartment and naïve CD4+ and CD8+ T 
compartments. Collectively, these results suggest that antigen receptor immunity is not 
“inherited”, but driven by other factors, such as environmental cues. 
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Given that IL-10 and SCFAs contribute to the transplacental programming of Treg cells, 
we aim to prove that IL-10 and SCFAs (refer to Chapter 4) could potentiate the generation 
of human Treg cells. IL-10 exerts its immunosuppressive actions at multiple levels of the 
immune system, including modulation of APCs and inhibition of innate immunity (343, 
344), inhibition of T cell proliferation (345, 346), and maintenance of the function and 
stability of established Treg cells (347, 348). The results presented here extend the role 
of IL-10 and demonstrate that in addition to TGF-, IL-10 augments iTreg cell 
differentiation and function. One of the unresolved issues arising from our study is 
whether IL-10 signalling in naïve CD4+ T cells is important for pTreg cell differentiation 
in vivo. Nevertheless, our current results prove that in humans, in addition to TGF-, IL-
10 could promote Treg cell generation, which explains the mechanisms of transplacental 
programming of Treg cells via IL-10 in utero, where immune tolerance is dominant.     
Tissue homing of T cells is an important aspect of immune function and regulation (349). 
The results of this chapter suggest that human naïve Treg and Tconv cells may be primed 
in early life for gut tropism, which reinforces the important role of early gut microbial 
colonization in shaping the developing immune system. Interestingly, 7 integrin was 
expressed largely by naïve rTreg cells and the proportion of 7+ Treg cells inversely 
correlated with age, suggesting that Treg cells acquired gut tropism early in life. 
Consistent with this, notable but variable proportion of peripheral blood 7+ Treg cells 
were CD31+ recent thymic emigrants (RTE), which is consistent with animal data where 
murine thymocytes acquired gut homing molecules at the RTE stage, although this study 
did not examine Treg cells specifically (350). Furthermore, only a small proportion of 
human CD4+Foxp3+ thymocytes expressed 7 integrin. A previous study suggested that 
murine RTEs undergo further progressive development in secondary lymphoid organs to 
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become “mature” naïve T cells (351). Following on from this, it seems likely that human 
naïve Treg cells also likely acquire their gut homing molecules outside the thymus, where 
they encounter environmental cues, such as SCFAs. 
In summary, our results provide another evidence of Treg cell transplacental 
programming in utero and postnatally. Moreover, we also explain in detail how the 
environmental factors (IL-10 and acetate) contribute to this progress.   
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Chapter 4 – Short Chain Fatty Acids Augment the 
Differentiation and Function of Human Induced 
Regulatory T Cells via Histone Deacetylation 
Inhibition  
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4.1 Introduction 
As discussed in the previous chapter, it is known that in addition to IL-10, SCFAs also 
play an essential role in the transplacental programming of Treg cells. In the animal 
models, it has already been proven that SCFAs contribute greatly to the pTreg induction 
in vivo, as well as iTreg induction in vitro (276-278, 331). SCFAs regulate the 
differentiation between effector and regulatory T cell lineage commitment by increasing 
the cellular ATP levels, thus activating the mTOR pathway (318). However, the major 
mechanism proposed for the regulatory effect of SCFAs on T cells is HDAC inhibition. 
SCFAs, especially butyrate, promote the generation of Treg cells by enhancing histone 
H3 acetylation at both promoter and CNS3 regions of the Foxp3 gene locus and the Foxp3 
protein via HDAC inhibition (276, 278). With their significant role in Treg cell 
generation, SCFAs have an integral contribution to immune tolerance and the protection 
against various diseases, including asthma (229-231), allergies (110, 230), inflammatory 
bowel disease (334-336), and Type 1 diabetes (352). 
Despite their profound effects on the Treg cells in mice, there is very limited evidence of 
the effects of SCFAs in humans, both in vivo or in vitro. To date, there has been only one 
publication on the generation of human Treg cells in vitro via SCFAs (acetate was not 
tested). Unfortunately, mouse findings were not reproducible in humans (353). Butyrate, 
but not propionate, did enhance the Foxp3 expression when cultured together with TGF-
β and IL-2. However, iTregs treated with butyrate had nearly no TSDR demethylation 
and showed no in vitro suppressive capacity. The addition of butyrate also increased the 
production of pro-inflammatory cytokine INF-γ.  
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In addition, there is still no agreement regarding the markers for human iTreg cells. Foxp3 
is a surrogate transcriptional marker for tTregs. However, growing evidence suggests that 
in humans, some CD4+ and CD8+ T cells can transiently up-regulate Foxp3 expression 
upon in vitro stimulation without acquiring Treg cell suppressive activities (60, 61). In 
addition, there is also a CD4+Foxp3+ subpopulation in human peripheral blood with no 
suppressive activity, which even produces pro-inflammatory IL-17 upon activation (354). 
Thus, the Foxp3 expression is normal following T cell activation, thus not a specific 
marker for human iTregs in vitro. Apart from Foxp3, various markers have been proposed 
to define human iTreg cells, including CTLA-4, CD127, HLA-DR, PD-1, PD-L1, CD39, 
GITR and ICOS (Refer to Section 1.2.1.6 for more details).  
Therefore, the aims of this chapter are to: a) compare the induction patterns of CBMCs 
and adult PBMCs; b) explore the precise role of SCFAs (including sodium acetate, 
butyrate and propionate) in human Treg cell induction, c) investigate the mechanism of 
SCFAs-mediated Treg induction, and d) identify the potential phenotypic marker for 
human iTregs.  
4.2 Subjects 
To determine the effect of SCFAs on Treg cell differentiation from naïve non-Treg cells, 
in addition to as adult PBMCs, CBMCs were also used in the study, since they are the 
perfect model for in utero transplacental programming. Immune cells from cord blood 
have a much more pronounced “naive” compartment, which have not been exposed to 
large amounts of antigens from outer environments, except for intrauterine stimuli.  
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In total 16 healthy adult volunteers and 12 healthy term pregnant women were recruited 
after informed consent was obtained. Cord blood samples were collected immediately 
after elective caesarean section from the umbilical vein. Individuals with any history of 
autoimmune diseases or allergies were excluded. 
4.3 Results 
4.3.1 Differential Induction Patterns in the Generation of Human Tregs in vitro 
via SCFAs 
In order to compare the iTreg cell induction patterns of CBMCs and adult PBMCs, FACS 
sorted naïve non-Treg cells (CD4+CD45RO-CD25-CD127hi) from both CBMCs and adult 
PBMCs were stimulated with anti-CD3/anti-CD28 in the presence of IL-2 and TGF-β, 
with or without SCFAs for 5 days (Section 2.2.3.1).   
Induction patterns differed between CBMCs and adult PBMCs in terms of their activation 
status. Naïve non-Tregs from adult PBMCs were unable to fully differentiate into Treg 
cells (Figure 4.1A, B). Gated on viable cells, there was a significant population of cells 
with smaller size and lack of the CD25 expression (Figure 4.1A), representing non-
activated cells. Activated cells, as opposed to non-activated cells, were much bigger in 
size and expressed a high level of CD25. The percentage of activated cells varied 
significantly across the study population and under different culture conditions (Figure 
4.1B). In particular, iTregs treated with butyrate had the smallest proportion of activated 
cells, roughly half of the proportion of other types of iTregs. In contrast, nearly all the 
naïve non-Tregs from CBMCs differentiated into Treg cells (Figure 4.1C).  
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Figure 4.1 Differential induction patterns in the generation of human Tregs in vitro 
via SCFAs. 
(A) Flow cytometric gating strategy for activated cells gated on viable cells after Treg 
induction from adult naive CD4+ cells. (B) Summary box and whisker graph showing 
Mean and SEM of the percentage of activated cells after induction from adult naive CD4+ 
cells under various conditions as indicated (13 independent experiments). (C) Flow 
cytometric gating strategy for activated cells gated on viable cells after Treg induction 
from CB naive CD4+ cells. *p < 0.05, **p < 0.01. 
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4.3.2 Butyrate and Propionate, but not Acetate, Potentiate the Expression of 
Phenotypic Markers of Human TGF-β–induced Tregs in vitro 
To determine the precise role of SCFAs (including sodium acetate, butyrate and 
propionate) in human Treg cell induction, FACS sorted naïve non-Treg cells 
(CD4+CD45RO-CD25-CD127hi) were stimulated with anti-CD3/anti-CD28 in the 
presence of IL-2 and TGF-β, with or without SCFAs for 5 days (Section 2.2.3.1).   
There were obvious differences between non-activated cells and activated cells generated 
from adult PBMCs in terms of the expression levels of various phenotypic markers, an 
example shown in flow cytometric gating strategy (Figure 4.2). The expressions of all the 
phenotypic markers tested were significantly different between non-activated and 
activated cells under various culture conditions (Figure 4.3), except for PD-L1 and 
CD127 expressions in control and acetate treated iTregs. Activated cells had a much 
higher expression of Foxp3, HLA-DR, CD39, GITR, ICOS, PD-1 and CTLA-4; whereas 
CD127 was the only marker being down-regulated after activation. The flow cytometric 
gating strategy for iTregs generated from CBMCs (Figure 4.4) showed a similar pattern 
as activated iTreg cells from adult PBMCs. 
Due to the significantly higher percentage of non-activated cells, butyrate-treated iTregs 
from adult PBMCs had the least Foxp3 expression and highest CD127 expression 
compared to other iTregs. The expression levels of Foxp3 and CD127 were similar among 
groups when analysing only the activated cells (Figure 4.5B and Figure 4.6B), as well as 
iTregs cells generated from CBMCs (Figure 4.5C and Figure 4.6C), except that butyrate-
treated iTregs from CBMCs had higher CD127 expression. 
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As for CD39 (Figure 4.7), GITR (Figure 4.8), ICOS (Figure 4.9), and PD-L1 expressions 
(Figure 4.10), the trend was the same for both activated iTregs from adult PBMCs and 
iTregs from CBMCs. Butyrate-treated iTregs had the highest expression for these four 
markers, followed by propionate-treated iTregs, though not always at statistically 
significant levels. The expression levels of these markers of iTregs treated with acetate 
were either the same or slightly higher compared to control. 
Butyrate/Propionate-treated iTregs generated from CBMCs had higher expression of PD-
1 than acetate-treated or control iTreg (Figure 4.11C). However, this trend was not seen 
in iTregs from adult PBMCs (Figure 4.11B). There were no significant differences in the 
expressions of CTLA-4 (Figure 4.12) and HLA-DR (Figure 4.13) across all groups. 
These results suggested that a) Foxp3 is an activation marker for human iTregs; b) GITR, 
ICOS, CD39, PD-1 and PD-L1 are potential candidate markers for human iTregs; c) 
Butyrate and propionate, but not acetate, potentiate the expression of phenotypic markers 
of human TGF-β induced Treg cells in vitro. 
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Figure 4.2 Flow cytometric gating strategy for the phenotypic markers of iTreg 
generated from adult naive CD4+ cells. 
(A) Flow cytometric gating strategy for lymphocytes, single cells, viable cells, CD4+ 
cells, non-activated and activated iTregs generated from adult naive CD4+ cells. (B) The 
representative dot plots showing the percentage of Foxp3, HLA-DR, and CD39 gated on 
either non-activated (left panels) or activated (right panels) iTreg cells. (C) The 
representative dot plots showing GITR, ICOS, PD-1, PD-L1, CTLA-4 and CD127 
expression patterns on either non-activated (left panels) or activated (right panels) iTreg 
cells. 
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Figure 4.3 Enhanced expression of phenotypic markers in activated cells generated 
from adult naive CD4+ cells. 
Summary box and whisker graphs showing %Foxp3+, %HLA-DR+, %CD39+, and MFI 
of GITR, ICOS, PD-1, PD-L1, CTLA-4 and CD127 gated on non-activated cells (Non-
A) and activated cells (A) generated from adult naive CD4+ cells under various 
conditions. All cells were cultured in the presence of IL-2, TGF-β and additional with: 
control (black), acetate (red), butyrate (blue), and propionate (green). Data are from 13 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.  
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Figure 4.4 Flow cytometric gating strategy for various phenotypic markers of iTreg 
generated from Cord Blood. 
(A) Flow cytometric gating strategy for lymphocytes, single cells, viable cells, and CD4+ 
iTregs. (B) The representative dot plots showing the percentage of Foxp3, HLA-DR, and 
CD39 gated on iTreg cells generated from CB naive CD4+ cells. (C) The representative 
dot plots showing GITR, ICOS, PD-1, PD-L1, CTLA-4 and CD127 expression patterns.  
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Figure 4.5 The effect of SCFAs on the Foxp3 expression of human iTregs. 
(A) Representative dot plots showing percentage of Foxp3+ cells gated on adult whole 
iTregs (top panel), adult activated iTregs (middle panel) and CB iTregs (bottom panel) 
generated under various conditions. All cells were cultured in the presence of IL-2, TGF-
β and additional with: control (black), acetate (red), butyrate (blue), and propionate 
(green). (B) Summary box and whisker graphs showing %Foxp3+ gated on whole iTregs 
(left panel) and only activated cells (right panel) from adult naive CD4+ cells (n=13). (C) 
Summary box and whisker graphs showing %Foxp3+ of iTregs from CB naive CD4+ cells 
(n=12). *p < 0.05, **p < 0.01, ***p < 0.001.  
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Figure 4.6 The effect of SCFAs on the CD127 expression of human iTregs. 
(A) Representative histogram showing MFI CD127 of adult whole iTregs (left panel), 
adult activated iTregs (middle panel) and CB iTregs (right panel) generated under various 
conditions. All cells were cultured in the presence of IL-2, TGF-β and additional with: 
control (black), acetate (red), butyrate (blue), and propionate (green). (B) Summary box 
and whisker graphs showing MFI CD127 of whole iTregs (left panel) and only activated 
cells (right panel) from adult naive CD4+ cells (n=9). (C) Summary box and whisker 
graphs showing MFI CD127 of iTregs from CB naive CD4+ cells (n=10). ***p < 0.001.  
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Figure 4.7 The effect of SCFAs on the CD39 expression of human iTregs. 
 (A) Representative histogram showing the percentage of CD39+ cells gated on adult 
whole iTregs (top panel), adult activated iTregs (middle panel) and CB iTregs (bottom 
panel) generated under various conditions. All cells were cultured in the presence of IL-
2, TGF-β and additional with: control (black), acetate (red), butyrate (blue), and 
propionate (green). (B) Summary box and whisker graphs showing %CD39+ gated on 
whole iTregs (left panel) and only activated cells (right panel) from adult naive CD4+ 
cells (n=7). (C) Summary box and whisker graphs showing %CD39+ of iTregs from CB 
naive CD4+ cells (n=10). *p < 0.05, **p < 0.01.  
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Figure 4.8 The effect of SCFAs on the GITR expression of human iTregs. 
 (A) Representative histogram showing MFI GITR of adult whole iTregs (left panel), 
adult activated iTregs (middle panel) and CB iTregs (right panel) generated under various 
conditions. All cells were cultured in the presence of IL-2, TGF-β and additional with: 
control (black), acetate (red), butyrate (blue), and propionate (green). (B) Summary box 
and whisker graphs showing MFI GITR of whole iTregs (left panel) and only activated 
cells (right panel) from adult naive CD4+ cells (n=7). (C) Summary box and whisker 
graphs showing MFI GITR of iTregs from CB naive CD4+ cells (n=10). *p < 0.05, **p < 
0.01, ***p < 0.001.  
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Figure 4.9 The effect of SCFAs on the ICOS expression of human iTregs. 
(A) Representative histogram showing MFI ICOS of adult whole iTregs (left panel), adult 
activated iTregs (middle panel) and CB iTregs (right panel) generated under various 
conditions. All cells were cultured in the presence of IL-2, TGF-β and additional with: 
control (black), acetate (red), butyrate (blue), and propionate (green). (B) Summary box 
and whisker graphs showing MFI ICOS of whole iTregs (left panel) and only activated 
cells (right panel) from adult naive CD4+ cells (n=6). (C) Summary box and whisker 
graphs showing MFI ICOS of iTregs from CB naive CD4+ cells (n=10). **p < 0.01, 
***p < 0.001.  
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Figure 4.10 The effect of SCFAs on the PD-1 expression of human iTregs. 
(A) Representative histogram showing MFI PD-1 of adult whole iTregs (left panel), adult 
activated iTregs (middle panel) and CB iTregs (right panel) generated under various 
conditions. All cells were cultured in the presence of IL-2, TGF-β and additional with: 
control (black), acetate (red), butyrate (blue), and propionate (green). (B) Summary box 
and whisker graphs showing MFI PD-1 of whole iTregs (left panel) and only activated 
cells (right panel) from adult naive CD4+ cells (n=6). (C) Summary box and whisker 
graphs showing MFI PD-1 of iTregs from CB naive CD4+ cells (n=6). **p < 0.01.  
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Figure 4.11 The effect of SCFAs on the PD-L1 expression of human iTregs. 
(A) Representative histogram showing MFI PD-L1 of adult whole iTregs (left panel), 
adult activated iTregs (middle panel) and CB iTregs (right panel) generated under various 
conditions. All cells were cultured in the presence of IL-2, TGF-β and additional with: 
control (black), acetate (red), butyrate (blue), and propionate (green). (B) Summary box 
and whisker graphs showing MFI PD-L1 of whole iTregs (left panel) and only activated 
cells (right panel) from adult naive CD4+ cells (n=6). (C) Summary box and whisker 
graphs showing MFI PD-L1 of iTregs from CB naive CD4+ cells (n=6). *p < 0.05, **p < 
0.01.  
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Figure 4.12 The effect of SCFAs on the CTLA-4 expression of human iTregs. 
(A) Representative histogram showing MFI CTLA-4 of adult whole iTregs (left panel), 
adult activated iTregs (middle panel) and CB iTregs (right panel) generated under various 
conditions. All cells were cultured in the presence of IL-2, TGF-β and additional with: 
control (black), acetate (red), butyrate (blue), and propionate (green). (B) Summary box 
and whisker graphs showing MFI CTLA-4 of whole iTregs (left panel) and only activated 
cells (right panel) from adult naive CD4+ cells (n=12). (C) Summary box and whisker 
graphs showing MFI CTLA-4 of iTregs from CB naive CD4+ cells (n=12). *p < 0.05, 
**p < 0.01.  
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Figure 4.13 The effect of SCFAs on the HLA-DR expression of human iTregs. 
(A) Representative histogram showing the percentage of HLA-DR+ cells gated on adult 
whole iTregs (top panel), adult activated iTregs (middle panel) and CB iTregs (bottom 
panel) generated under various conditions. All cells were cultured in the presence of IL-
2, TGF-β and additional with: control (black), acetate (red), butyrate (blue), and 
propionate (green). (B) Summary box and whisker graphs showing %HLA-DR+ gated on 
whole iTregs (left panel) and only activated cells (right panel) from adult naive CD4+ 
cells (n=10). (C) Summary box and whisker graphs showing %HLA-DR+ of iTregs from 
CB naive CD4+ cells (n=11). *p < 0.05, ***p < 0.001.   
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4.3.3 Butyrate and Propionate, but not Acetate, Enhance the Suppressive 
Capacity of Human TGF-β–induced Tregs in vitro 
To test the suppressive capacity of iTreg cells treated with different SCFAs, these iTreg 
cells were cocultured with autologous CFSE-labelled CD4+CD25- responder cells 
(freshly beads-isolated) under various ratios in vitro. Then on day 3, the differences in the 
proliferation of responder cells were compared (section 2.2.3.2). 
Firstly, the suppressive capacity of the whole cultured cells generated from adult naive 
CD4+ cells was tested. There were no significant differences between SCFAs-treated 
iTregs and control iTregs (Figure 4.14). Only propionate-treated iTregs showed 
significantly higher suppressive capacities compared to acetate-treated iTregs at the 
suppressor: responder cell ratios 1:4, 1:8 and 1:16.  
Next, we wanted to test the suppressive capacity of activated iTreg cells generated from 
adult naive CD4+ cells, considering the significantly different activation status observed 
in section 4.3.1. Whole cultured cells incubated under various conditions were subjected 
to CD25 MicroBeads positive selection, to isolate purified CD25high cells (activated cells) 
for in vitro suppression assay. When comparing activated cells and their pair-matched 
whole cultured cells, the differences in the suppressive capacity were greater in butyrate-
treated iTregs, compared to iTregs cultured under other conditions (Figure 4.15). These 
increases between activated cells and whole cultured cells were significant for butyrate-
treated iTregs at the suppressor: responder cell ratios 1:2, 1:8 and 1:16.  
In addition, we found that results of the suppression assay for activated iTreg cells were 
very promising for the first time in human studies. Butyrate-treated iTreg cells reduced 
the in vitro proliferation of autologous CD4+CD25- responder cells compared to both 
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control and acetate-treated iTreg cells (Figure 4.17). This was statistically significant and 
consistent at all suppressor: responder cell ratios from 1:2 to 1:16. Additionally, 
propionate-treated iTreg cells also had increased suppressive capacity compared to 
control iTreg cells, only to a lesser extent and did not reach significance at all cell ratios. 
On the contrary, the addition of acetate failed to achieve a similar effect.  
Finally, we tested the suppressive capacity of iTreg cells generated from CB naive CD4+ 
cells. The results mimicked the same trend found in activated iTregs generated from adult 
naive CD4+ cells. The addition of butyrate and propionate increased the suppressive 
capacity of iTregs at all suppressor: responder cell ratios from 1:1 to 1:16. Significant 
differences were found at ratios from 1:4 to 1:16 for both butyrate-treated and propionate-
treated iTregs. Like the activated iTregs generated from adult naive CD4+ cells, the 
addition of acetate was unable to increase the suppressive capacity of iTreg cells 
generated from CB naive CD4+ cells. 
These results demonstrate that the addition of butyrate and propionate, but not acetate, 
augments the suppressive capacity of in vitro induced human Treg cells.  
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Figure 4.14 The suppressive capacity of iTreg cells generated from adult naive CD4+ 
cells. 
Line graph (upper panel) showing percentages of suppression using whole iTreg cells 
generated from adult PB naive CD4+ cells under various conditions. All cells were 
cultured in the presence of IL-2, TGF-β and additional with: control (black), acetate (red), 
butyrate (blue), and propionate (green). Various suppressor: responder ratios ranging 
from 1:1 to 1:16 were applied. Summary dot plots (lower panel) showing the statistical 
analysis of the suppressive capacity of whole iTreg cells as indicated. Percentage of 
suppression was calculated as (proliferation of T responder alone – the proliferation of 
co-cultured T responder) / proliferation of T responder alone x 100. Data represent 8 
independent experiments in each group. *p < 0.05.    
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Figure 4.15 Improved suppressive capacity of activated iTregs generated from adult 
naive CD4+ cells. 
Summary bar graphs showing percentages of suppression using whole cultured iTregs 
(blank) versus activated iTreg cells (black, whole cultured iTregs went through CD25 
MicroBeads positive selection) generated from adult naive CD4+ cells under normal 
conditions. Cells were cultured in the presence of IL-2, TGF-β and additional with: (A) 
control, (B) acetate, (C) butyrate, and (D) propionate. Data represent 6 independent 
experiments in each group. *p < 0.05.  
135 
 
 
Figure 4.16 The effects of SCFAs-treated iTregs on the proliferation of responder 
cells.  
Representative histograms showing reduced proliferation of CFSE-labelled responder 
cells by activated iTregs cultured in the presence of IL-2, TGF-β and additional with: 
acetate (red), butyrate (blue) and propionate (green), compared to iTregs cultured under 
normal conditions in the absence of SCFAs (Ctrl, black). The proliferation of responder 
cells alone is shown in the grey background. Data show suppressor: responder ratio of 
1:8. 
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Figure 4.17 Butyrate and propionate enhance the suppressive capacity of activated 
iTregs generated from Adult naive CD4+ cells. 
Line graph (upper panel) showing percentages of suppression using activated iTreg cells 
(whole cultured iTregs went through CD25 MicroBeads positive selection) generated 
from adult PB naive CD4+ cells. All cells were cultured in the presence of IL-2, TGF-β 
and additional with: control (black), acetate (red), butyrate (blue), and propionate (green). 
Various suppressor: responder ratios ranging from 1:1 to 1:16 were applied. Summary 
dot plots (lower panel) showing the statistical analysis of the suppressive capacity of 
activated iTreg cells as indicated. Data represent 6 independent experiments in each 
group. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 4.18 Butyrate and propionate enhance the suppressive capacity of iTregs 
generated from CB naive CD4+ cells. 
Line graph (upper panel) showing percentages of suppression using iTreg cells generated 
from CB naive CD4+ cells under various conditions. All cells were cultured in the 
presence of IL-2, TGF-β and additional with: control (black), acetate (red), butyrate 
(blue), and propionate (green). Various suppressor: responder ratios ranging from 1:1 to 
1:16 were applied. Summary dot plots (lower panel) showing the statistical analysis of 
the suppressive capacity of iTreg cells as indicated. Data represent 10 independent 
experiments in each group. *p < 0.05, **p < 0.01, ***p < 0.001.   
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4.3.4 Butyrate and Propionate Augment iTreg cell Phenotype and Function 
through Histone Deacetylation Inhibition  
To understand the mechanism of SCFAs-mediated augmentation of iTreg cells, CD4+ 
cells generated from adult naive non-Tregs were harvest on day 3, while CD4+ cells 
generated from cord blood were harvest on day 1 and day 3 respectively. Cells were then 
processed for ChIP-qPCR analysis (Section 2.2.6). As SCFAs treatment inhibits global 
histone deacetylation (refer to Section 1.5.3 for more details), the values within each 
sample were initially subjected to cross-sample adjustment based on the read counts of 
the housekeeping gene (refer to Section 2.2.6.3 for more details). Then the relative 
enrichment for the seven genes tested was compared as a whole or separately. 
In terms of the total and average relative enrichment of all the seven genes tested (Table 
4-1 and Figure 4.19), we found that butyrate treated cells of both adult and cord blood 
origins had the highest amounts of acetylated histones, followed by propionate treated 
cells. On the contrary, the addition of acetate had less or no effects on the histone 
acetylation. It was also interesting to notice that histone 4 experienced more acetylation 
changes compared to histone 3. In addition, the levels of acetylated histones were 
comparable between cells harvested on day3 of adult origin and day1 of cord blood origin; 
whereas cells from CB day3 had reduced histone acetylation compared to day1. Looking 
at chromatin modifications in seven different gene loci (Figure 4.20 to 4.26), the trends 
were similar to the protein expression of the corresponding gene.   
Collectively, these results indicate that a) butyrate, propionate and acetate (to a lesser 
extent) enhanced histone 3 and histone 4 acetylation of different gene loci, thus 
augmenting the expressions of these genes; b) the epigenetic modification due to SCFAs 
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treatment initiated much later in adult cells compared to cord blood cells, another 
evidence supporting differential induction patterns. 
 
Table 4-1 Sums of Relative Enrichment of Acetylated Histone 3 and 4 of Human 
iTregs with or without SCFAs.  
 Control Acetate Butyrate Propionate 
Adult (n=7) Day3 
Histone 3 3.328 3.443 4.838 3.986 
Histone 4 4.318 5.139 9.330 10.393 
Cord Blood 
(n=6) 
Day1 
Histone 3 1.747 6.410 6.765 6.279 
Histone 4 6.973 5.582 10.918 8.184 
Day3 
Histone 3 2.988 2.150 5.581 2.226 
Histone 4 2.811 3.376 4.186 6.278 
Data are shown as the sums of relative enrichment of acetylated histone 3 or histone 4 at 
seven different gene loci, including Foxp3, CD39, GITR, ICOS, PD-1, PD-L1 and CTLA-
4.   
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Figure 4.19 Average of Relative Enrichment of Acetylated Histone 3 and 4 of Human 
iTregs with or without SCFAs 
Summary bar graphs showing the average relative enrichment of acetylated histone 3 (top 
panel) and histone 4 (bottom panel) at seven different gene loci, including Foxp3, CD39, 
GITR, ICOS, PD-1, PD-L1 and CTLA-4. Cells generated from adult PB naive CD4+ cells 
for 3 days (n=7), CB naive CD4+ cells for 1 day (n=6), and CB naive CD4+ cells for 3 
days (n=6).  
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Figure 4.20 Chromatin modification at the Foxp3 locus by SCFAs. 
ChIP-qPCR analysis of the Foxp3 locus was performed in CD4+ T cells cultured in the 
absence (black) or presence of acetate (red), butyrate (blue), and propionate (green) using 
anti-AcH3 and anti-AcH4 antibody. Summary bar graphs showing the relative 
enrichment of acetylated histone 3 (left panel) and histone 4 (right panel) of cells 
generated from (A) adult PB naive CD4+ cells for 3 days, (B) CB naive CD4+ cells for 1 
day, and (C) CB naive CD4+ cells for 3 days.  
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Figure 4.21 Chromatin modification at the CD39 locus by SCFAs. 
ChIP-qPCR analysis of the CD39 locus was performed in CD4+ T cells cultured in the 
absence (black) or presence of acetate (red), butyrate (blue), and propionate (green) using 
anti-AcH3 and anti-AcH4 antibody. Summary bar graphs showing the relative 
enrichment of acetylated histone 3 (left panel) and histone 4 (right panel) of cells 
generated from (A) adult PB naive CD4+ cells for 3 days, (B) CB naive CD4+ cells for 1 
day, and (C) CB naive CD4+ cells for 3 days.  
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Figure 4.22 Chromatin modification at the GITR locus by SCFAs. 
ChIP-qPCR analysis of the GITR locus was performed in CD4+ T cells cultured in the 
absence (black) or presence of acetate (red), butyrate (blue), and propionate (green) using 
anti-AcH3 and anti-AcH4 antibody. Summary bar graphs showing the relative 
enrichment of acetylated histone 3 (left panel) and histone 4 (right panel) of cells 
generated from (A) adult PB naive CD4+ cells for 3 days, (B) CB naive CD4+ cells for 1 
day, and (C) CB naive CD4+ cells for 3 days.  
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Figure 4.23 Chromatin modification at the ICOS locus by SCFAs. 
ChIP-qPCR analysis of the ICOS locus was performed in CD4+ T cells cultured in the 
absence (black) or presence of acetate (red), butyrate (blue), and propionate (green) using 
anti-AcH3 and anti-AcH4 antibody. Summary bar graphs showing the relative 
enrichment of acetylated histone 3 (left panel) and histone 4 (right panel) of cells 
generated from (A) adult PB naive CD4+ cells for 3 days, (B) CB naive CD4+ cells for 1 
day, and (C) CB naive CD4+ cells for 3 days.  
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Figure 4.24 Chromatin modification at the PD-1 locus by SCFAs. 
ChIP-qPCR analysis of the PD-1 locus was performed in CD4+ T cells cultured in the 
absence (black) or presence of acetate (red), butyrate (blue), and propionate (green) using 
anti-AcH3 and anti-AcH4 antibody. Summary bar graphs showing the relative 
enrichment of acetylated histone 3 (left panel) and histone 4 (right panel) of cells 
generated from (A) adult PB naive CD4+ cells for 3 days, (B) CB naive CD4+ cells for 1 
day, and (C) CB naive CD4+ cells for 3 days.   
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Figure 4.25 Chromatin modification at the PD-L1 locus by SCFAs. 
ChIP-qPCR analysis of the PD-L1 locus was performed in CD4+ T cells cultured in the 
absence (black) or presence of acetate (red), butyrate (blue), and propionate (green) using 
anti-AcH3 and anti-AcH4 antibody. Summary bar graphs showing the relative 
enrichment of acetylated histone 3 (left panel) and histone 4 (right panel) of cells 
generated from (A) adult PB naive CD4+ cells for 3 days, (B) CB naive CD4+ cells for 1 
day, and (C) CB naive CD4+ cells for 3 days.  
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Figure 4.26 Chromatin modification at the CTLA-4 locus by SCFAs. 
ChIP-qPCR analysis of the CTLA-4 locus was performed in CD4+ T cells cultured in the 
absence (black) or presence of acetate (red), butyrate (blue), and propionate (green) using 
anti-AcH3 and anti-AcH4 antibody. Summary bar graphs showing the relative 
enrichment of acetylated histone 3 (left panel) and histone 4 (right panel) of cells 
generated from (A) adult PB naive CD4+ cells for 3 days, (B) CB naive CD4+ cells for 1 
day, and (C) CB naive CD4+ cells for 3 days.  
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4.4 Discussion 
SCFAs have been well established as essential immune regulators for pTreg and iTreg 
cell induction in animals (276-278, 331). SCFAs exert their effects on Treg cells via three 
different mechanisms: a) energy metabolism, b) HDAC inhibition, and c) indirectly via 
APCs. Firstly, SCFAs are converted to Acetyl-CoA during energy metabolism (316), 
which then increase the cellular ATP levels (317). Thus, the ATP sensing mTOR pathway 
is activated to regulate the differentiation of Treg cells (318, 319). Second, the major 
mechanism proposed is HDAC inhibition, considering the lack of significant levels of 
GPRs on the T cell surface (288-290). SCFAs promote the generation of pTregs by 
enhancing Histone 3 acetylation at both promoter and CNS3 regions of the Foxp3 gene 
locus and the Foxp3 protein via HDAC inhibition (276, 278). In addition, the expressions 
of IL-10, IFN-γ and IL-17 are also elevated in T cells (290). Lastly, SCFAs also exert 
their regulatory effects on Treg cells via APCs. They suppress the expression of pro-
inflammatory cytokines of DCs via HDAC inhibition, thus promoting Treg induction 
(276). Alternatively, the activation of GPR109a by butyrate can skew colonic 
macrophages and dendritic cells towards tolerogenic phenotype to promote the 
differentiation of Treg cell and IL-10 producing cells (295). 
The biggest questions about human in vitro induced Treg cells were a) whether they were 
stable for long periods; and b) if they had an equivalent suppressive capacity compared 
to ex vivo nTreg cells (86, 107, 355). Neither of these problems was seen in mice (356). 
To solve this challenge, various reagents, in addition to IL-2 and TGF-β, have been 
described to improve the suppressive capacity of human iTreg cells in vitro. These 
included retinoic acid (353, 357, 358), rapamycin (353, 358, 359), vitamin D (360), and 
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IL-10 (1). However, only one paper has been published describing the effects of butyrate 
and propionate on the generation of human Treg cells in vitro, and it failed to prove their 
efficacy (353).  
In view of these recent advances, our results in this chapter showed the novel role of 
SCFAs in the generation of human iTregs for the first time. The addition of butyrate and 
propionate, but not acetate, significantly enhanced the suppressive capacity of iTregs. In 
particular, this conclusion is applied to not only activated iTregs generated from adult 
naive CD4+ T cells, but also iTregs of cord blood origin. This differential induction 
pattern was observed previously using completely different methodology (361). This 
group found that a significantly higher percentage (2.7±0.5-fold, p<0.002) of CB 
CD4+CD25+ cells were induced upon allogeneic MUTZ3-iDC stimulation (not TGF-β 
plus anti-CD3/anti-CD28), compared to that from Adult PB CD4+CD25- cells (not naive 
cells). Hence, the differences should attribute to the much higher percentage of naive 
“inducible” cells in CB. 
We postulated that this differential induction patterns of adult iTregs might explain the 
controversy of the effectiveness of human iTregs as well as the concealment of the effects 
of SCFAs on adult iTregs. In our study, naïve non-Tregs isolated from adult CD4+ cells 
were unable to fully differentiate into Treg cells, and there was a significant non-activated 
subpopulation displaying a smaller cell size. Among all the culture conditions, butyrate 
treated iTregs had the most non-activated cells, around 40% of the whole cultured cells. 
We speculated that this population was nonresponsive and did not share iTreg characters. 
Indeed, these cells had the minimal expression of all the phenotypic markers, except for 
CD127 (which expressed at higher levels). We then compared the suppressive capacity 
between activated iTreg cells and their pair-matched whole cultured cells generated from 
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adult naive CD4+ cells. As expected, the activated iTregs had a higher percentage of 
suppression compared to their counterparts. The differences were much greater in 
butyrate-treated iTregs when taking into account the large proportion of non-activated 
cells. Interestingly, this differential induction pattern was not present in the iTregs 
generated from CB naïve CD4+ cells. All naïve non-Tregs sorted from CB naïve CD4+ 
cells were fully differentiated into iTregs. Another evidence for this differential induction 
pattern is that the epigenetic histone acetylation due to SCFAs treatment was initiated 
much later in adult cells compared to cord blood cells. Therefore, when analysing iTregs 
generated from CB naïve CD4+ cells and the activated rather than the whole iTregs 
generated from adult PB naïve CD4+ cells, we were able to conclude the same finding 
discovered in animal studies. 
Since the only difference in the methodology is the origin of naïve CD4+ T cells and only 
adult iTregs show partial proliferation, it raises the question as to whether CD45RO- T 
cells are really “naïve” in adults compared to cord blood. Although the size and scope of 
the naïve CD4+ T cell pool are maintained by both thymic output and peripheral 
homeostatic proliferation throughout adulthood (362, 363), there are functional 
alterations in these naive T cells. TCR sequencing studies have shown that clonal 
expansion also happens in human naive T cells, and most of these clonally expanded cells 
still retain a naive phenotype with the expression of CD45RA, CD28, CD27, and CCR7 
(364). In addition, telomere attrition, DNA damage, as well as changes in microRNAs, 
occur in naive T cells when ageing, which partially account for defective T cell responses 
(365, 366). However, there is missing data on the conclusive transcriptional and 
epigenetic profiling exploring the influence of ageing on naive T cells in humans. 
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The ChIP-qPCR results demonstrated the possible mechanism of butyrate and propionate 
mediated augmentation of human iTreg cells. Butyrate, propionate and to a lesser extent 
acetate, enhanced histone 3 and histone 4 acetylation of different gene loci via histone 
deacetylation inhibition, thus increasing the accessibility of these genes and initiation of 
protein expression. The delayed histone acetylation in adult iTregs also provided evidence 
of lower responsiveness and proliferation of adult naive CD4+ T cells. However, we could 
not exclude the possibility that SCFAs can also contribute in other ways, such as energy 
metabolism.  
Consistent with previous studies, the expression of Foxp3 and CD127 of iTregs in our 
experiment proved that they were only activation markers for human iTregs. 
Additionally, we showed that the expression patterns of GITR, ICOS, CD39, PD-1 and 
PD-L1 on iTregs treated with SCFAs were similar to that of the functional assay results, 
suggesting that GITR, ICOS, CD39, PD-1 and PD-L1 are potential candidate markers for 
human in vitro induced Treg cells.  
In summary, the current results show that in addition to IL-2 and TGF-β, SCFAs enhance 
gene transcription of potential iTreg candidate genes. This is achieved by acetylation of 
Histone 3 and Histone 4 via HDAC inhibition, which increases the accessibility of these 
genes for transcription. These proteins, in turn, potentiate the differentiation of iTreg cells 
and bestow them with suppressive capacity. This novel role of SCFAs on iTregs is seen 
for the first time in a human study, providing evidence for future therapeutic and 
preventative dietary modification strategies for several immune diseases.  
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Chapter 5 – Short Chain Fatty Acids Skew 
Monocyte-Derived Dendritic Cells towards a 
Tolerogenic Status  
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5.1 Introduction 
The results from the previous chapter suggest that in addition to IL-2 and TGF-β, SCFAs 
(butyrate and propionate, but not acetate) potentiate the induction of human iTregs and 
enhance the suppressive capacity of these iTregs via HDAC inhibition. This is the first 
time that this novel role of SCFAs on iTregs has been seen in a human study. Apart from 
Treg cells, SCFAs can also affect APCs to modulate immune tolerance.  
DCs play an essential role in directing the immune response towards either immunity or 
tolerance, depending on the context of antigen exposure and different environmental 
stimuli. Several signals are required for DCs to activate T cell responses in addition to 
MHC-II complexes, such as upregulated co-stimulatory factors on the DC cell surface 
and the cytokine milieu (164). Therefore, the expressions of costimulatory factors and 
MHC molecules, as well as cytokine production, are of vital importance to distinguish 
tolerogenic DCs from immunogenic DCs. SCFAs suppress the expression of pro-
inflammatory cytokines by murine DCs, thus promoting Treg induction (276). Butyrate 
can also activate the GPR109a signalling pathway, thus skewing murine colonic 
macrophages and DCs towards a tolerogenic phenotype to promote the differentiation of 
Treg cell and IL-10 producing cells (295).  
The effect of butyrate on DCs has been thoroughly examined in human MoDCs, including 
their differentiation, maturation, cytokine production and immune-stimulatory capacity. 
The addition of butyrate during the MoDC differentiation process downregulated the 
expression of costimulatory factors, such as CD80, CD83, CD86, CD40, and ICAM-1 
(CD54) of immature MoDCs and to a much greater extent, mature MoDCs (325, 367-
369). The expressions of MHC class including HLA-A/B/C and HLA-DR/DQ, as well as 
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group 1 CD1 family (CD1a, CD1b and CD1c),  were also reduced by butyrate treatment 
(325, 367-369). Taken together, this profound downregulation of costimulatory factors 
and antigen presentation MHC molecules by butyrate indicated that both the 
differentiation and maturation of DCs were compromised. Moreover, butyrate 
significantly reduced the production of pro-inflammatory cytokines (IL-12, IL-6, and 
TNF-α) and chemokines (for example, CXCL9) (368, 369), while increasing IL-10 
production (367). The presence of butyrate also resulted in less T cell stimulatory activity 
(325, 367). Other types of HDAC inhibitors, like VPA and MS-275, showed similar 
influence on human DCs (370). However, there is very limited research on the effects of 
other SCFAs (acetate and propionate) on human DCs. Woetmann et al. found that acetate 
only exerted minimal effects on the gene expression of human MoDCs, whereas 
propionate strongly reduced the production of pro-inflammatory chemokines CXCL9 and 
CCL19 (369).  
Therefore, the aims of this chapter are to: a) explore the precise role of SCFAs (including 
sodium acetate, butyrate and propionate) on human MoDCs, including the expression of 
costimulatory factors, adhesion factors, migration factors, MHC-II molecule, chemokines, 
and cytokines; b) investigate how SCFA-treated MoDCs influence the proliferation of 
autologous CD4+ T cells; and c) compare the suppressive capacity of CD4+ T cells 
cocultured with SCFA-treated MoDCs.  
5.2 Subjects 
To determine the effect of SCFAs on the human MoDCs, a total of 14 healthy adult 
volunteers were recruited. For MoDC flow cytometric analysis, eight adult PBMCs were 
used, while for functional analysis, peripheral blood samples were collected twice over 
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two consecutive weeks from six healthy adults. Individuals with any history of 
autoimmune disease or allergies were excluded. 
5.3 Results 
5.3.1 SCFAs Skew Human Monocyte-Derived Dendritic Cells towards a 
Tolerogenic Phenotype 
To understand the precise role of SCFAs (including sodium acetate, butyrate and 
propionate) on human MoDCs (Section 2.2.3.3), bead selected CD14+ monocytes were 
cultured in the presence of GM-CSF and IL-4 with or without SCFAs for 7 days to induce 
immature MoDCs (im-MoDCs). LPS was added to selected cultures to induce MoDC 
maturation (m-MoDCs) 24 hours prior to harvesting. 
First, we examined whether the addition of LPS could successfully induce the MoDC 
maturation. There was significant upregulation of the costimulatory factors in both 
control and SCFAs-treated m-MoDCs, including CD80, CD83, CD86, and PD-L1 (Figure 
5.1). In addition, the expression of MHC class (HLA-DR) was also significantly increased 
in m-MoDCs, while the expression of CD1a was decreased (Figure 5.2). The changes in 
CD1a expression was diminished in butyrate-treated m-MoDCs compared to im-DCs. 
The trend was similar for other DC markers (DC-Sign, CD11c) and migration markers 
(lymph node homing receptor CCR7) (Figure 5.3). m-MoDCs had significant higher 
expressions of CD11c, TLR-4, and CCR7. However, it was not always significant for 
butyrate or propionate treated MoDCs. DC-Sign was downregulated after the addition of 
LPS, and CD14 expression slightly increased. As for the cytokine signature, LPS 
significantly increased the expressions of chemokines and cytokines, such as CXCL9, IL-
12 p35, and IL-12/23 p40 determined by flow cytometric analysis (Figure 5.4). The level 
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of CXCL9 was similar for butyrate treated MoDCs.  However, we failed to find 
significant changes in TNF-α and TGF-β expressions.  
Next, we tested the effects of SCFAs on both immature and mature MoDCs. The 
expressions of CD80, CD83, CD86, HLA-DR, and PD-L1 were at very low levels in im-
MoDCs (Figure 5.5 to Figure 5.7). As for m-MoDCs, butyrate and propionate treatment 
reduced the expression of these markers compared to control and acetate treated groups. 
There was a significant decrease in CD1a (a nonclassical antigen presenting molecule 
(371) ) expression for butyrate and propionate treated MoDCs in both immature and 
mature groups (Figure 5.7 right panel). Butyrate and propionate also reduced the 
expressions of CD11c in the m-MoDC group (Figure 5.8 left panel). As for DC-Sign, 
TLR-4, and CCR7, there were no significant differences compared to control MoDCs 
(Figure 5.9 and 5.10). The expression of CD14 shared the same trend found in CD1a 
(Figure 5.10). The upregulation of CXCL9 was least in the butyrate and propionate treated 
m-MoDCs, and these cells also had the highest expression of TGF-β (Figure 5.11). 
However, the flow cytometric results for the other cytokine signatures were not consistent 
with the previously published ELISA results. 
Taken together, these results indicated that both butyrate and propionate, but not acetate, 
could inhibit the differentiation and maturation of MoDCs, skewing towards immature or 
tolerogenic status. In addition, butyrate and propionate also modulate cytokine production 
by MoDCs. 
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Figure 5.1 The expression of costimulatory factors in human immature and mature 
MoDCs. 
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(A) Representative histograms showing the expressions of CD80, CD83, CD86, and PD-
L1 of both im-MoDCs (grey shade) and mature MoDCs (maturation with LPS for 24 
hours, black thick line) cultured under normal conditions (GM-CSF+IL-4). (B) Bar 
graphs showing the MFI of CD80, CD83, CD86, and PD-L1 of both im-MoDCs (white) 
and mature MoDCs (black) cultured under various conditions: Ctrl (GM-CSF+IL-4), 
acetate (GM-CSF+IL-4+acetate), butyrate (GM-CSF+IL-4+butyrate), and propionate 
(GM-CSF+IL-4+propionate). Data represent 8 independent experiments. **p < 0.01.   
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Figure 5.2 The expression of HLA-DR and CD1a in human immature and mature 
MoDCs. 
(A) Representative histograms showing the expressions of HLA-DR and CD1a of both 
im-MoDCs (grey shade) and mature MoDCs (maturation with LPS for 24 hours, black 
thick line) cultured under normal conditions (GM-CSF+IL-4). (B) Bar graphs showing 
the MFI of HLA-DR and CD1a of both im-MoDCs (white) and mature MoDCs (black) 
cultured under various conditions: Ctrl (GM-CSF+IL-4), acetate (GM-CSF+IL-
4+acetate), butyrate (GM-CSF+IL-4+butyrate), and propionate (GM-CSF+IL-
4+propionate). Data represent 8 independent experiments. **p < 0.01.  
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Figure 5.3 The expression of DC markers and migration markers in human 
immature and mature MoDCs. 
(A) Representative histograms showing the expressions of DC-Sign, CD11c, CD14, 
TLR-4, and CCR7 of both im-MoDCs (grey shade) and mature MoDCs (maturation with 
LPS for 24 hours, black thick line) cultured under normal conditions (GM-CSF+IL-4). 
(B) Bar graphs showing the MFI of DC-Sign, CD11c, CD14, TLR-4, and CCR7 of both 
im-MoDCs (white) and mature MoDCs (black) cultured under various conditions: Ctrl 
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(GM-CSF+IL-4), acetate (GM-CSF+IL-4+acetate), butyrate (GM-CSF+IL-4+butyrate), 
and propionate (GM-CSF+IL-4+propionate). Data represent 8 independent experiments. 
*p < 0.05, **p < 0.01.  
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Figure 5.4 The expression of cytokine signatures in human immature and mature 
MoDCs. 
(A) Representative histograms showing the expression of CXCL9, TNF-α, TGF-β, IL-12 
p35, and IL-12/35 p40 of both im-MoDCs (grey shade) and mature MoDCs (maturation 
with LPS for 24 hours, black thick line) cultured under normal conditions (GM-CSF+IL-
4). (B) Bar graphs showing the MFI of CXCL9, TNF-α, TGF-β, IL-12 p35, and IL-12/35 
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p40 of both im-MoDCs (white) and mature MoDCs (black) cultured under various 
conditions: Ctrl (GM-CSF+IL-4), acetate (GM-CSF+IL-4+acetate), butyrate (GM-
CSF+IL-4+butyrate), and propionate (GM-CSF+IL-4+propionate). Data represent 8 
independent experiments. *p < 0.05, **p < 0.01.  
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Figure 5.5 The effects of SCFAs on the expression of CD80 and CD83 in human 
MoDCs. 
 (A) Representative pseudocolour dot plots showing the effects of SCFAs on the 
expression of CD80 and CD83 of both im-MoDCs (upper) and mature MoDCs 
(maturation with LPS for 24 hours, lower). Scattered dot plots showing the MFI of (B) 
CD80 and (C) CD83 of both im-MoDCs (left panel) and mature MoDCs (right panel) 
cultured under various conditions: Ctrl (GM-CSF+IL-4, black), acetate (GM-CSF+IL-
4+acetate, red), butyrate (GM-CSF+IL-4+butyrate, blue), and propionate (GM-CSF+IL-
4+propionate, green). Data are from 8 independent experiments. *p < 0.05, **p < 0.01, 
***p < 0.001. 
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Figure 5.6 The effects of SCFAs on the expression of CD86 and HLA-DR in human 
MoDCs. 
 (A) Representative pseudocolour dot plots showing the effects of SCFAs on the 
expression of CD86 and HLA-DR of both im-MoDCs (upper) and mature MoDCs 
(maturation with LPS for 24 hours, lower). Scattered dot plots showing the MFI of (B) 
CD86 and (C) HLA-DR of both im-MoDCs (left panel) and mature MoDCs (right panel) 
cultured under various conditions: Ctrl (GM-CSF+IL-4, black), acetate (GM-CSF+IL-
4+acetate, red), butyrate (GM-CSF+IL-4+butyrate, blue), and propionate (GM-CSF+IL-
4+propionate, green). Data are from 8 independent experiments. *p < 0.05, **p < 0.01. 
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Figure 5.7 The effects of SCFAs on the expression of PD-L1 and CD1a in human 
MoDCs. 
 (A) Representative pseudocolour dot plots showing the effects of SCFAs on the 
expression of PD-L1 and CD1a of both im-MoDCs (upper) and mature MoDCs 
(maturation with LPS for 24 hours, lower). Scattered dot plots showing the MFI of (B) 
PD-L1 and (C) CD1a of both im-MoDCs (left panel) and mature MoDCs (right panel) 
cultured under various conditions: Ctrl (GM-CSF+IL-4, black), acetate (GM-CSF+IL-
4+acetate, red), butyrate (GM-CSF+IL-4+butyrate, blue), and propionate (GM-CSF+IL-
4+propionate, green). Data are from 8 independent experiments. *p < 0.05, **p < 0.01, 
***p < 0.001. 
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Figure 5.8 The effects of SCFAs on the expression of CD11c and DC-Sign in human 
MoDCs. 
 (A) Representative pseudocolour dot plots showing the effects of SCFAs on the 
expression of CD11c and DC-Sign of both im-MoDCs (upper) and mature MoDCs 
(maturation with LPS for 24 hours, lower). Scattered dot plots showing the MFI of (B) 
CD11c and (C) DC-Sign of both im-MoDCs (left panel) and mature MoDCs (right panel) 
cultured under various conditions: Ctrl (GM-CSF+IL-4, black), acetate (GM-CSF+IL-
4+acetate, red), butyrate (GM-CSF+IL-4+butyrate, blue), and propionate (GM-CSF+IL-
4+propionate, green). Data are from 8 independent experiments. *p < 0.05. 
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Figure 5.9 The effects of SCFAs on the expression of TLR-4 and CCR7 in human 
MoDCs. 
 (A) Representative pseudocolour dot plots showing the effects of SCFAs on the 
expression of TLR-4 and CCR7 of both im-MoDCs (upper) and mature MoDCs 
(maturation with LPS for 24 hours, lower). Scattered dot plots showing the MFI of (B) 
TLR-4 and (C) CCR7 of both im-MoDCs (left panel) and mature MoDCs (right panel) 
cultured under various conditions: Ctrl (GM-CSF+IL-4, black), acetate (GM-CSF+IL-
4+acetate, red), butyrate (GM-CSF+IL-4+butyrate, blue), and propionate (GM-CSF+IL-
4+propionate, green). Data are from 8 independent experiments. *p < 0.05, **p < 0.01. 
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Figure 5.10 The effects of SCFAs on the expression of CD14 in human MoDCs. 
 (A) Representative histogram showing the effects of SCFAs on the expression of CD86 
and HLA-DR of im-MoDCs (grey shade) and mature MoDCs (maturation with LPS for 
24 hours, different colour lines). (B) Scattered dot plots showing the MFI of CD14 of 
both im-MoDCs (left panel) and mature MoDCs (right panel) cultured under various 
conditions: Ctrl (GM-CSF+IL-4, black), acetate (GM-CSF+IL-4+acetate, red), butyrate 
(GM-CSF+IL-4+butyrate, blue), and propionate (GM-CSF+IL-4+propionate, green). 
Data are from 8 independent experiments. **p < 0.01. 
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Figure 5.11 The effects of SCFAs on the expression of cytokine signatures in human 
MoDCs. 
(A) Representative histogram showing the effects of SCFAs on the expression of CXCL9, 
TNF-α, TGF-β, IL-12 p35, and IL-12/35 p40 of im-MoDCs (grey shade) and mature 
MoDCs (maturation with LPS for 24 hours, different colour lines). (B) Scattered dot plots 
showing the MFI of CXCL9, TNF-α, TGF-β, IL-12 p35, and IL-12/35 p40 of both im-
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MoDCs (left panel) and mature MoDCs (right panel) cultured under various conditions: 
Ctrl (GM-CSF+IL-4, black), acetate (GM-CSF+IL-4+acetate, red), butyrate (GM-
CSF+IL-4+butyrate, blue), and propionate (GM-CSF+IL-4+propionate, green). Data are 
from 8 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.  
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5.3.2 The Proliferation of Naïve CD4+ T Cells were Influenced by SCFA-treated 
Monocyte-Derived Dendritic Cells 
We learnt from the previous section that SCFAs, especially butyrate and propionate, 
affected the proliferation, maturation of MoDCs. Next, we wanted to test the function of 
these SCFA-treated MoDCs and how they influence the proliferation of autologous naive 
CD4+ T cells. So, MoDCs were first pulsed with anti-CD3, then added to the FACS sorted 
autologous naïve CD4+ cells at a ratio of 1:4-5, in the presence of IL-2 only for 5 days 
(Section 2.2.3.4). The same phenotypic markers used for iTregs were also tested for the 
proliferated CD4+ T cells, since these markers were closely related to immune tolerance. 
CD4+ T cells differentiated from naive CD4+ cells in the presence of butyrate and 
propionate treated im-MoDCs had higher expression levels of Foxp3, GITR, ICOS, HLA-
DR, PD-1, PD-L1, and CTLA-4, whereas the expression of these markers was similarly 
lower in CD4+ cells cultured with control or acetate treated im-MoDCs (Figure 5.12 and 
5.13). CD127 expression, on the contrary, was least in butyrate and propionate treated 
groups. There was no difference in the expression of CD39. All these results were not 
significant (small sample size, n=6). 
Naive CD4+ T cells were also cultured in the presence of m-MoDCs treated under various 
conditions. The same trend of upregulated immune tolerance markers was found in these 
settings as well (Figure 5.14). Cells differentiated in the presence of butyrate-treated m-
MoDCs had the highest expression of ICOS, PD-1, PD-L1, and CTLA-4; followed by 
propionate treated cells. The expression of Foxp3 and HLA-DR was also higher in CD4+ 
cells cultured with butyrate and propionate treated m-MoDCs, while CD127 expression 
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was least in butyrate and propionate treated groups. There was no difference in the 
expression of CD39 and GITR. 
These results suggested: a) all the immune tolerance related phenotypic markers were 
upregulated in the CD4+ T cells cultured with butyrate and propionate treated MoDCs; 
and b) butyrate and propionate treated MoDCs (both im-MoDCs and m-MoDCs) were 
more tolerogenic, compared to control and acetate treated MoDCs.  
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Figure 5.12 The effects of SCFAs treated MoDCs on the proliferation of naive CD4+ 
T cells. 
(A) Flow cytometric gating strategy for lymphocytes, single cells, viable cells, and CD4+ 
T cells. (B) The representative pseudocolour dot plots showing the percentage of Foxp3, 
CD127, CD39, and GITR gated on CD4+ T cells cocultured with autologous MoDCs 
treated under different conditions (from left to right: control, acetate, butyrate, and 
propionate). (C) The representative histograms showing CTLA-4, PD-1, PD-L1, HLA-
DR, and ICOS expression of CD4+ T cells cocultured with autologous MoDCs treated 
under different conditions: control (black line), acetate (red line), butyrate (blue line), and 
propionate (green line).  
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Figure 5.13 The effects of SCFAs treated im-MoDCs on the proliferation of naive 
CD4+ T cells. 
The summary bar graphs showing the % Foxp3+, % CD127+, % CD39+, % GITR+, MFI 
ICOS, MFI HLA-DR, MFI PD-1, MFI PD-L1, and MFI CTLA-4 of CD4+ T cells 
cocultured with autologous im-MoDCs treated under different conditions (from left to 
right): control (black), acetate (red), butyrate (blue), and propionate (green). Data 
represent 6 independent experiments. *p < 0.05. 
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Figure 5.14 The effects of SCFAs treated m-MoDCs on the proliferation of naive 
CD4+ T cells. 
The summary bar graphs showing the % Foxp3+, % CD127+, % CD39+, % GITR+, MFI 
ICOS, MFI HLA-DR, MFI PD-1, MFI PD-L1, and MFI CTLA-4 of CD4+ T cells 
cocultured with autologous m-MoDCs treated under different conditions (from left to 
right): control (black), acetate (red), butyrate (blue), and propionate (green). Data 
represent 6 independent experiments. *p < 0.05. 
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5.3.3 CD4+ T Cells cocultured with SCFA-treated Monocyte-Derived Dendritic 
Cells Had Enhanced Suppressive Capacity  
We learnt from the previous section that all the immune tolerance related phenotypic 
markers were upregulated in the CD4+ T cells cultured with butyrate and propionate 
treated MoDCs. To test whether these CD4+ T cells were tolerogenic or immunogenic, 
we cocultured them with freshly bead-isolated autologous CFSE-labelled CD4+CD25- 
responder cells under various ratios for 3 days in vitro, then compared the differences in 
the proliferation of responder cells (section 2.2.3.2). 
CD4+ cells cultured in the presence of SCFA-treated im-MoDCs reduced the in vitro 
proliferation of autologous CD4+CD25- cells, compared to cells cultured with control im-
MoDCs (Figure 5.15 and 5.16). Butyrate-treated cells had the highest suppressive 
capacity, followed by propionate and acetate. However, it was only statistically 
significant at suppressor: responder cell ratio 1:2.  
The results of CD4+ cells cultured in the presence of SCFA-treated m-MoDCs mimicked 
the same trend found above. Compared to the cells cultured with control m-MoDCs, 
SCFA-treated MoDCs increased the suppressive capacity of CD4+ cells at all suppressor: 
responder cell ratios from 1:1 to 1:4. However, only butyrate-treated cells reached 
significance at suppressor: responder cell ratios 1:2 and 1:4. 
These results demonstrate that a) T cells induced with SCFA-treated MoDCs had 
increased suppressive capacity; b) addition of SCFAs, including acetate, butyrate and 
propionate, did skew MoDCs towards tolerogenic status.  
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Figure 5.15 The effects of CD4+ T cells cocultured with SCFAs treated MoDCs on 
the proliferation of responder cells.  
Representative histogram showing the proliferation of responder cells alone (grey shaded) 
and compared with CD4+ cells cultured from naïve CD4+ cells in the presence of im-
MoDCs treated under different conditions: control (black line), acetate (red line), butyrate 
(blue line), and propionate (green line).  Data show suppressor: responder ratio of 1:2. 
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Figure 5.16 CD4+ T Cells cocultured with SCFAs treated im-MoDCs Had Enhanced 
Suppressive Capacity. 
(A) Line graph showing percentages of suppression using CD4+ cells cultured from naïve 
CD4+ cells in the presence of im-MoDCs treated under different conditions: control 
(black line), acetate (red line), butyrate (blue line), and propionate (green line). Various 
suppressor/responder ratios ranging from 1:1 to 1:4 were applied. (B) Summary dot plots 
(down) showing the statistical analysis of the suppressive capacity of these im-MoDC 
induced CD4+ cells. Data represent 6 independent experiments in each group. **p < 0.01, 
***p < 0.001.   
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Figure 5.17 CD4+ T Cells cocultured with SCFAs treated m-MoDCs Had Enhanced 
Suppressive Capacity. 
(A) Line graph showing percentages of suppression using CD4+ cells cultured from naïve 
CD4+ cells in the presence of m-MoDCs treated under different conditions: control (black 
line), acetate (red line), butyrate (blue line), and propionate (green line). Various 
suppressor/responder ratios ranging from 1:1 to 1:4 were applied. (B) Summary dot plots 
(down) showing the statistical analysis of the suppressive capacity of these m-MoDC 
induced CD4+ cells. Data represent 6 independent experiments in each group. *p < 0.05, 
**p < 0.01.   
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5.4 Discussion 
In this chapter, we thoroughly investigated the precise role of SCFAs on DCs, and 
extended the existing understanding from butyrate to other two major types of SCFAs. 
Our observations were consistent with previous studies on butyrate. We found that both 
butyrate and propionate could significantly inhibit the differentiation and maturation of 
MoDCs, while the addition of acetate again was less effective. In addition, butyrate and 
propionate also modulate cytokine production by downregulating the secretion of 
chemokines and pro-inflammatory cytokines. Therefore, butyrate and propionate skewed 
MoDCs towards a tolerogenic status.  
The functional capacity of these SCFA-treated MoDCs was also tested. In vitro 
suppression assays demonstrated that CD4+ T cells cocultured with SCFA-treated 
MoDCs (both immature and mature MoDCs) had significantly higher suppressive 
capacities compared to control MoDCs. We also tested the expression of immune 
tolerance related phenotypic markers, such as GITR, CD39, ICOS, PD-1, and PD-L1. The 
flow cytometric analyses suggested that all these markers were upregulated on CD4+ T 
cells co-cultured with butyrate and propionate treated MoDCs (both immature and mature 
MoDCs), compared to control and acetate treated MoDCs.  
It is postulated that SCFAs exert their regulatory effects on macrophages and DCs via 
either HDAC inhibition or GPRs-mediated signalling. SCFAs act as HDAC inhibitor to 
reduce the expression of NF-kB transcriptional factor and suppress the expression of pro-
inflammatory cytokines of DCs, thus promoting Treg induction (276, 323-325). In 
addition, the GPR109a signalling pathway could also be activated by butyrate, skewing 
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murine colonic macrophages and dendritic cells towards tolerogenic phenotype to 
promote the differentiation of Treg cell and IL-10 producing cells (295).  
However, it has recently been questioned whether HDAC inhibition and GPR109a 
signalling were mandatory for butyrate to effectively promote a tolerogenic phenotype in 
human DCs (372). Only the simultaneous addition of both niacin and TSA could replicate 
the effects of butyrate, whereas single niacin (another GPR109a ligand) or TSA (a general 
HDAC inhibitor) treatment was insufficient to induce tolerogenic MoDCs. In addition, 
silencing of GPR109a led to the ineffectiveness of butyrate. 
In contrast to these observations, the results presented in this chapter showed that 
propionate also had similar tolerogenic effects as butyrate and to a lesser extent, acetate. 
Most importantly, both propionate and acetate are not GPR109a ligands (293). Therefore, 
we assumed that GPR109a signalling is only a complementary mechanism for butyrate, 
and HDAC inhibition is the major pathway for SCFA-mediated tolerogenicity. 
Unfortunately, there is still a paucity in the understanding of underlying mechanisms of 
how SCFAs induce tolerogenic DCs and prime Treg cell induction, thus further studies 
are warranted.       
Collectively, our results proved that the addition of SCFAs, especially butyrate and 
propionate, skewed MoDCs towards tolerogenic status in humans. They influenced the 
function of DCs via significantly reduced co-stimulation, MHC presentation and pro-
inflammatory cytokines. These tolerogenic DCs upregulated immune tolerance related 
genes, and in turn influenced T cell polarization (the ratio between Treg cells and Teff 
cells), hence resulting in a higher suppressive capacity of the CD4+ T cells. To our 
knowledge, this is for the first time that butyrate, as well as propionate and acetate, has 
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been shown to effectively induce tolerogenic DCs and these DCs can prime T cell 
responses towards a tolerogenic status. In addition to Treg cells, this chapter provides in 
vitro evidence of the effects of SCFAs on another type of immune cells.  
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Chapter 6 – Short Chain Fatty Acids Regulate 
Immune Tolerance related Gene Expression in 
Human Peripheral Mononuclear Cells in vitro  
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6.1 Introduction 
PBMCs consists of various types of immune cells, including B cells, T cells, NK cells, 
monocytes, and very rare dendritic cells (<2%). Due to the presence of these highly 
sophisticated immune cells and their crosstalk networks, PBMCs have been widely used 
in immunological studies. Research had been recently conducted on the effects of SCFAs 
on human PBMCs, but restricted mainly to their effects on cytokine production. PBMCs 
are capable of producing pro-inflammatory cytokines (such as TNF-α, IL-12 and IFN-γ) 
in response to different stimuli. Meanwhile, anti-inflammatory cytokines (such as IL-10 
and TGF-β1) are released as well. Asarat et al. measured the cytokine levels (including 
IL-1β, IL-2, IL-6, IL-12, IL-17, IL-21, IL-23, TNF-α, IFN-γ, and TGF-β1) produced by 
PBMCs in the presence of LPS with or without SCFAs using ELISA. The addition of 
SCFAs significantly reduced the production of pro-inflammatory IL-1β, IL-2, IL-6, IL-
12, IL-17, IL-21, TNF-α, and IFN-γ, with a lesser reduction of IL-23 and TGF-β1. 
Moreover, IL-10 secretion was augmented by SCFAs, particularly butyrate (373, 374).  
SCFAs also exert their influence on the numbers of Th17 and Treg cells in human PBMCs. 
Asarat et al. found that the percentage of Th17 cells was reduced, while the percentage of 
Treg cells was increased in the presence of SCFAs. Among SCFAs, butyrate was the most 
effective inducer for Treg cells (373, 374). The mechanism was not investigated, but the 
changes in cytokine milieus may play an important role. The expression of the key 
immune tolerance related markers has not been examined yet. 
Our results from the previous two chapters extensively explored the effects of SCFAs on 
the differentiation of human iTregs and MoDCs in vitro. Both these cell types are part of 
PBMCs. We found that butyrate and propionate, but not acetate, not only potently induced 
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highly functional iTregs, but also skewed the MoDCs towards a tolerogenic status. These 
results were concluded based on in vitro experiments using a single cell type, which did 
not mimic the actual in vivo environment where cell crosstalk is always present.   
Therefore, the aims of this chapter are to: a) explore the effects of SCFAs (including 
acetate, butyrate and propionate) on human PBMCs, in terms of phenotypic expression; 
b) assess and compare the expression of phenotypic markers related to Treg-mediated 
immune tolerance on other T cell subsets. 
6.2 Subjects 
To determine the effect of SCFAs on the human PBMCs, a total of 7 healthy adult 
volunteers were recruited. Individuals with any history of autoimmune disease or allergies 
were excluded. 
6.3 Results 
To explore the effects of SCFAs (including acetate, butyrate and propionate) on human 
PBMCs in terms of phenotypic expression, and to assess and compare the expression of 
phenotypic markers related to Treg-mediated immune tolerance on other T cell subsets, 
freshly isolated PBMCs were stimulated with anti-CD3/anti-CD28 in the presence of IL-
2, with or without SCFAs for 5 days (Section 2.2.3.5).   
6.3.1 The tolerogenic effects of SCFAs (including acetate, butyrate and 
propionate) on human PBMCs 
Figure 6.1 showed the gating strategy for all the T cell subsets, including CD4+ cells, 
CD4+Foxp3+ cells, CD4+Foxp3- cells, CD8+ cells, CD8+Foxp3+ cells, and CD8+Foxp3- 
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cells. The percentage of Foxp3+ cells within CD4+ cells was much lower when treated 
with butyrate and propionate, compared to cells treated under normal condition or with 
acetate (approximately 22% versus 27%) (Figure 6.2). The addition of propionate resulted 
in the least amount of Foxp3+ cells within CD8+ cells, followed by butyrate, control and 
acetate. As for the expression of CD39 and CD127, the addition of SCFAs did not make 
any difference to the expression in any of the T cell subsets (Figure 6.3 and 6.4).  
As for other phenotypic markers related to immune tolerance, the expression of PD-1, 
PD-L1, CTLA-4, GITR and ICOS were consistently higher in all T cell subsets when 
treated with butyrate compared to control (Figure 6.4). The effects of acetate were similar 
to that of propionate, both of which were to a lesser extent compared to butyrate. 
These results suggested that SCFAs could potentiate the expression of immune tolerance 
related phenotypic markers on human PBMCs in vitro, and these SCFA-induced 
differential expression patterns were the same regardless of the Foxp3 expression or type 
of T cells.  
6.3.2 The same effects of SCFAs on different T cell subsets 
Next, we wanted to assess and compare the expression of phenotypic markers related to 
Treg-mediated immune tolerance on other T cell subsets. It was interesting to find that 
there was a comparable frequency of Foxp3+ cells within CD8+ cells (20-30%) to that 
within CD4+ cells (Figure 6.2). Another finding was that around 60% of CD8+ cells 
expressed CD39, whereas in CD4+ cells, this number dropped to 20% (Figure 6.3). 
Interestingly, in both CD4+ and CD8+ cells, the percentages of CD39+ cells were only 
slightly higher in Foxp3+ cells, compared to Foxp3- cells. CD127 expression was slightly 
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less in the CD4+Foxp3+ subset, while there were no differences found in other subsets 
(Figure 6.4). 
The expression was generally higher for other Treg-related immune tolerance markers in 
CD4+ cells compared to CD8+ cells, but to a different extent (Figure 6.4). The biggest 
difference was in the expression of PD-L1, followed by GITR, PD-1, ICOS and CTLA-
4. In terms of the influence by the Foxp3 expression, the phenotypic expression of PD-1, 
GITR, ICOS and CTLA-4 were all upregulated in Foxp3+ cells compared to Foxp3- cells, 
whereas PD-L1 expression remained unchanged. 
To conclude, all the immune tolerance related phenotypic markers were expressed in 
different T cell subsets. Most of them were relatively rich in CD4+ T cells, whereas the 
expression of CD39 was much less. These markers were also upregulated in the Foxp3+ 
cells upon in vitro stimulation.  
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Figure 6.1 Flow cytometric gating strategy. 
Flow cytometric gating strategy for lymphocytes, single cells, viable cells, CD4+ cells, 
CD8+ cells and Foxp3+ cells gated on CD4+ and CD8+ cells after adult PBMCs culture.  
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Figure 6.2 The effect of SCFAs on the Foxp3 expression of human PBMCs. 
(A) Representative pseudocolour plots showing percentage of Foxp3+ cells gated on 
CD4+ cells cultured from adult PBMCs under various conditions: control (IL-2), acetate 
(IL-2+acetate), butyrate (IL-2+butyrate), and propionate (IL-2+propionate). (B) 
Summary dot plots showing %Foxp3+ gated on CD4+ cells (left panel) and CD8+ cells 
(right panel) from adult PBMCs (n=7). *p < 0.05.  
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Figure 6.3 The effect of SCFAs on the CD39 expression of human PBMCs. 
(A) Representative pseudocolour plots showing percentage of CD39+ cells gated on CD4+ 
cells cultured from adult PBMCs under various conditions: control (IL-2), acetate (IL-
2+acetate), butyrate (IL-2+butyrate), and propionate (IL-2+propionate). (B) Summary 
dot plots showing %CD39+ gated on CD4+ cells, CD4+Foxp3+ cells, CD4+Foxp3- cells, 
CD8+ cells, CD8+Foxp3+ cells, and CD8+Foxp3- cells (from left to right) from adult 
PBMCs (n=7). *p < 0.05.   
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Figure 6.4 The effect of SCFAs on the expression of phenotypic markers of human 
PBMCs. 
(A) Representative histograms showing PD-1, PD-L1, CTLA-4, GITR, ICOS and CD127 
expression of CD4+ cells cultured from adult PBMCs under various conditions: control 
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(IL-2), acetate (IL-2+acetate), butyrate (IL-2+butyrate), and propionate (IL-
2+propionate). (B) Summary dot plots showing MFI PD-1, PD-L1, CTLA-4, GITR, 
ICOS and CD127 of CD4+ cells, CD4+Foxp3+ cells, CD4+Foxp3- cells, CD8+ cells, 
CD8+Foxp3+ cells, and CD8+Foxp3- cells (from left to right) from adult PBMCs (n=7). 
*p < 0.05, **p < 0.01.  
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6.4 Discussion 
It was clearly demonstrated in the previous two chapters that SCFAs exerted their 
tolerogenic effects on human iTregs as well as MoDCs in vitro. In this chapter, we 
extended our understanding of SCFAs to PBMCs, which simulate the in vivo environment 
with cell crosstalk. We were able to show that SCFAs could potentiate the expression of 
phenotypic markers related to Treg-mediated immune tolerance in different T cell subsets 
apart from Tregs in vitro. These SCFA-induced differential expressions were consistent 
regardless of the Foxp3 expression. Moreover, the expression of all phenotypic markers 
related to Treg-mediated immune tolerance was not restricted to only CD4+ T cells, and 
they also had a relatively lower expression in CD8+ T cells, except for CD39. These 
markers were likely to be upregulated in Foxp3+ cells upon in vitro stimulation.  
It was postulated that SCFAs regulate T cells directly via either HDAC inhibition (288-
290) or energy metabolism by converting to Acetyl-CoA (316). Our ChIP-qPCR results 
from Chapter Four demonstrated the possible mechanism of HDAC inhibition. However, 
SCFAs could also exert their regulatory effects on T cells indirectly by other immune 
cells. They suppressed the expression of pro-inflammatory cytokines of DCs via HDAC 
inhibition, thus changing T cell polarization conditions (276). Alternatively, the 
activation of GPR109a by butyrate skewed colonic macrophages and dendritic cells 
towards tolerogenic phenotype to promote the T cell differentiation (295).  
A previous study on human PBMCs showed that the addition of SCFAs significantly 
reduced the production of pro-inflammatory cytokines while it increased the IL-10 
secretion (373, 374). It proved that the immunological cytokine milieu was altered by 
SCFAs in order to favour T cell differentiation towards a tolerogenic status (more Treg 
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cells and IL-10 producing cells than effector T cells). Our findings provide another 
perspective as to how SCFAs manipulate immune cells in vitro. We have shown that in 
addition to cytokine changes, SCFAs also modify the expression of genes related to Treg-
mediated immune tolerance in T cell subsets other than Treg cells, mostly via HDAC 
inhibition. Among the three types of SCFAs, butyrate is the most effective in promoting 
the regulatory effects. Previous chapters have already demonstrated the close interlink 
between gene expressions and the in vitro suppressive capacity of T cells. Therefore, 
SCFAs also exert their tolerogenic effects on human PBMCs in vitro. 
Moreover, it was noticed that the percentage of Foxp3+ cells within CD8+ cells was 
similar to that within CD4+ cells, between 20% and 30%. Since the percentage of CD8+ 
Tregs was normally much less (0.1–1%) in ex vivo human PBMCs (42), it was another 
proof that Foxp3 was only an activation marker, but not an iTreg specific marker.  
In summary, our findings of the broad tolerogenic effects of SCFAs on T cell phenotypes, 
together with the previous cytokine results, indicate that through the production of anti-
inflammatory cytokines and the induction of immune tolerance related gene expression, 
SCFAs have in vitro anti-inflammatory effects and exert their tolerogenic effects on 
immune tolerance in peripheral blood.   
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Chapter 7 – General Discussion and Conclusions  
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7.1 Treg cell transplacental programming during early life  
Whilst there is abundant indirect evidence from clinical observations for transplacental 
immune programming (215-217),  there is a paucity of direct mechanistic data. It is 
known that appropriate stimulation to the maternal immune system in utero may educate 
and shape the fetal immune system, specifically Treg cells. In BALB/c mouse models, 
maternal Th1 and regulatory immune responses to schistosome infection could protect 
the offspring from the onset of allergic airway inflammation. Associated schistosome-
specific cytokine and gene expression changes were also seen within the fetal-maternal 
interface (228). In addition, the offspring of tolerised mice were completely protected 
against asthma due to the transplacental transfer of allergen-specific IgG (218). 
Furthermore, microbial stimulation of the pregnant mice could lead to decreased levels 
of atopic sensitisation and asthma in the offspring (229-231). Chapter 3 summarises 
collaborative works to prove that Treg cell transplacental immune programming occurs, 
and partially explained the mechanism behind this phenomenon. 
Our group previously made a surprising discovery that there was a specific and significant 
correlation of Treg cells between maternal-fetal dyads (209). Gene microarray analysis 
suggested that IL-10 pathway may contribute to the Treg alignment between maternal-
fetal dyads and it was confirmed by the specific alignment of serum IL-10 at a protein 
level (209). The mechanism by which IL-10 contributes to Treg generation was 
investigated in section 3.3. We showed that in addition to TGF-, IL-10 enhanced the 
phenotype of iTreg cells and augmented the suppressive capacity of these iTreg cells in 
vitro (1). However, whether IL-10 signalling in naïve CD4+ T cell differentiation is 
dispensable for pTreg cell differentiation in vivo remained unclear. 
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In addition to anti-inflammatory cytokine IL-10, various other environmental factors, 
such as pregnancy-related hormones or microbiota metabolites-SCFAs, also contribute to 
the transplacental programming of Treg cells (331, 342).  In section 3.1.1, our 
collaborators were able to demonstrate how the maternal microbial composition 
influences fetal thymus and Treg cell development. The absence of maternal gut 
microbiota (GF mice) led to significantly reduced fetal thymus size, fewer thymic CD4+ 
T cells and Foxp3+ Treg cells. Supplementation of acetate in maternal drinking water, 
which is the most abundant SCFA in human serum (279), could rescue all these reductions 
in thymus size and thymic output. These results are also consistent with the fetal-maternal 
correlation of serum acetate levels we found in human pregnancy, which implies that 
maternal acetate likely crosses the placenta. TCR sequencing data in section 3.1.2 from 
our collaborators also suggests that fetal antigen receptor immunity is not inherited, but 
rather driven by local immunomodulatory factors. Taken together, it can be concluded 
that maternally acquired metabolites (acetate) play an important role in shaping fetal 
thymic development and output, hence exerting their influences on fetal immunity. 
Apart from in utero stage, the programming of T cells happens after birth as well (333). 
(375). Together with our collaborators from the Children’s Hospital at Westmead, we 
found that circulating 7+ gut homing Treg cells were most abundant early in life and 
decreased with age. Treg cells probably acquire gut tropism early in their development. 
However, the induction of 7 expression mostly occurs after thymic emigration. 
Furthermore, in vitro experiment done by myself showed that IL-2 specifically skews the 
expression of human Treg cell homing molecules to favour gut homing. Overall, section 
3.2 indicates that human naïve Treg cells are primed early in life for gut tropism, which 
reinforces the important role of early gut microbial colonization in shaping the developing 
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immune system. It seems likely that human naïve Treg cells also likely acquire their gut 
homing molecules outside the thymus, where they encounter environmental cues, such as 
SCFAs. 
The concept of Treg cell transplacental programming provides a new perspective for non-
pharmaceutical approach during pregnancy. Maternal dietary interventions, prebiotic 
intakes or direct SCFAs supplementation, may alleviate or treat various non-
communicable diseases, or even prevent the development of autoimmune diseases in 
early life. Mouse models have confirmed the beneficial effects of maternal SCFAs 
supplementation on the development of allergic airway disease, asthma and 
haematopoiesis in the offspring (221, 376). Additionally, butyrate or propionate 
supplementation commenced antenatally ameliorated and interfered with the course of 
Type 1 diabetes in the offspring of rats (377). Moreover, the relationship between 
maternal butyrate supplementation and improved lipid metabolisms, insulin resistance 
and mitochondria biogenesis have also been studied in rats (378-380).  
However, there were only observational studies in humans, showing the association 
between maternal SCFAs and diseases. One prospective cohort study with 1,538 pregnant 
women showed that increased dietary fibre intake in early pregnancy was associated with 
decreased preeclampsia risk (381). Dietary modification during pregnancy is mainly 
designed to alleviate gestational diabetes (382). The specific preventive mechanisms 
induced by different SCFA supplementation approaches are still poorly understood.  
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7.2 The tolerogenic effects of SCFAs on immune tolerance, particularly 
Treg cell differentiation 
In addition to the context of pregnancy, SCFAs also have profound regulatory effects on 
immune tolerance. Although their effects have been consistently proven in different 
animal models, their efficacy in modulating immune cells in humans still remains unclear. 
Therefore, we conducted in vitro experiments using primary cells from humans to show 
the precise role of SCFAs in different types of immune cells, especially Treg cells. The 
results presented in Chapter 4, 5 and 6 highlight the important role of SCFAs in immune 
tolerance, particularly in Treg cell physiology.  
The most essential finding is that we are the first to demonstrate the effectiveness of 
SCFAs in Treg cell differentiation in vitro in humans. The addition of butyrate and 
propionate, but not acetate, potentiated the expression of phenotypic markers and 
augmented the suppressive capacity of induced human Treg cells. Compared to CBMCs, 
adult PBMCs had a completely different induction pattern with a reduced level of 
activation. We postulated that this differential induction patterns of adult iTregs may 
account for the inconsistent effectiveness of human iTregs as well as the concealment of 
SCFAs’ effects, considering the higher proportion of non-activated iTregs in adults. ChIP 
analyses also provided additional evidence for the observed differential induction patterns 
in adults. The epigenetic histone acetylation due to SCFAs treatment initiated much later 
in adult cells compared to cord blood cells.  
Additionally, we have also proved the tolerogenic effects of SCFAs on other immune 
cells in humans, including MoDCs and different T cell subsets. We showed that both 
butyrate and propionate, but not acetate, inhibited the differentiation and maturation of 
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MoDCs, skewing them towards immature or tolerogenic status. When cocultured with 
naive CD4+ T cells, these tolerogenic MoDCs upregulated the immune tolerance related 
phenotypic markers and increased the suppressive capacity of cultured CD4+ T cells. 
These tolerogenic effects of SCFAs also applied to different T cell subsets regardless of 
their Foxp3 expression in vitro. 
Another interesting finding is that acetate, which is the most abundant SCFA in human 
serum (279, 285, 286), only showed reduced or almost no effects on Treg cell and MoDC 
differentiation. In animal models, acetate also failed to promote the generation of pTregs 
and tolerogenic DCs in vivo, but could still promote the accumulation of Treg cells in 
the colon (276-278). Moreover, Woetmann et al. found that acetate (1mM) only exerted 
minimum effects on the gene expression of human MoDCs in vitro (369). We postulated 
that the inefficiency of HDAC inhibition by acetate contributed to this result. Acetate 
normally has a little effect on the HDAC activity (383).  However, this lack of HDAC 
inhibition by acetate might change depending on the cell type and the concentration used 
in the experiments. In HeLa Mad 38 cells transfected with an HDAC-dependent reporter 
gene construct, acetate was unable to trigger HDAC inhibition at all concentrations tested 
(0-20mM) (326). On the contrary, T cells were shown to be suppressed by acetate in a 
dose-dependent manner. Acetate had significant HDAC inhibitor activity at 
concentrations (10mM) much higher than butyrate and propionate (290). In our 
experiments, the concentration used for acetate was only 1mM (same as Woetmann’s 
group), which is much lower than the concentration needed to be effective. This specific 
concentration was chosen because it did not affect the cell viability and it was more 
similar to the concentration found in peripheral blood rather than colon concentration. 
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Finally, we confirmed that Foxp3 is only an in vitro activation marker rather than a 
surrogate human iTregs marker. It is always upregulated upon different types of in vitro 
stimulation (such as anti-CD3) and correlates to the activation status. Our findings are 
consistent with previous findings in humans. CD4+ and CD8+ T cells can transiently up-
regulate the Foxp3 expression upon in vitro stimulation without acquiring Treg cell 
suppressive activity (60, 61). In addition, there is also a CD4+Foxp3+ subpopulation in 
human peripheral blood with no suppressive activity which even produces pro-
inflammatory IL-17 upon activation (354). Whilst Foxp3 is not suitable for defining 
iTregs, the expression patterns of GITR, ICOS, CD39, PD-1 and PD-L1 of iTregs treated 
with SCFAs were in accordance with functional assay results. It was demonstrated in our 
MoDC and PBMCs cultures that SCFAs induced the same expression patterns of these 
markers on other immune cells. Collectively, these results suggest that GITR, ICOS, 
CD39, PD-1 and PD-L1 are potential candidate markers for the human in vitro induced 
Treg cells, and their expression levels are closely related to the SCFA-mediated immune 
tolerance. 
In conclusion, butyrate and propionate can potentiate the expression of immune tolerance 
related phenotypic markers via HDAC inhibition, promote the differentiation of 
tolerogenic human iTregs and MoDCs in vitro, and augment the suppressive capacity of 
iTregs.  
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7.3 SCFAs as new immune therapeutic manipulation 
Immune therapy has developed rapidly during the past two decades. Treg cell 
immunotherapy (adoptive Treg cell transfer) have been promising for treating human 
autoimmune diseases and preventing GVHDs (106). Compared to non-specific 
immunosuppressive drugs, Tregs are safer, more effective, and have fewer side effects. 
Due to limited numbers of Tregs and instability of the in vitro induced human Tregs, ex 
vivo expanded nTregs are most commonly used for immunotherapy. However, there are 
several problems encountered during the process, including difficulty in isolating 
adequate amounts of nTregs and deterioration of the function after several rounds of 
proliferation. Therefore, new immune therapeutic manipulation methods are needed.  
It is well known that gut microbiota and its metabolites, SCFAs, have profound 
tolerogenic effects on immune homeostasis, thus play a beneficial role in various diseases. 
Since diet is closely interlinked with the composition of gut microbiota and SCFAs 
production, various human and animal studies have been conducted to reveal the 
therapeutic effects of SCFAs on the prevention and treatment of autoimmune and 
inflammatory diseases by dietary modification or direct SCFAs supplementation.  
In mice, it was proved that a high fibre diet altered the gut microbiota and increased the 
production of SCFAs, particularly acetate and butyrate (384). It promoted oral tolerance 
and protected mice from the peanut allergy. This effect was dependant on mucosal 
CD103+ DCs, which promote differentiation of Treg cells via epithelial GPR43 and 
immune cell GPR109a. Specialised diets designed to release acetate or butyrate also 
provided protection against Type 1 diabetes in NOD mice (352). Since key features of 
this autoimmune disease were inversely associated with SCFAs concentrations, NOD 
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mice were fed with different types of diets offering acetate, or butyrate, or combined 
acetate and butyrate production. Combination feeding achieved complete protection, 
whereas acetate or butyrate feeding only had partial effects, thus suggesting that acetate 
and butyrate might operate through distinct mechanisms. They found that acetate affected 
auto-reactive T cells in lymphoid tissues through B cells while butyrate augmented Treg 
cells. Apart from allergies and Type 1 diabetes, high fibre diet and acetate 
supplementation significantly reduced blood pressure, cardiac and renal fibrosis, and left 
ventricular hypertrophy in a hypertensive mouse model (385).  
In humans, dietary intervention studies have been carried out within different 
populations, including obese men and women, IBD remission patients (Australian 
Clinical Trial Registry Number 12614000271606, http://www.anzctr.org.au) (386), 
irritable bowel syndrome patients (Australian Clinical Trial Registry Number 
12614000271606, http://www.anzctr.org.au) (387), and healthy individuals (388). These 
dietary interventions resulted in changes in the gut microbiota composition and faecal or 
serum SCFAs concentrations. However, the prognosis of disease was not significantly 
influenced. There are also clinical trials investigating the beneficial effects of butyrate 
enema on colonic health (National Clinical Trial 02451189, 
https://www.clinicaltrials.gov). The role of acetate and propionate has also been studied 
on the satiety and glucose homeostasis for obese population. A double-blind, randomized 
clinical trial was conducted to investigate the effects of adjunct butyrate therapy in 
shigellosis (389). Butyrate enema alleviated the symptoms due to an early decline in 
inflammatory cells of rectal mucosa and pro-inflammatory cytokines in the stool. More 
clinical trials have been registered and started their recruitment. For example, an 
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investigation about the effects of sodium butyrate on the cognitive function in 
schizophrenia (National Clinical Trial 03010865, https://www.clinicaltrials.gov).  
In conclusion, SCFAs offer a new approach as immune therapeutic manipulation.  This 
new intervention is effective and non-pharmaceutical, aiming to lessen immunological 
defects and treat autoimmune and inflammatory diseases. Our results about the 
tolerogenic effects of SCFAs on human immune cells provide further theoretical 
support to this manipulation.  
7.4 Limitations and future directions 
7.4.1 Limitations 
This thesis mainly focused on human studies. In contrast to animal models, human 
studies are limited by multiple cofounders, which are difficult to account for. In this 
thesis, we did not control for factors such as diet, age, gender, socioeconomic status 
and ethnicity. Moreover, the results from each chapter are from different cohorts, and 
we infer that these results from different cohorts would be consistent if applied to a 
single cohort.   
7.4.2 Future directions 
Our observational studies showed promising results of the tolerogenic effects of SCFAs, 
hence it might indicate that a high fibre diet, which would fuel the production of SCFAs, 
might be used as an intervention to prevent or treat allergies and autoimmune diseases. 
This simple dietary approach would have the potential to transform treatment for these 
aberrant immune responses in the future.  
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APPENDICES 
Table S-1 Primers used for quantitative assessment of H3 or H4 histone acetylation by 
PCR following ChIP. 
Target Forward primer Reverse primer 
FOXP3 
promoter 
TTCTTTCCCCAGAGACCCTC AGGGCTCATGAGAAACCACA 
FOXP3 
CNS-2 
TACCACATCCACCAGCACC TCCGCCATTGACGTCATG 
FOXP3 
CNS-3 
CCTTTACTGTGGCACTGGG GGATTTTCTTGGCCCTGCAA 
CTLA-4 
promoter 
TGCCTAGACAAATCCTGCCA TCCTGGAGTACAAGGGTCCT 
CD39 
promoter 
GTCCTGTCCCACATCCAGAA TGACAGTGTGAGACCCTGTC 
GITR 
promoter 
GGCTCCATGGTTGAGGCTCT GCGGCGTTTATAGCACCTTGT 
ICOS 
promoter 
TGATTCAGAGAAGTAGGGTGGT TGCTGGAAAGGAAGTGGGTT 
PD1 
promoter 
AAGATCTGGAACTGTGGCCA CTCAACCCCACTCCCATTCT 
PD-L1 
promoter 
TCTTCCCGGTGAAAATCTCATT TTCCTGACCTTCGGTGAAATC 
RPL32 
(control 
gene) 
GGAAGTGCTTGCCTTTTTCC GGATTGCCACGGATTAACAC 
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